var title_f20_9_20624="Granuloma annulare foot PI";
var content_f20_9_20624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Granuloma annulare on the foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a photo of granuloma annulare on a child's foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20624=[""].join("\n");
var outline_f20_9_20624=null;
var title_f20_9_20625="Secretin regulation";
var content_f20_9_20625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Regulation of secretin release",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the regulation of secretin release.",
"    <br/>",
"    <ol>",
"     <li>",
"      Duodenal acidification causes release of secretin releasing factor (SRF) from the proximal small bowel.",
"     </li>",
"     <li>",
"      Secretin releasing factor elaborates secretin from specialized enteroendocrine cells (S cells) of the small intestine.",
"     </li>",
"     <li>",
"      Secretin is secreted into the blood and binds to specific secretin receptors on the pancreas to cause exocrine pancreatic secretion.",
"     </li>",
"     <li>",
"      Pancreatic exocrine secretion includes pancreatic proteases, which terminate secretin release by degrading secretin-releasing factor.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20625=[""].join("\n");
var outline_f20_9_20625=null;
var title_f20_9_20626="Patient information: Ear tubes (The Basics)";
var content_f20_9_20626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83798\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30677\">",
"         Normal ear",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/44/27332\">",
"          Ear infection (otitis media)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/8/23680\">",
"           Surgery to treat fluid in the ear (tympanostomy tube)",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/38/44642\">",
"         Patient information: Ear infections (otitis media) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/45/25298\">",
"         Patient information: Eustachian tube problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/45/36561\">",
"         Patient information: Ruptured eardrum (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/16/15619\">",
"         Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ear tubes (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ear-tubes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1667279033\">",
"      <span class=\"h1\">",
"       What are ear tubes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ear tubes are tiny tubes that a doctor puts in a child&rsquo;s eardrum to make an opening. The eardrum is the thin layer of tissue between the ear canal and the middle ear (",
"      <a class=\"graphic graphic_figure graphicRef55121 \" href=\"UTD.htm?29/61/30677\">",
"       figure 1",
"      </a>",
"      ). To put ear tubes in, doctors need to do surgery. Ear tubes are also sometimes called &ldquo;tympanostomy tubes&rdquo; or &ldquo;PE (short for &lsquo;pressure equalization&rsquo;) tubes.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667279065\">",
"      <span class=\"h1\">",
"       Why might children get ear tubes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Children might get ear tubes if they:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get a lot of ear infections &ndash; This includes children who get 3 or more ear infections in 6 months, or 4 or more infections in 1 year (",
"        <a class=\"graphic graphic_figure graphicRef54739 \" href=\"UTD.htm?26/44/27332\">",
"         figure 2",
"        </a>",
"        ). Ear tubes can help prevent children from getting more ear infections.",
"       </li>",
"       <li>",
"        Have fluid in the middle ear that won&rsquo;t go away &ndash; Ear tubes let the fluid drain out of the middle ear (the part of the ear behind the eardrum) (",
"        <a class=\"graphic graphic_figure graphicRef67163 \" href=\"UTD.htm?23/8/23680\">",
"         figure 3",
"        </a>",
"        ). This is helpful because fluid in the middle ear can cause hearing loss. Long-term hearing loss can lead to language and speech problems in children, especially in young children.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are other benefits of ear tubes, too. They:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Let air into the middle ear, which helps the middle ear heal",
"       </li>",
"       <li>",
"        Keep the pressure between the middle ear and the ear canal the same",
"       </li>",
"       <li>",
"        Can keep a growth of cells (called a &ldquo;cholesteatoma&rdquo;) from collecting in and damaging the middle ear",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667279126\">",
"      <span class=\"h1\">",
"       What does ear tube surgery involve?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before the surgery, your child&rsquo;s doctor will give you instructions about what to do. Children should not eat or drink for a certain number of hours before surgery.",
"     </p>",
"     <p>",
"      When the surgery starts, the doctor will give your child medicine to make him or her fall asleep. Then the doctor will make a small cut in the eardrum. He or she will place the ear tube in the eardrum.",
"     </p>",
"     <p>",
"      Most children can go home a few hours after surgery. They can usually do their normal activities the next day.",
"     </p>",
"     <p>",
"      After surgery, the doctor will see your child for a follow-up visit. The doctor will check that the tube is in the correct place and that fluid is draining well. He or she will also check your child&rsquo;s hearing. This might involve getting a hearing test.",
"     </p>",
"     <p>",
"      Your child&rsquo;s doctor will also tell you if you need to keep water out of your child&rsquo;s ear. He or she might recommend that your child wear ear plugs when swimming or bathing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667279141\">",
"      <span class=\"h1\">",
"       What problems can happen with ear tubes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The following problems can happen with ear tubes. They can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep draining &ndash; Sometimes, fluid or pus keeps draining out of the tube.",
"       </li>",
"       <li>",
"        Get blocked",
"       </li>",
"       <li>",
"        Move out of place and fall into the middle ear",
"       </li>",
"       <li>",
"        Fall out after only a short time",
"       </li>",
"       <li>",
"        Make a long-lasting hole in the eardrum",
"       </li>",
"       <li>",
"        Damage the eardrum tissue",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667279156\">",
"      <span class=\"h1\">",
"       When should I call my child&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After surgery, call your child&rsquo;s doctor or nurse if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Gets a fever",
"       </li>",
"       <li>",
"        Has bloody drainage from the ear",
"       </li>",
"       <li>",
"        Has trouble hearing",
"       </li>",
"       <li>",
"        Has ear pain that doesn&rsquo;t get better or gets worse",
"       </li>",
"       <li>",
"        Is dizzy or falls down a lot",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667279171\">",
"      <span class=\"h1\">",
"       How long do ear tubes stay in?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most ear tubes fall out on their own after 6 to 18 months. This is normal. If the ear tube doesn&rsquo;t fall out on its own after a few years, the doctor will probably do surgery to remove it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667279186\">",
"      <span class=\"h1\">",
"       How can I decide if my child should get ear tubes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;This decision depends on your child and his or her individual situation. You should talk with your child&rsquo;s doctor about the benefits and downsides of ear tubes, and how much they can help your child.",
"     </p>",
"     <p>",
"      The decision will probably depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How old your child is",
"       </li>",
"       <li>",
"        How many ear infections he or she gets, or how long he or she has had fluid in the middle ear",
"       </li>",
"       <li>",
"        Whether your child has hearing loss",
"       </li>",
"       <li>",
"        Whether your child is talking",
"       </li>",
"       <li>",
"        Whether your child has other ear conditions",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667279201\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=see_link\">",
"       Patient information: Ear infections (otitis media) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=see_link\">",
"       Patient information: Ruptured eardrum (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/45/25298?source=see_link\">",
"       Patient information: Eustachian tube problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"       Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/9/20626?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83798 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20626=[""].join("\n");
var outline_f20_9_20626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279033\">",
"      What are ear tubes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279065\">",
"      Why might children get ear tubes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279126\">",
"      What does ear tube surgery involve?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279141\">",
"      What problems can happen with ear tubes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279156\">",
"      When should I call my child&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279171\">",
"      How long do ear tubes stay in?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279186\">",
"      How can I decide if my child should get ear tubes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667279201\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/61/30677\">",
"      Normal ear",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/44/27332\">",
"       Ear infection (otitis media)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/8/23680\">",
"        Surgery to treat fluid in the ear (tympanostomy tube)",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/45/25298?source=related_link\">",
"      Patient information: Eustachian tube problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=related_link\">",
"      Patient information: Ruptured eardrum (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_9_20627="Foot ankle circles PI";
var content_f20_9_20627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Foot/ankle circles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With your leg resting against something and your foot in the air, point and flex your foot. Then make circles with your foot by rotating your ankle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20627=[""].join("\n");
var outline_f20_9_20627=null;
var title_f20_9_20628="Doxercalciferol: Patient drug information";
var content_f20_9_20628=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Doxercalciferol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/12/44229?source=see_link\">",
"     see \"Doxercalciferol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hectorol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hectorol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12676144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop bone disease in dialysis patients.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to doxercalciferol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, high phosphate levels, or high vitamin D levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take with cholestyramine, mineral oil, or antacids or magnesium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High calcium level. Signs include weakness, confusion, feeling tired, headache, upset stomach and throwing up, hard stools (constipation), or bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop other vitamins that have vitamin D.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12400 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20628=[""].join("\n");
var outline_f20_9_20628=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163084\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163085\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12676144\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011991\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011990\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011995\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011996\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011998\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011993\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011994\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011999\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012000\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/12/44229?source=related_link\">",
"      Doxercalciferol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_9_20629="Proton plan lumbar vert EFT";
var content_f20_9_20629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proton radiation therapy treatment plan for a patient with a lumbar vertebral Ewing's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note significant sparing of normal tissue anterior and lateral to the vertebrae with protons.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John A Jackson, Medical Dosimetrist, Massachusetts General Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20629=[""].join("\n");
var outline_f20_9_20629=null;
var title_f20_9_20630="Tinea versicolor shoulder";
var content_f20_9_20630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea versicolor. Hypopigmented macules and patches are scattered on the shoulder and arm of this patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20630=[""].join("\n");
var outline_f20_9_20630=null;
var title_f20_9_20631="Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy";
var content_f20_9_20631=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20631/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20631/contributors\">",
"     Paul T Twydell, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20631/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20631/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20631/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20631/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/9/20631/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral plexopathies represent a distinct group of disorders of the peripheral nervous system due in part to their anatomic location, rarity, and wide array of etiologies (",
"    <a class=\"graphic graphic_table graphicRef52765 \" href=\"UTD.htm?25/61/26587\">",
"     table 1",
"    </a>",
"    ). The most common causes of lumbosacral plexopathy are diabetic amyotrophy and the clinically similar condition of idiopathic (nondiabetic) lumbosacral radiculoplexus neuropathy.",
"   </p>",
"   <p>",
"    This topic will review diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy. Other conditions affecting the lumbosacral plexus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link\">",
"     \"Lumbosacral plexus syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The types of neuropathy associated with diabetes are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=see_link\">",
"     \"Epidemiology and classification of diabetic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/1\">",
"     1",
"    </a>",
"    ] is also known as Bruns-Garland syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], diabetic myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/4\">",
"     4",
"    </a>",
"    ], proximal diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/5\">",
"     5",
"    </a>",
"    ], diabetic polyradiculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/6\">",
"     6",
"    </a>",
"    ], diabetic motor neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/7\">",
"     7",
"    </a>",
"    ], diabetic radiculoplexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/8\">",
"     8",
"    </a>",
"    ], diabetic lumbosacral plexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/9\">",
"     9",
"    </a>",
"    ], and diabetic lumbosacral radiculoplexus neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetic amyotrophy is not a pure lumbosacral plexopathy because it also affects the lumbosacral nerve roots and peripheral nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The extensive list of monikers for this condition reflects the debate regarding its neuroanatomic localization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional debate has been waged regarding which pathophysiologic mechanisms (eg, ischemic, metabolic [hyperglycemia],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammatory) are responsible for diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/3,10-14\">",
"     3,10-14",
"    </a>",
"    ]. However, the most likely cause is ischemic injury from a nonsystemic microvasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. There is also evidence that a nonsystemic microvasculitis is responsible for idiopathic lumbosacral radiculoplexus neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic amyotrophy typically occurs in patients with type 2 diabetes mellitus that has been recently diagnosed or has been under fairly good control. The traditional features include the acute, asymmetric, focal onset of pain followed by weakness involving the proximal leg, with associated autonomic failure and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/1-3,6,16\">",
"     1-3,6,16",
"    </a>",
"    ]. Progression occurs over months and is followed by partial to full recovery in most patients. However, onset in the distal leg is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Furthermore, the condition becomes more widespread and symmetric with time. In nearly all cases, the symptoms and signs progress to affect the contralateral limb and the distal legs.",
"   </p>",
"   <p>",
"    These points are illustrated by a prospectively studied series of 33 patients with diabetic amyotrophy. The following clinical observations were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age of the patients was 65 years (range 35 to 80), and the median duration of diabetes was 4 years (range 0 to 36). All but one patient had type II diabetes. These patients tended to lack evidence of other diabetic end-organ damage such as retinopathy or nephropathy.",
"     </li>",
"     <li>",
"      Diabetic amyotrophy was the presenting feature of diabetes in 21 percent.",
"     </li>",
"     <li>",
"      The most severe symptom at onset was pain in 82 percent and weakness in 18 percent.",
"     </li>",
"     <li>",
"      The distribution of symptoms and signs at presentation was proximal (hip, thigh, buttock, or back) in 64 percent of patients and distal (foot or leg) in the remaining 36 percent.",
"     </li>",
"     <li>",
"      The onset was unilateral in 88 percent of patients. However, bilateral involvement eventually was present in 97 percent; spread to the contralateral limb occurred over a median time of approximately three months.",
"     </li>",
"     <li>",
"      Most patients in the series had proximal and distal sensory loss, and approximately one-half developed new autonomic symptoms such as orthostatic hypotension, urinary dysfunction, constipation, diarrhea, tachycardia, and sexual dysfunction.",
"     </li>",
"     <li>",
"      The majority of patients needed ambulatory aids and approximately one-half required wheelchair assistance at some point during the illness.",
"     </li>",
"     <li>",
"      Weight loss of &gt;10 pounds was recorded in 85 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the same series, the following laboratory findings were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median glycated hemoglobin (A1C) was 7.5 percent (range 5.1 to 12.9 percent)",
"     </li>",
"     <li>",
"      The median fasting plasma glucose was 145",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (8",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      with a range of 75 to 225",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.2 to 12.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      The cerebrospinal fluid protein was typically elevated to a median 90",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      with a range of 44 to 214",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.4 to 11.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cervical and thoracic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper limb and thoracic involvement has also been observed as part of the syndrome of diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Some have pain or weakness involving the chest or abdominal wall, suggesting a thoracic radiculopathy, while others have symptoms consistent with a brachial plexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Arm involvement occurs in up to one-third of patients and may be in the form of mononeuropathies of the ulnar and median nerves, or may affect more proximal sites in the brachial plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Most upper limb symptoms occur in association with lumbosacral plexus involvement.",
"   </p>",
"   <p>",
"    In one retrospective series of 85 patients diagnosed with diabetic cervical radiculoplexus neuropathy who presented with pain, paraesthesia or weakness involving the cervical nerve roots, brachial plexus, or upper extremity nerves, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age was 62 years (range 32 to 83 years).",
"     </li>",
"     <li>",
"      The most common symptom at onset was pain in 62 percent. The most frequent symptoms at evaluation were weakness, pain, and numbness in 99, 81, and 66 percent, respectively. Onset was unilateral in 81 percent, with eventual involvement of the contralateral side in 35 percent. Autonomic symptoms, such as orthostatic dizziness and changes in sweating, were noted in 15 percent.",
"     </li>",
"     <li>",
"      Involvement of the upper, middle, and lower brachial plexus was approximately equal, with each occurring in 50 to 60 percent, and pan plexopathy was present in 30 percent. Involvement of lumbosacral and thoracic regions was noted in 24 and 19 percent. Some patients had isolated or superimposed involvement of the phrenic, long thoracic, axillary, suprascapular, or anterior interosseus nerves.",
"     </li>",
"     <li>",
"      Type 2 and type 1 diabetes mellitus were present in 79 and 7 present. Most of the remaining patients had impaired fasting glucose, gestational diabetes, or steroid-induced diabetes.",
"     </li>",
"     <li>",
"      Among 28 patients who had lumbar puncture, the most common cerebrospinal fluid abnormality was elevated protein.",
"     </li>",
"     <li>",
"      Neurophysiologic testing showed a predominantly axonal neuropathy; nerve biopsy, obtained in 11 patients, was interpreted as showing mainly ischemic injury from microvasculitis.",
"     </li>",
"     <li>",
"      Weight loss &gt;10 lbs was recorded in 35 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are similar in many respects to those described above for diabetic amyotrophy with lower limb involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IDIOPATHIC LUMBOSACRAL RADICULOPLEXUS NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic lumbosacral radiculoplexus neuropathy (LRPN) &mdash; also known as idiopathic lumbosacral plexopathy and lumbosacral plexitis &mdash; is similar to diabetic amyotrophy with respect to its pathophysiology, clinical features, prognosis, and management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like diabetic amyotrophy, patients with idiopathic LRPN present with severe, debilitating pain in one proximal lower limb, typically followed by weakness of the ipsilateral limb and eventual spread to the contralateral limb within weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11,15,18,19\">",
"     11,15,18,19",
"    </a>",
"    ]. As in diabetic amyotrophy, weight loss and autonomic symptoms occur as well.",
"   </p>",
"   <p>",
"    Despite the similarities between diabetic amyotrophy and LRPN, patients with LRPN typically do not go on to develop diabetes. In a retrospective series of 42 patients with LRPN and two or more years of follow-up, diabetes developed in only two (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/15\">",
"     15",
"    </a>",
"    ]. Nevertheless, there may be a low level of diabetic impairment or glucose intolerance in some patients with LRPN, as the median glycated hemoglobin in this cohort was 5.5 percent (range 4.3 to 7.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other laboratory features of idiopathic LRPN are essentially identical to diabetic amyotrophy, including cerebrospinal fluid protein elevation in some to a median 67",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.67",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    with a range of 18 to 283",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.18 to 2.83",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of diabetic amyotrophy is based mainly upon the presence of suggestive clinical features in a patient with known or newly diagnosed diabetes mellitus, and appropriate laboratory investigations, particularly electrodiagnostic studies. In select cases, neuroimaging may be useful to exclude other peripheral and central nervous system etiologies as a cause of the neurologic symptoms and signs.",
"   </p>",
"   <p>",
"    In patients who do not have diabetes, idiopathic lumbosacral radiculoplexus neuropathy is the primary consideration in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Idiopathic lumbosacral radiculoplexus neuropathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cytomegalovirus and HIV can rarely cause a lumbosacral radiculoneuropathy that is similar to diabetic amyotrophy electrophysiologically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link&amp;anchor=H10#H10\">",
"     \"Lumbosacral plexus syndromes\", section on 'Specific disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link&amp;anchor=H27#H27\">",
"     \"Lumbosacral plexus syndromes\", section on 'Infectious, inflammatory, and infiltrative causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sections below will review the evaluation of patients with suspected diabetic amyotrophy or idiopathic lumbosacral radiculoplexus neuropathy. A detailed discussion of the evaluation of lumbosacral plexopathy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link&amp;anchor=H4#H4\">",
"     \"Lumbosacral plexus syndromes\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggested routine blood tests for the evaluation of possible diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy are a complete blood count, coagulation profile, fasting blood glucose, hemoglobin A1C, and sedimentation rate. A glucose tolerance test may be informative for select patients with impaired fasting glucose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with diabetic amyotrophy or idiopathic lumbosacral radiculoneuropathy, electrodiagnostic study findings generally reflect axonal degeneration more than segmental demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. Abnormalities typically involve the lumbar and sacral roots, the lumbosacral plexus, and the lower extremity peripheral nerves. In cases with upper limb symptoms, abnormalities are found in the cervical nerve roots, brachial plexus, or upper extremity nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerve conduction studies show markedly reduced amplitudes of the compound muscle action potentials and sensory nerve action potentials, while conduction velocities show only mild slowing [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/10,15\">",
"       10,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Needle electromyography (EMG) shows fibrillation potentials, decreased motor unit recruitment, and long-duration, high amplitude motor unit action potentials. Paraspinal muscles are often involved [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/6,17\">",
"       6,17",
"      </a>",
"      ]; this finding demonstrates that pathology must exist outside of the lumbosacral and brachial plexuses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the above findings are initially more prominent in proximal muscles, distal and bilateral involvement is likely to develop in the first few months after disease onset.",
"   </p>",
"   <p>",
"    Regardless of the presence of diabetic amyotrophy, patients with diabetes often have electrodiagnostic evidence of other neuropathies, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mild, primarily axonal, length-dependent sensorimotor polyneuropathy",
"     </li>",
"     <li>",
"      Mononeuropathies at typical sites of compression, such as ulnar neuropathies the elbow or median neuropathies at the wrist manifesting as slowed nerve conduction velocity or conduction block at the ulnar groove or carpal tunnel, respectively",
"     </li>",
"     <li>",
"      Thoracic radiculopathies, manifesting as increased fibrillation potentials and positive sharp waves in the corresponding thoracic paraspinous musculature on needle examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging has superseded CT as the imaging method of choice for plexus evaluation. It is useful to rule out other causes of neurologic impairment, such as structural lesions of the lumbosacral plexus, brachial plexus, or spinal cord. Neuroimaging does not provide definitive visualization of pathology in diabetic amyotrophy or idiopathic radiculoplexus neuropathy, but MRI may reveal slightly to moderately increased T2 signal, gadolinium enhancement or enlargement of the nerve roots, plexus, and peripheral nerves (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76544 \" href=\"UTD.htm?30/2/30760\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80779 \" href=\"UTD.htm?3/24/3463\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/17,20,21\">",
"     17,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While clinical improvement is the rule with diabetic amyotrophy, most patients will not recover completely. Foot drop and, at times, lingering neuropathic pain can persist for years. In the series of 33 patients with diabetic amyotrophy cited earlier, 48 percent required wheelchair assistance at some point during the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11\">",
"     11",
"    </a>",
"    ]. At a mean follow-up of two years, 9 percent needed a wheelchair and only 6 percent felt they had recovered completely. In another study that reported two patients with diabetic amyotrophy who progressed to fulminant quadriparesis, one patient remained wheelchair-bound and severely disabled at 42 months, while the other made a good recovery with mild residual truncal and proximal leg weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasional patients have recurrent attacks of diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11\">",
"     11",
"    </a>",
"    ], although the precise rate of recurrence is uncertain.",
"   </p>",
"   <p>",
"    Idiopathic lumbosacral radiculoplexus neuropathy is also associated with long-term morbidity with residual pain, weakness, and sensory symptoms predominating [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. Like diabetic amyotrophy, recurrent bouts have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/11,24,25\">",
"     11,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No treatments are proven to be effective for diabetic amyotrophy or for the clinically similar condition of idiopathic lumbosacral radiculoplexus neuropathy.",
"   </p>",
"   <p>",
"    The results from some [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/12,16,26\">",
"     12,16,26",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/9\">",
"     9",
"    </a>",
"    ] retrospective studies suggested that treatments employing immune suppression were associated with clinical improvement in diabetic amyotrophy. These regimens included such therapies as oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , intravenous immune globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and plasma exchange.",
"   </p>",
"   <p>",
"    However, a 2012 systematic review found no published randomized controlled trials evaluating immunotherapy for diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/27\">",
"     27",
"    </a>",
"    ]. A blinded randomized controlled study presented only in abstract form found that pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    therapy was",
"    <strong>",
"     not",
"    </strong>",
"    beneficial compared with placebo for functional improvement in diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no compelling data to support the use of intravenous immune globulin for the treatment of diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small retrospective studies reported that immunomodulatory therapies were helpful in the recovery of LRPN [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20631/abstract/15,30-32\">",
"     15,30-32",
"    </a>",
"    ]. However, there have been no randomized controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Symptomatic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic management of diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy should be approached from a multidisciplinary standpoint. Although data are scant, clinical experience suggests that the concurrent use of narcotic analgesics and agents for neuropathic pain is beneficial in the initial phase. Neuropathic pain treatments include tricyclic antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of diabetic neuropathy\", section on 'Pain control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antidepressants may be helpful to combat the emotional component of the illness. Physical and occupational therapy with emphasis on exercise, gait training, and",
"    <span class=\"nowrap\">",
"     equipment/orthotic",
"    </span>",
"    needs should round out the therapeutic regimen. Patient education and reassurance are a necessity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=see_link\">",
"       \"Patient information: Nerve damage caused by diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"       \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic amyotrophy is not a pure lumbosacral plexopathy because it also affects the lumbosacral nerve roots and lower extremity peripheral nerves. In addition, it may involve cervical nerve roots, brachial plexus, or upper extremity nerves. The most likely cause of diabetic amyotrophy and the clinically similar condition of idiopathic lumbosacral radiculoplexus neuropathy is ischemic injury from a nonsystemic microvasculitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic amyotrophy typically occurs in patients with type 2 diabetes mellitus. The traditional features include the acute, asymmetric, focal onset of pain followed by weakness involving the proximal leg, with associated autonomic failure and weight loss. Progression occurs over months and is followed by partial recovery in most patients. However, onset in the distal leg is not uncommon. Furthermore, the condition becomes more widespread and symmetric with time. In nearly all cases, the symptoms and signs progress to affect the contralateral limb and the distal legs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upper limb and thoracic involvement has also been observed as part of the syndrome of diabetic amyotrophy. Symptoms and signs reflect involvement of cervical or thoracic nerve roots, brachial plexus, or upper extremity nerves. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cervical and thoracic involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic lumbosacral radiculoplexus neuropathy is similar to diabetic amyotrophy with respect to its pathophysiology, clinical features, prognosis, and management. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Idiopathic lumbosacral radiculoplexus neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of diabetic amyotrophy is mainly based upon the presence of suggestive clinical features in a patient with known or newly diagnosed diabetes mellitus. Appropriate laboratory investigations, particularly electrodiagnostic studies, and neuroimaging in select patients, are useful to exclude other peripheral and central nervous system etiologies as a cause of the neurologic symptoms and signs. In patients who do not have diabetes, idiopathic lumbosacral radiculoplexus neuropathy is the primary consideration in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While clinical improvement is the rule with diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy, most patients do not recover completely. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No treatments are proven to be effective for diabetic amyotrophy or for idiopathic lumbosacral radiculoplexus neuropathy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/1\">",
"      GARLAND H. Diabetic amyotrophy. Br Med J 1955; 2:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/2\">",
"      Bruns, L. Ueber neuritsche Lahmungen beim diabetes mellitus. Berlin Klin Wochenschr 1890; 27:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/3\">",
"      Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol 1991; 48:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/4\">",
"      GARLAND H, TAVERNER D. Diabetic myelopathy. Br Med J 1953; 1:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/5\">",
"      Williams IR, Mayer RF. Subacute proximal diabetic neuropathy. Neurology 1976; 26:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/6\">",
"      Bastron JA, Thomas JE. Diabetic polyradiculopathy: clinical and electromyographic findings in 105 patients. Mayo Clin Proc 1981; 56:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/7\">",
"      Thomas PK. Clinical features and investigation of diabetic somatic peripheral neuropathy. Clin Neurosci 1997; 4:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/8\">",
"      Katz JS, Saperstein DS, Wolfe G, et al. Cervicobrachial involvement in diabetic radiculoplexopathy. Muscle Nerve 2001; 24:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/9\">",
"      Zochodne DW, Isaac D, Jones C. Failure of immunotherapy to prevent, arrest or reverse diabetic lumbosacral plexopathy. Acta Neurol Scand 2003; 107:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/10\">",
"      Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999; 53:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/11\">",
"      Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002; 25:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/12\">",
"      Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994; 35:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/13\">",
"      Llewelyn JG, Thomas PK, King RH. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 1998; 245:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/14\">",
"      Kelkar P, Masood M, Parry GJ. Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy). Neurology 2000; 55:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/15\">",
"      Dyck PJ, Norell JE, Dyck PJ. Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety. Brain 2001; 124:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/16\">",
"      Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997; 72:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/17\">",
"      Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain 2012; 135:3074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/18\">",
"      Sander JE, Sharp FR. Lumbosacral plexus neuritis. Neurology 1981; 31:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/19\">",
"      Evans BA, Stevens JC, Dyck PJ. Lumbosacral plexus neuropathy. Neurology 1981; 31:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/20\">",
"      Ishii K, Tamaoka A, Shoji S. MRI of idiopathic lumbosacral plexopathy. Neurology 2004; 63:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/21\">",
"      Cianfoni A, Luigetti M, Madia F, et al. Teaching NeuroImage: MRI of diabetic lumbar plexopathy treated with local steroid injection. Neurology 2009; 72:e32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/22\">",
"      Taylor BV, Dunne JW. Diabetic amyotrophy progressing to severe quadriparesis. Muscle Nerve 2004; 30:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/23\">",
"      Hinchey JA, Preston DC, Logigian EL. Idiopathic lumbosacral neuropathy: a cause of persistent leg pain. Muscle Nerve 1996; 19:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/24\">",
"      Yee T. Recurrent idiopathic lumbosacral plexopathy. Muscle Nerve 2000; 23:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/25\">",
"      Awerbuch GI, Nigro MA, Sandyk R, Levin JR. Relapsing lumbosacral plexus neuropathy. Report of two cases. Eur Neurol 1991; 31:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/26\">",
"      Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995; 52:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/27\">",
"      Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev 2012; 6:CD006521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/28\">",
"      Dyck PJ, O'Brien P, Bosch EP, et al. The multi-centre double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology 2006; 66 Suppl 2:A191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/29\">",
"      Donofrio PD, Berger A, Brannagan TH 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 2009; 40:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/30\">",
"      Bradley WG, Chad D, Verghese JP, et al. Painful lumbosacral plexopathy with elevated erythrocyte sedimentation rate: a treatable inflammatory syndrome. Ann Neurol 1984; 15:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/31\">",
"      Verma A, Bradley WG. High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy. Neurology 1994; 44:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20631/abstract/32\">",
"      Triggs WJ, Young MS, Eskin T, Valenstein E. Treatment of idiopathic lumbosacral plexopathy with intravenous immunoglobulin. Muscle Nerve 1997; 20:244.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5268 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BAD001EFC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20631=[""].join("\n");
var outline_f20_9_20631=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cervical and thoracic involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IDIOPATHIC LUMBOSACRAL RADICULOPLEXUS NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory investigations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Symptomatic management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5268|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/2/30760\" title=\"diagnostic image 1\">",
"      MRI diabetic amyotrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/24/3463\" title=\"diagnostic image 2\">",
"      Idiopathic LS plexopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5268|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/61/26587\" title=\"table 1\">",
"      Causes of lumbosacral plexopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=related_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=related_link\">",
"      Lumbosacral plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=related_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=related_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=related_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_9_20632="Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention";
var content_f20_9_20632=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20632/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20632/contributors\">",
"     David R Holmes, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20632/contributors\">",
"     Paul Sorajja, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20632/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20632/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20632/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20632/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20632/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/9/20632/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5971548\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprocedural and long-term antithrombotic (anticoagulant or antiplatelet) therapy is an integral part of percutaneous coronary intervention (with either coronary artery stenting or percutaneous transluminal coronary angioplasty). Antithrombotic therapy has been shown to prevent periprocedural and long-term cardiovascular events such as stent thrombosis and recurrent myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current antithrombotic regimens have the potential to result in either new gastrointestinal (GI) bleeding or to exacerbate chronic episodic GI bleeding. For those with GI bleeding, there is significant attributable morbidity and mortality. However, in many such patients, alternatives to percutaneous coronary intervention (PCI) may be limited. Given the fact that over one million PCI procedures are performed annually, and that antithrombotic therapy has become more aggressive, there is a need to understand the unique challenges in the prevention and management of GI bleeding in this patient population. Furthermore, with the increasing adoption of a radial as compared to femoral artery approach, GI bleeding may be the most common type of bleeding associated with PCI.",
"   </p>",
"   <p>",
"    This topic focuses on periprocedural and long-term GI bleeding in patients undergoing PCI. Issues of GI bleeding in patients on chronic anticoagulant or nonsteroidal antiinflammatory therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periprocedural bleeding not related to the GI tract in patients undergoing PCI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=see_link\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971556\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While strict definitions of peri-procedural bleeding in PCI patients have been adopted, there is less consensus on what constitutes clinically significant GI bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=see_link\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Common types of GI bleeding in PCI patients are the occurrence of hematemesis, melena, or red blood per rectum, and endoscopic evidence of the source of GI bleeding. Significant reduction in hemoglobin (&ge;2",
"    <span class=\"nowrap\">",
"     g/dl)",
"    </span>",
"    or need for transfusion has also been required in some, but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971563\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker, which is common after PCI with stenting, is associated with an increased risk of GI bleeding (overall incidence of 0.7 to 2.4 percent at 30 days), which accounts for approximately 15 percent of all periprocedural bleeding events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/1-3,5,6\">",
"     1-3,5,6",
"    </a>",
"    ]. This increase in early GI bleeding has also been associated with the intensity of antithrombotic therapy, advanced age, primary PCI for ST-elevation myocardial infarction, shock or inotrope requirement, cardiac arrest, baseline anemia, smoking, diabetes, duration of antithrombotic study drug administration, female sex, prior stroke, chronic kidney disease, and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk factors for GI bleeding in patients on long-term therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are a history of complicated peptic ulcer disease, bleeding (15 percent recurrence of GI bleeding at one year on 100 mg aspirin per day for example), or at least two of the following: age &gt;65 years (1 percent per year increase per decade), concurrent use of a second nonsteroidal antiinflammatory drug (two- to fourfold increase in risk), glucocorticoid therapy, or anticoagulant, high-dose aspirin or nonsteroidal antiinflammatory drug, a history of an uncomplicated ulcer, or Helicobacter pylori (H. pylori) infection (fivefold increase in risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10194391\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    <strong>",
"    </strong>",
"    (and other",
"    <strong>",
"    </strong>",
"    nonsteroidal antiinflammatory drugs) cause gastrointestinal bleeding due to their irritation of the gastroduodenal mucosa. However, for patients undergoing PCI with stenting, withholding aspirin is an option only in rare cases. These issues are discussed in detail elsewhere (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971578\">",
"    <span class=\"h2\">",
"     Platelet P2Y12 receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    and other platelet P2Y12 receptor blockers inhibit platelet activation by binding the platelet adenosine diphosphate ADP receptor, leading to inhibition of ADP-dependent activation of the glycoprotein IIb-IIIa complex. While the use of these drugs is associated with an increase in the risk of GI bleeding, the magnitude of the increase has not been well studied. In a large cohort study from Denmark that included over 75,000 patients who took clopidogrel, the long-term risk of GI events (bleeding, ulcer, or gastritis) increased from about 2 to about 6 percent, comparing never-users to users [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/12\">",
"     12",
"    </a>",
"    ]. Among individuals taking no antiplatelet therapy, the crude risk of GI events was 1.6 percent; among non-clopidogrel",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    users, the risk was 4.1 percent; among clopidogrel non-aspirin users, the risk was 6.1 percent; and among patients on both agents the risk was 6.6 percent.",
"   </p>",
"   <p>",
"    Platelet P2Y12 receptor blockers are not believed to be directly ulcerogenic. In a Scandinavian study of healthy volunteers with upper endoscopy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75 mg per day), unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (325 mg per day), was not associated with macroscopic changes in gastroduodenal mucosa after eight days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, some have advocated P2Y12 receptor blocker monotherapy for patients with gastrointestinal intolerance to aspirin. However, clopidogrel and other adenosine diphosphate-receptor antagonists can impair ulcer healing, and have been associated with increased hemorrhagic risk in patients with a prior history of GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Platelet aggregation leads to the release of platelet-derived growth factors (eg, vascular endothelial growth factor or VEGF) that promote angiogenesis and endothelial cell proliferation required for ulcer healing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newer agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ) have been examined in conjunction with daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use for risk of periprocedural bleeding in PCI patients. In these studies, the rates of bleeding not related to cardiac surgery have ranged from 2.4 to 5.5 percent. However, these studies have not specifically reported on the incidences or outcome from GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971585\">",
"    <span class=\"h2\">",
"     Dual antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence, predictors, and outcomes of GI bleeding were evaluated in an observational study of 1852 patients who underwent PCI with drug-eluting stent placement and were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/20\">",
"     20",
"    </a>",
"    ]. The rate of GI bleeding was 2.7 percent; a history of GI bleeding was the most important independent predictor of future GI bleeding (odds ratio 5.0). The 30-day mortality after GI bleeding was 3.7 compared to 0 percent in a group of comparable individuals who had not bled.",
"   </p>",
"   <p>",
"    Little or no data exist on periprocedural incidence of GI bleeding, possibly due to the subacute time course required for pathogenesis in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971608\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;GI bleeding is associated with increased early and late mortality, as well as ischemic outcomes and a higher incidence of stent thrombosis. The reasons for poorer outcome in patients with GI bleeding are not clear, but bleeding may be either directly causative or be a marker for morbidity and heightened patient risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=see_link&amp;anchor=H13#H13\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\", section on 'Clinical outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are examples of this association:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A comprehensive evaluation of the prognostic impact of GI bleeding was performed in the ACUITY trial of 13,819 ACS patients (7789 patients with PCI) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/3\">",
"       3",
"      </a>",
"      ]. GI bleeding occurred in 1.3 percent and was a significant independent predictor of outcomes at 30 days with hazard ratios of 4.87 for mortality, 1.74 for nonfatal myocardial infarction, and 1.94 for composite ischemia. The increased risk of each of the endpoints persisted at one-year follow-up Moreover, the stent thrombosis rate was significantly higher than in those with, as compared to those without, GI bleeding (5.8 versus 2.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/3\">",
"       3",
"      </a>",
"      ]. In a study examining patients enrolled in the Primary Angioplasty in Myocardial Infarction (PAMI) trials, GI bleeding was associated with a significantly longer hospital stay (12.6 &plusmn;13 days vs. 6.4 &plusmn;5.3 days) and a higher incidence of death both in-hospital (10 versus 2.8 percent) and at six-month follow-up (14 versus 4.6) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of over 20,000 PCI patients, the 30-day mortality was significantly increased in those with GI bleeding compared to those without (20.5 versus 2.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The CHARISMA trial enrolled patients with either established atherosclerosis or multiple risk factors, and randomized patients to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or placebo, in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 mg to 162",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      GI bleeding was more common in the clopidogrel-treated patients, occurred most frequently in the first year of the study, and was independently and significantly associated with all cause mortality (1.82, 95% CI, 1.24 to 2.69) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971615\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;GI bleeding in a patient who has recently undergone percutaneous coronary intervention (PCI) poses unique therapeutic challenges. The need to attain hemostasis often requires the premature discontinuation of antithrombotic therapies, which leads to an increased risk of recurrent myocardial ischemic events, including stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H11407792#H11407792\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Risk of bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, acute bleeding itself leads to platelet activation and initiation of the clotting cascade for hemostasis, potentially increasing the risk of thrombosis in the absence of antiplatelet therapy.",
"   </p>",
"   <p>",
"    In the event of acute GI bleeding, the decision to discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , P2Y12 receptor blockers, or other antithrombotic therapy is made on an individual patient basis, balancing the likelihood and consequences for either a thrombotic or a hemorrhagic event action [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/24\">",
"     24",
"    </a>",
"    ]. The following should be kept in mind when deciding further management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      while continuing a P2Y12 receptor blocker has not been shown to reduce recurrence of GI bleeding or its complications. Monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      is potentially associated with an increased risk of stent thrombosis, although one small study suggested comparable efficacy with ticlopidine monotherapy compared to ticlopidine plus aspirin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple, randomized trials have demonstrated increased risk of ischemic events in PCI patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      monotherapy in comparison to dual antiplatelet therapy (aspirin and P2Y12 receptor blocker) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/26-30\">",
"       26-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Efforts should be made to continue antiplatelet therapy unless the bleeding is life threatening, particularly if coronary stenting has been recently performed.",
"     </li>",
"     <li>",
"      For patients with clinically suspected GI bleeding, a gastroenterology evaluation should be pursued in a timely fashion, with appropriate endoscopy performed for both confirmation of the diagnosis and deliverance of therapy. It is important to note that bleeding from endoscopy itself can occur, with a risk that varies according to procedure type and whether mucosal biopsies are performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"       \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients for whom it has been determined that antiplatelet therapy absolutely needs to be discontinued, there are no data on optimal timing for reintroduction of these agents or the appropriate doses that should be used. One small, prospective investigation (n=156) examined reintroduction of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in patients with cardiovascular disease and GI bleeding. All patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      and then randomly assigned to either aspirin 80 mg daily or placebo after endoscopic therapy. Patients in the aspirin group had a nonsignificant increase in the incidence of recurrent GI bleeding (10.3 versus 5.4 percent; p=0.25), but demonstrated a significantly lower all-cause mortality (1.3 versus 12.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/31\">",
"       31",
"      </a>",
"      ]. In the placebo group, 5 of the 10 deaths were attributed to cardiovascular causes.",
"     </li>",
"     <li>",
"      Blood transfusion may be considered in patients with GI bleeding. However, the benefit of transfusion for periprocedural bleeding remains controversial, with some studies demonstrating the potential for harm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=see_link&amp;anchor=H25#H25\">",
"       \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\", section on 'Blood transfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proton pump inhibitors (PPI) promote ulcer healing and prevent recurrence. Thus, for patients with GI bleeding, we recommend treatment with a PPI. The role of PPI in the management of GI bleeding related to ulcer disease is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"       \"Overview of the natural history and treatment of peptic ulcer disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link\">",
"       \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079756#H5079756\">",
"       \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Acid suppression'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      The potential interaction between PPI and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H32#H32\">",
"       \"Nonresponse and resistance to clopidogrel\", section on 'Proton pump inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971641\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary prevention of gastrointestinal toxicity from nonsteroidal antiinflammatory drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Prevention strategies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108005888\">",
"    <span class=\"h2\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;With regard to bleeding after PCI, observational studies have suggested that the use of proton pump inhibitors (PPIs) is associated with a significantly lower incidence of upper GI bleeding within the first 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/2\">",
"     2",
"    </a>",
"    ]. The COGENT trial tested the hypothesis that PPI therapy reduces the risk of GI bleeding in patients on long-term dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/32\">",
"     32",
"    </a>",
"    ]. In this trial, 3761 patients with an acute coronary syndrome or undergoing percutaneous coronary intervention were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg or placebo daily. The following findings were noted with omeprazole therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary GI endpoint (a composite of overt or occult GI bleeding, symptomatic gastroduodenal ulcers or erosion, obstruction, or perforation) was significantly reduced (1.1 versus 2.9 percent; hazard ratio 0.34, 95% CI 0.18-0.63) at 180 days.",
"     </li>",
"     <li>",
"      The rate of overt upper GI bleeding was significantly reduced (hazard ratio 0.13, 95% CI 0.03-0.56).",
"     </li>",
"     <li>",
"      There was no negative impact of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      therapy on the primary composite cardiovascular endpoint in the COGENT trial (hazard ratio 0.99, 95% CI 0.68-1.44), despite some concern from observational studies that PPIs might have an adverse effect on cardiovascular outcomes in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H184413231\">",
"       'Potential interaction with clopidogrel'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      However, because of the small number of cardiovascular events (109), the 95 percent confidence limits for this hazard ratio include a 32 percent decrease in cardiovascular events as well as a 44 percent increase in such events, leaving open the question of a clinically meaningful difference in CV events due to the use of a PPI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H32#H32\">",
"       \"Nonresponse and resistance to clopidogrel\", section on 'Proton pump inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In terms of secondary prevention, proton pump inhibitors (PPIs) reduce the risk of recurrent upper gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H10#H10\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Secondary prevention of GI bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184413231\">",
"    <span class=\"h3\">",
"     Potential interaction with clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports in 2008 and 2009 raised concerns that some PPIs interfere with the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to inhibit platelet function and thereby increase the likelihood of coronary artery stent thrombosis (ST), myocardial infarction, or cardiovascular death. In addition, there may be genetic factors that influence the risk of drug interactions and the effectiveness of clopidogrel. More data are needed to clarify in which patients the risk of gastrointestinal bleeding outweighs the risk of a cardiovascular event associated with the possible drug interaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H41#H41\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H32#H32\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The COGENT trial, discussed in the section above, gives reassurance of the safety of PPI therapy in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198538053\">",
"    <span class=\"h3\">",
"     Recommendations for use of PPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend gastrointestinal prophylaxis for all patients undergoing PCI who are at high risk of an adverse gastrointestinal event consequent to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (or any other P2Y12 receptor blocker). Our approach to identifying patients at high risk for gastrointestinal bleeding is discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H5971563\">",
"     'Incidence and risk factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of a PPI in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a P2Y12 receptor blocker not at high risk is also reasonable. PPI should be started as soon as possible after the initiation of dual antiplatelet therapy and continued indefinitely. For these lower-risk patients, factors such as complexity of the medical regimen, cost, or concern for the potential interaction between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and PPIs should be taken into account when deciding whether to prescribe PPIs indefinitely.",
"   </p>",
"   <p>",
"    These recommendations are consistent with those made in the 2010 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Gastroenterology/American",
"    </span>",
"    Heart Association expert consensus document on the concomitant use of PPI and P2Y12 receptor blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20632/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108005881\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;H2 receptor antagonists have",
"    <strong>",
"     not",
"    </strong>",
"    been shown to prevent ulcer bleeding in patients taking dual antiplatelet therapy, and are therefore of unproven benefit as an alternative to proton pump inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H18#H18\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'H2 receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the known ulcerogenic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , the lowest dose for therapeutic efficacy should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H2#H2\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H10#H10\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Dose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H7#H7\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5971648\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal (GI) bleeding occurs in 1.2 to 2.4 percent of percutaneous coronary intervention (PCI) patients. (See",
"      <a class=\"local\" href=\"#H5971563\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GI bleeding is associated with increased early and late mortality, including a heightened risk of stent thrombosis. (See",
"      <a class=\"local\" href=\"#H5971608\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk factors for GI bleeding can be identified preprocedurally. (See",
"      <a class=\"local\" href=\"#H5971563\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and a P2Y12 receptor blocker (see",
"      <a class=\"local\" href=\"#H5971641\">",
"       'Prevention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients felt to be at high risk of GI bleeding, we recommend GI prophylaxis with a proton pump inhibitor (PPI) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      For patients felt not to be at high risk of GI bleeding, we suggest GI prophylaxis with a PPI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Such therapy should be started as soon as possible after the initiation of dual antiplatelet therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the event of GI bleeding, appropriate management includes timely gastroenterology evaluation, endoscopy, and PPI administration. (See",
"      <a class=\"local\" href=\"#H5971615\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antithrombotic therapy should not be withheld unless the GI bleeding is life threatening. (See",
"      <a class=\"local\" href=\"#H5971615\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/1\">",
"      Abbas AE, Brodie B, Dixon S, et al. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 96:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/2\">",
"      Chin MW, Yong G, Bulsara MK, et al. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 2007; 102:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/3\">",
"      Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/4\">",
"      Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med 2009; 48:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/5\">",
"      Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv 2009; 2:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/6\">",
"      Gaglia MA Jr, Torguson R, Gonzalez MA, et al. Correlates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention. Am J Cardiol 2010; 106:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/7\">",
"      Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/8\">",
"      Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/9\">",
"      S&oslash;rensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/10\">",
"      Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007; 23:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/11\">",
"      Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/12\">",
"      Grove EL, W&uuml;rtz M, Schwarz P, et al. Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med 2013; 28:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/13\">",
"      Fork FT, Lafolie P, T&oacute;th E, Lindg&auml;rde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 2000; 35:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/14\">",
"      Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med 2005; 352:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/15\">",
"      Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/16\">",
"      Ma L, Elliott SN, Cirino G, et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 2001; 98:6470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/17\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/18\">",
"      Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/19\">",
"      Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/20\">",
"      Alli O, Smith C, Hoffman M, et al. Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Clin Gastroenterol 2011; 45:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/21\">",
"      Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010; 121:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/22\">",
"      Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/23\">",
"      Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/24\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/25\">",
"      Machraoui A, Germing A, Lindstaedt M, et al. Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study. J Invasive Cardiol 2001; 13:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/26\">",
"      Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/27\">",
"      Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/28\">",
"      Sch&ouml;mig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/29\">",
"      Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/30\">",
"      Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/31\">",
"      Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/32\">",
"      Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/33\">",
"      Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010; 153:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20632/abstract/34\">",
"      Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 122:2619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13605 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-E63CECF6F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20632=[""].join("\n");
var outline_f20_9_20632=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5971648\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971548\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971556\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971563\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10194391\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5971578\">",
"      Platelet P2Y12 receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5971585\">",
"      Dual antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971608\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971615\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971641\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108005888\">",
"      Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184413231\">",
"      - Potential interaction with clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H198538053\">",
"      - Recommendations for use of PPI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108005881\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971648\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40089?source=related_link\">",
"      Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_9_20633="Intermediate case 13 answer";
var content_f20_9_20633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Hypercalcemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 331px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFLAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1/TrHTHt5S9nZMfMuBk2g7TnHf049hxSahY6YlrEVsrJT5tuMi0HQzjPf049xxUunPMttNixvG/eXJyEg/wCfg/7X+e3FN1CSZrWLNjeKPNtzkpB/z8D/AGv8nrxT93lPrOaftfi+138y0NO0rzYP9AsPvnP+hj++evPNVLKx0z+0pEaysiot7Y4NoCMmR8nr6Yz61f8AMn823/4l97zIf4Lf++f9qqli851KQ/Ybwk29rwEgyP3knPLf5703ymcZT5Ze/wDj5ktvp+leau6xsSPOHW0B4w36dOKrWdjpj6RbsbKyLmCEk/ZBknnPOf8A9dXbaSczKBp97/rgOFg9G9W/+t+lVbSSZdHtsWF4QIIOQkGD1/2s/wCeafu3HzT19/quvqSS2GlLPYj7FYgNMgb/AEMcjyX68884/Hmki07S8pmxsf8AUDObQddh/X3qWV5zPY/6Bej9+mPkt+f3L/7X+frSRSzlo/8AiX3v/HuD92D+4f8Aa/8Ar0ly6k807fH07rzK1rY6W2o3waysSqzRhR9kGAPIHQZ9efrzTb+w0xNGnZbKyDi3mIItRkHyuDn6/l1qa1ecalff6DeEmaPjZBkf6OP9r8f/AK9Mv5J20afNheAG3m5KwYH7r/ez/n1pe7Y0Up+0j7/SPXyHNp+lmBSLGyycf8ugH/LIe/r/AI1DfWOmDU4lWysgrJdHAtQASAmO/bnHpVppZxAP9AvOo52Qf88h/tf5+tQ3zzf2nGTY3gKpd8FYMnhPRu3f9Kb5bIKcp8y9/o+vkyafTtK82fFjY4wcYtAO6dOeO/6+tV7Cx0x0uy1lZHE10Bm0HAEgwBzxgdPSrlxLOJbj/iX3vAP8MHqn+1/n86r2DzKl4BY3jfvrs8JBx+8HH3vz/Sj3bomMp8nx/j5EGq2OmpYMyWdkrbkGRagH/j4H9OPpxV+XTtK8+LFhYY81s/6GAMeYPf07fhVPVXnbT2BsbxRuQ5KwY/4+B/tfh9fatCaSf7RCP7PveZmH3Lf/AJ6D/a/z9KPduDlPlXv9X18kUobDS/tgU2Vjt8hDg2gPPnHnr6fpxU9vp2lee+bGxI85cZtAeNzfp04/wpkDzm8VvsF5n7OnAWD/AJ7Hn73+fpU1vLObh/8AiX3v+vUfdg/vP/tf/W/Shcuopynr7/4opWFhpj6dAzWVkWMSZJtRknzDnv6f4Ut7Y6Yv9n7bKxGbm3VsWg5GDkHnn39adYSTrpsAFjeEeVHyFgwf3h/2v89+KdevOw07NjeD/SbYjKwc8NwPm/n+NL3eUvmn7R+/1fUfBp2lbos2Nif3Qzm0B5w/v9Ofp6VWsrHTDqdyrWVkUU2+AbQEDMTZ4+vX161dt5Zy0P8AxL73mIHhYPR/9r/P5VWsXn/tS4Isbwktb8BYMj903+1/nvzTfLclSnafv9O/mhsun6YumyEWVkHEbnP2UZ/1Pr9f15pIrDTG06ImysixjQ5+yjP+p9fr+vNSSyztpj/6BeAGN+dsGP8AUf72f8+tJFLOumx/6BeECNOdsGP9R/vZ/wA+tP3blc07fH+JFf2OmDUrdUsrIKxuMgWgAOIhj9enoeatT6dpW6XFjY/6o4xaAc4T/wCvz/jUOoSTf2lATY3gKm44KwZP7pfRv89uatXEs4ab/iX3vERPKQeif7X/ANf9aS5SXKdoe/07+bKllY6Y39obrKxOLm4Vc2g4GBgDnj29KZqlhpiaZcMllZKwR8EWoBH70e/p/hU9i86/2jixvD/pNyThYOOF4Pzfy/Co9VkmbTLgGxvFGx+SsGB+9H+1/ntxS93lLUp+1j7/AFXUtXOnaV58eLGwA85s4tAON6/p14qtLYaZ9qKiyssfZ3OBaDr5w56+n6cVdupJxcR/8S+9/wBcw5WD++v+1/8AW/Wq0rz/AGot9gvP+Pd+NsH/AD2HP3v8/Sm+UypynZe/+KJYdO0r7TNmwsMeauAbMEY8w+/HHb8Kp6bY6Y9ijPZWTN83JtRn/Xn+nH04rQhln+1Tj+z73IlUfdt/+eh/2v8AP0qlpsk62KAWN4w+Y5Cwf89z/tf5+lHu3GpT5X7/AFXXyYl/Y6YkdpssrEEz2oOLQcgvyDzznv61Yt9O0rzYN1jY4285tAe7+/Pb/IqO/edorPNjeL+/tDykHP7w8fe/L9asW0s5mt/+Jfe8r/cgPd/Vv5/4Ue7dhKU/Z/H+PkULKx0w6nKrWVkVVLU4NqCBkPnv34z61Mmn6WLck2Nlkc5NqD/yyPv6/wCNNsXnOpyEWN4SUtOAsGRw/q3f/wDXUscs5tv+PC8577YP+eR/2v8AP1oXLYupKfM/f6Lr5FewsNMfRoGaysi5t4SSbUZJ8rk5+v59aW7sdMXULJVsrIK0sgIFoMEfZz7+vP15p1hJOujQYsLwgW8PIWDB/df72f8APrTrx5jqFlmxvARNJwUgyf8ARz/tfj/9el7th80/aS9/pLr5D5dO0vDYsbH/AFB6WgHOxffr70y2sdLabUAbKxIW4cL/AKGOB5S8DnjnP481PLLP83/Evvf9QT92D+4v+1/9em27zifUP9AvD/pEmfkt+P3KcH5v5fzpvl0M1KfK/f6d15FW8sNMTSrhlsrIOIJiD9lGQeMc5/8A1Vau9O0rzPlsbEDzj0tAOPl/T2qC8knbSbjNjeKDbz8lIMDp/tZ/zxVu8lnEnOn3v+vI5WD/AGfRv/rfrT924+aenv8AV9fQqXdhpf29VWysgpguDgWgHPmJjv6Zx6VaGnaT50/+gWGPMGP9DHTeOnPFQ3rzi/BNheDFvc8FIM/6xPRv89uKtLJP58//ABL73iQD7lv/AHx/tUlykylPlj7/AOK7mbp9jpj2spaysmPm3AybUdBOcd/Tj2HFO1Ox0xLeIpZWSnzLcEi0HecZ7+nB9RxS6fJMLWXFjeMPNuDkJB/z8H/a/wAnpxTtTedreEGxvF/eWxyUg/57j/a/z34pe7ymvNP2vx/a7+ZMmnaV58H+g2ON3P8Aog/vnr6/5FVLSx0w6mymzsiohtjg2gIzvkz374GfWrySz+fbj+z73lv7sH/PRv8Aa/z9Kq2jzHU2IsbwkwWowEgz/rJP9r/PftTfKRGU7S9/8fMmh0/SsjNjY/6wdbQH+Fvf6VV0qx0x9EtGeysmka2hJY2oJJ2nPOevv3q7BLOSMafe/wCsUfcg/ut/tf5/Kq2kyTjQrTFjeMBbQfMEgwflPP3s/wBfWj3bhzT5X7/VdfUbcWOmLe6cBZWQVrgBh9kGCPs7cHnnnB+vNTPp2l5GLGx/1H/PoOuw/r70k7zm+03/AEG8BFyMDZBz/o7cD5vx5/nUsks+R/xL73/j3z92D+4f9r/69C5bsHKfu+/07+bI7ew0pru6BsbEhZlAH2McDyB7+vP15qGew0xdHuGFlZBxDMQfsoyDsGOf84q1bvOLu6/0C9JMy8bLfj/Rx/tf5+tQzSTto1x/oF4AYJudsGB8g/2s/wCeKPdsClPmXv8Abr5HM+cr/FW90Iafp39lpo0WoqTaKrBzIYzj2Pp6jPHNdFqFjpg1KBVsrIK0d0SBaAAkbMd+3OPSuUEjL8eL/fazxOfC0YVG8vdJ/pJ5AU7R+fauv1F5xqUJNjeAiK74KQZP3PRu3f8ASloYYStUnJpy2v18iWXTtK3XWLGx9v8ARAO69OeO/wDk1Us7HTHivC1lZEie6A/0UcASDAHPHHT0q/LLPuu/+Jfe8f7MHqn+1/L/ABqpZvMsN5ixvD++ujwkHH7wcfe7f/qp+7dG8JT5Pj7dfIj1ax01LAsllZK2Y+RagH/Xrnv6cfTirh07SvOi/wBAscea2f8ARB08we/p29OKrau8xsCDY3ijMZyVg/5+F9G/D/61XWln86L/AIl97zKw+5B/z1A/vf5+lHu3BynyL3+r6+SM6Gx0z+0yhsrLaLaE4+ygjPnNk9fT8xxV2PTtK8//AI8bDHmr1tB03N+nTj/Cq0Mk39qFvsN5k20Py7IM/wCvbn73+e/FXY5J/tP/ACD73/XIPuwf3n/2v/rfpQuUKsp6+/8AivI5nwffaLq9te2Q02BLvTPIimMtmuX3jcHBz0I455OK23sNMV7P/QrEAzQg/wCiA5Gxs5/zzXl/wavnuPGPxAKwTStG9jFsQISNvmLzuIFeqM87PZf6BeD99AR8sHP7tv8Aa/z3pK3LqRCrUnKbcusuvmA07S/Oh/0Gxx5Iz/og67W/Xpz/AIU22sNLN7MGsrEqskPH2QHA8rnv6/41MJZ/OhH9n3vMIP3YP7r/AO1/9f8ASmWrz/bZT9gvDmSHgLBx+5/3v89+ab5Suadn7/Tuu5C+n6Yulyn7FZBxFIc/ZBkHyvX6/rzUunWGmG0iLWVkSY4yT9lHJ8tc96RpJ20mX/QLwAxSc7YMD91/vZ/z61Lpsk/2SICxvDiOPnbBz+7X/ao924SlPlfv/iQ6Yx+yy8Wn+tuP7v8Az3Pv+XtSakx+yRf8en+ut+u3/nuPf/Ip2nQzm2mIurlf3lzwFg/5+D7f57cUmoQTi0izdXLfvbfqsH/PwPb/AD34ov7uw9Pa7r4vPv6F3efMg4tPvn+5/fPXmqdk5/tWbi0/49rbrs/56Se/51dEE/m23+l3X+sP8MH98+1U7CCf+05B9quci3teQsHP7yT1H+e9NvyM425Zar8e/oWbdz5q8Wv+tHXbjo3v0/8ArVVsWP8AY1txa/6iHptz39/zq3bW8/nr/pd1/r16LB6P7f8A1v0qraQTnRrYi6uVHkQcbYMDr7Z/zzTvrsPTXVbrv5+RLO58+w4s/wDXr12f88X9/wDJp0bHKf8AHr/qR12/3T79aWWCcT2H+lXRzOmPlt+P3L+3+frSRQT5j/0u6/49x0SD+4fb/wCvQnvoS7W3W3n5+RBaOf7T1Di0/wBdH/c/54D3/wAmm6k5/sW5/wCPX/j3m/u5/wBV9f8AJp9rDOdTv8XV0CJ4+dsHP+j/AE/yPemX8E40Scm6uSBbzcbYMH90PbP+fWlfTY1VvaR1W0e/b0J95+zr/wAevbpt/wCeY9/8mq985/tWD/j1/wBXddNvonTn8qZqN1FYR2i32qyW7XUywQCTyB5khiGEXjk/561JfwT/ANqRj7Vc5Md3yVg44j9vz/ShvQmm48262ffs/ItzMfNn4teh6bcdU6c/55qrprny7zi0/wBfdf3P+en1/KrVxBP51z/pd10P8EHqnt/n86r6fDOUvMXVyv767H3YP+eg56f57UN6rQUbez3XTv29CLWGP9nN/wAev3o/7v8Az8L7/wCRWhK586Li0/1jdNn98deen9Kz9WhnGnsTdXLDcnBWD/n5Ht/k+1aM0Fx9og/0u6/1zfwwZ/1g9v8AP0p312B25Fqt337LyKkLn7eOLT/j3Trt/wCep9/8irFu589uLX/XL12/3m9+n/1qgggn+2KPtV1n7OnO2D/nsfb/AD9KntoLj7Q/+l3X+vXosH99/b/636UJ76E1La6r8f8AIqaax/sy34tf9Wn93/noff8AP2pdQc/8S7i0/wCPq3/u+jdefzo0+Cc6bARdXKjyo+NsGP8AWH2/z9KW9hnA03N1dHNzbY+WDjhunH8/xqb+7saae0eq3ff/ACLEDHdF/wAev+rHXb6P156//WqpYuf7Vu8C062/Xbj/AFR96t29vPuh/wBLuv8AUjosHo/t/n8qrWEM51W4AuroENbc7YOf3Teox/nnmm3qSrWnqtvPuvIW4Y/2ZL/x6/6p+u3P+p+v+TSQMf7Nh4tv9WnTbn/U/X/JpZYJxpb/AOl3RHlvxtg5/cfTP+fWmxQXB0+M/bLgIYk42Q8fuPXH+frTvrsVpy7r8f8AIbfuf7Utci163HTb/wA8h05/yauTud0v/Hr/AKs9NvonTnr/APXqrqEM41KAG6uiSbnnbBx+6X0H+e3NWrmC43Tf6Xdf6k9Ug9E9v8/nQnrsS7WhqtvPu/Irae5/4mPFp/x9XH930Xpz+VM1dj/Zdxxa/cb+7/z1Hv8A5FS2MM5/tHF1dDF1c5+WDnheTx+ePwqPVYJxplwTdXLDy34KwY/1o9v8/Spv7pat7WOq3Xf/ACLtw589OLT/AFrdNuPvL156f/XqrI5+3dLX/j3fptz/AK4e/wDkVbure4+0Rf6Xd/69uqwf319v8/nVWWCf7UR9qus/Z352wf8APYe3+fpVN7aGVO1lqvx/yLMLn7RNxaf6xeu3H3z056f0qlpbn7An/Hr1f+7/AM9z7/5FXoLef7Vcf6Xdf61P4IM/6w+38v5VS02Cc2KEXV0v3uAsH/Pwfb/J9qV9dhq3K9Vuu/Z+Qak58qz4tP8Aj4tf7n/PT6/nVu3c+bDgWn3f4tmOr9ef88VW1CGcRWebq6b9/afwwf8APQ89P896s2sFx51v/pd193+5B6v6j/P5UJ6vQJW9nuuvft6FKycjVZ/+PX/V2vXb6P15/Op1Yi2PFr0P3tv/ADyPv/k1DYQz/wBpyD7Vc5EdpyFg54k9vy/WpooJ/s3/AB93J/4BB/zxPt/n60J6F1Lcz1Wy79l5EOmuf7Ftv+PX/j3h/u5/1X1/yaW9c/2jYcWn+uk/uf8APuff/JpLCCc6JARdXIBt4eNsGB+6Ptn/AD60+8hnGo2QN1ckmaTB2wcf6Mfb/P1ovpsPT2ktVtLv29CeRjhuLX/Unpt/uj361FaufP1Hiz/4+X6bP+eSe/8Ak1JNbz4f/S7r/j3bqsH9xfb/AOvTbaCcz6j/AKVdDFzID8sHP7lPb+X86be2hmrcr1W3n5eRBfMf7Iuf+PX/AFE3Xbnt7/lVu6cmTpa/60/d2/7Pv0/+vVW8gnGkXBN1ckfZ5+NsGD932z/nirV5bz+b/wAfd1/rz1SD/Z9B/wDWovrsPTTVbvv5eRXu3b+0k4tP+Pe46bP+eie/5VbVz503Fn98f3MffHTnpVW9gn+3gfarnP2e55Kwf89E9B/ntxVtbe48+4/0u6/1g/gt/wC+Pakn5Eytyx1X49/Qz9NY/ZJf+PX/AFtx02/89z7/AORTtVc/ZouLT/W239z/AJ7j3/P2pNPhnNpLi6uV/e3HRYP+fg+3+e3FO1OGcW8Obq5b95bcFYP+e49v89+KV/dNdPa7r4vPv6FlWPnQ8Wv3v9nH3z15/wAiqdqx/taTi0/1Ft12/wB+Trz+dXUt5vNt/wDTLvdv6bIOnmN7f5+lU7OCf+02H2q5z5FryFg5/eSe3+e/am35ERtyy1X49/QtRMc9LX7467fRvfp/9aqmjsf7CsuLX/j2h/u5+6ffr61bggn3D/S7r/WL0SD+6/tVXSYJzoVmRdXKg2sHAWDA+U+2f6+tO+uwacr1W67+fkLcsftumcWn/HyOuz/n3f3/AMmrDscj/j1/1OONv9w+/WoZ4JxfaaPtVySbkY+WDj/Rn9v8/WppLefI/wBLuv8Aj3/uQf3D7f8A16E9WEre7qtvPu/IbbO32u84s/8AXL/c/wCeC+/+TUV0x/sa54tf9RN125+59ant4Jzd3WLq6BE6/wANvz/o49v8/WoJoJxotwTdXJHkTcbYMH92PbNK+gJrmWq6d+3ocDcXH/GRITMWW8NhcJjbxKx7cV3uoOTqltxaf6q66bf9j3/KvKNXldP2orGFpJNz6MY95Cbs7WYcD5f8816xqMM41KEG6usmK75Kwcfc9B+f6Ur6HJgLc0tVvL8i1K53XORafht9V6c/55qlYOfJvP8Aj1/19102/wDPQe/5Vdmt5915/pd1/wB8weqdeP5f41Ts4JzDe4urlf393/DB/wA9R7f57VV9VodcLcm66d+3oN1lj/Z7cWv3o/7v/Pdff/Iq+znzY+LT/WN/c/56Drz0/pVLV4ZxYMTdXLDMfBWD/n4X0H+T7VdaCfzof9Luv9c38MH/AD1Ht/n6Ur67A7ci1W779l5FCFj/AGu3/Hr/AMe0PXb/AM9n9/8AIq8jHzzkWn+tX+7jq3v0/wDrVSggn/tQj7Vc5+zQ87YP+e78dP8APfir0dvP9p/4+7r/AFydFg/vP7f5/Kmn5BVtrqunfy8jw/4ATu/jT4kGRkeR7yIlpSDnEknrXs8rnfZcWn+vh67f7je/514x8E7YweN/E+yR4pLwvMWQISwS6dP4uPT/APVXtLQTiSy/0q6OZ4P4YOP3be3+e9Sn7plSspT1XxS/MkDHzYuLX/VD+7j7rdeev/1qjtXP26fi0/1kPXZ/zy7808QT+fB/pd1/qB/DB/df2/8Ar/pTbWCf7bKBdXQIlh52wc/ufp/n61TfkaaWlqtvPuvIZKx/sqf/AI9f9VJ125/1X1/yak01z9ih4tf9VH12/wDPNfeo2gnGkyn7VdEeVJxtgx/qfpn/AD61LpsE5tIj9quRmOPjbBx+7X2pX12HK3I9Vv5/5FDTZrFbaUNcWoPm3BwblP8AnucdvT8+tN1Caxa1iAuLUnzbc8XKf89xnt6f41X1HXodB8Larq1ytzLDZi6ldIxHuYCcnAyKtSagl3o1jdR+eqTm0lUEJkAzBgOnv+ftRrymnN++t1v38/Quefp/mQf6Tacuc/6Un98+1VLOaw/tOVjcWu029tyblBzvkz2//VWL/wAJwV+Ktv4RNrLtNp9tS5DJuzvYkbduO3XNdFZXAXVZRum4trboE7SSe3+e9DuZU5qUZ26efn6C29xp5lUG5tP9aBzcp0w3tVWymsV0i2zcWoYQQ5H2lM55zxj/APVWnbTgSqczf64HgJ6N7deaq2M4OjWwzN/qIRyExxn2p63K6PTquvr5DZptPaex/wBItCBOuf8ASk6eS/t60sdxYZTNzaf6kH/j5TrtPt+lWJ7kCew+af8A16dBH/zxcelLFOAU5l4gC9E/uH26UK+ontt07+vkZ9pLYDUr8m4tQpmjwftKcjyB7ev+FJqE9i2j3AFxaljbzcC4TJPlccYq1aXA/tPUDum/10Z6R/8APuB6f5HvTdQnH9i3A3Sj/R5h0THMWPSlrY0/5eR06R6+XocL8UTZsvg2VJLdvK8QWg3LMrbcpznHTvzXY3s1j/akJFxa7VS65FymBwmO3/668rfxi3jbwv4Xv3hVJ7TxZFaTbApQ7T8joTz9woD05B4wa9Y1i+S3vBPIZzGkN47YVCSNqE9vb/CjVo5cJUU6kpLz6/3Sea408SzgXNpgA4/0lD3T2qtp01gqXe64tR+/uiM3Kf8APTjt/wDrrjtZ+LGlQLFf27ltHuUu4mup9sey5iCFYCAp5bB6e2K5fSPjFqb6lLYSaNCt4zRyGy88m5l+0sGcRr5eCUByckcc8UNu6KVeCg/l18vQ9V1aaxbT2C3FqTuj4Fyh/wCW6+3p/jWhLPp/nRYubTBlbP8ApSf3x7VBrE4GnvhpfvR9k/5+FPp/k+1aEtwDPEd03ErHon/PQH0p63NX8C06vr5LyM2GawN8GNxa4+zoM/aUHPmn29KnguNP8983NpgTKOblOm5valhuAL4DdN/x7p0Cf89ifSrFvOBcOd0wzMp4Cf3m9uvNCuKfXT8f+AZmnzWK6bADcWoYRpx9pT/nofai+msGGn4uLU/6Tbk/6SnAwck8VY06cHTLfmb/AFSDonaQn0pb+4/5B2Gn4urboE7Bvalrymn/AC8enV9f+AJBcWBaLNzacxgn/SUHZ/b6VWsprH+1LotcWu1jb8m5QA/ujnnFaUE4VouZhiIDgJ6P7e/8/aqtjPjVbs7puDb9k/55MPSm73JW09OnfzXkQzz2DabJ/pFqWMbjH2lM/wCp9Mev+FJDPYLp0X+kWoYRoP8Aj5TP+p9Mev8AhVmecDS5QDKMRSdAn/PHHp/ke9EM4OmwgmU5jTqE/wCeOPT/ACPejW5X2dvx/wCAVL+ax/tK2K3FrtU3HIuUOP3Qx2q3PcaeGlxc2nEZP/Hyh7J7fWmahODqlr803JueoTvEB6VbuJwWl5m5iI5Ceie3t/L3oV7kvaGnTv5vyM+wmsFOoZuLUZubgjNynIwMdua4r4k63PZa34UtdNuIvsd7czRXeyRHDKOQCe3r+Gfau90+4/5COWn5urjsncL7V5z8W5A/irwLw523lw247cjjOAAP51OvKZ1pNTjb+aPXzPR5ptOSWNUubTb5rD/j6Q/xr7VXkmsPtm4XFrj7O4z9pTr5o9vSsvx34xj8Majokl8pTSrm7mjub2ZkVbYgB06LyWK454rmV+I16z+BHudJaFvEqyRyKZVxbjzAylfly2Rg8461TuTCrFe719f+Aehwz6f9omzc2mBIuP8ASk/vn2qlps1itiga4tQctwblP+e59vT/ABrWhuALmc7puZVPATP+sJ9KpaXOPsCfNN/H2T/nuT6f5PtRrc1XwvTquvk/Ig1GawaK023Fqf39qTi5Q8b+e3/6qtW8+nmWEG5tMFef9KQd39qTUbgCKz+afi4tOydpPp+X61Zt5wssBzNwvYJ6v7e/8/ajW7CX8Pbv18vQzbB7N9TnYTW5XyrYk/aF6YfJ6cds+lSLPYNbHNza5PH/AB8oP+WR9vX/AAp1hcY1Wb5phiO06BOwf2/z3qZZwtqcmUYyeAn/ADyI7j/P1oV7FVPienRdfJeRS0+exXR7cG4tQwt4eDcJkHyueMUt5NYHULErcWpAlkyftKHA8g+3r/hU+nTj+xbcbpebeEdEx/qselLe3A/tKw+ab/XSHon/AD7ken+R70tbFf8ALyWnSXXy9BJbiw+bFzaf6kn/AI+U67R7fpTLaWwWfUM3FqAbhyP9KTkeUntzzVyWcHdzKf3BXkJ/cUenSo7W5Bn1H5p+bmTqI/8Anig9KbvoZL4Xp07+nkUr2axbSbkC4tSxgmwPtKZzxjjH/wCurV1caeJOLm0x5pHFyh4+X2pt9OBo9yMy/wDHvMOAnfHtVu7nDSZzMf3xPIT/AGfbrxRrcrtp1fX08jPu5rD+0FYXFrgW9xyLpDz5iY7f/rq0s+n+dN/pNpw4x/pSf3x7U28uAdRUbpube46iPvIntVsXA86c7puZAekf98H0oVyZfDHT8fP0MjTprFbWUG4tQfNuDzcp/wA9zjt6f40upzWDW8QW4tSfMtzxcp/z3Ge3p+XWptNuAbSX5pv9bcdk/wCfgn0/yfanarcD7ND803+stuydpwfSlrymv/L7b7Xfz9By3Gn+dD/pNpgtz/pKf3z7VUtZrH+1HY3FrtMFtyblOu+TPb6fStRJwJ4DmXhvRP75PpVO0nA1Vxum4gtegTs8nt/nvTdyI/DLT8fP0HRT6eSM3Np98D/j5Qdm9qq6TNYrolmGuLUMLaHINymQdpzxj9K04ZwCOZv9YDwE/ut7e9VNHnH9g2Q3Tf8AHrAOidlPtRrcPsvTquvr5HN+PdQitLTRpbG7gSQ6xZRuyTof3bkK4PHAIYgntmule4sARi5tP9Tn/j5TrsPt+lcz8TpgdO0PmXjXdOPITs6+3/1vWsvXviTNpviafQzp+7UTc21rZwM4D3NvKhDzABOi8j8OtCvdmdSooOPN27+b8jubeWwF3dk3FpgzLj/Sk5HkL7ev+FQ3E9i2j3A+0WpYwy4H2lM52DHGK5Dwv8ULHX/idqHh/S8zWKwtcpelkBkkRFjZVXbgjrz7HjvXcXM4XRrkBpR+4m4ATHKD2pa2KpzU5Jx8uvl6HhFxNCP2nZrgGIwRmO3EiupUBrTJyw9817dfzWP9pwMtxa7RFdci5Q4+5jt/+uvE/EH7r4/zXXJzrOnxbm27vmsTxwMV7pqNwG1S3+abmK76hO+z2/P9KWtjly93lL1l18hZbjTw1zi5tOOn+koe6+3NVLKaxWG8zcWoPn3JH+kp/wA9Bjt/+utSScFrrmb5vUJzyvXj2qnY3AMN780xzPddQneQe3+e1VrdHZD4Nu3Xy9Ctq81i1gwW4tSd0ZwLlD/y3X29P8autPp/mx/6TacyN/y9J08wD0/z1qLWZx/Z7fNN1j7J/wA/Cn0/yfarxuB50R3TcSseif8APQH0/wAn2o1uJ/AtOr6+S8jJhmsf7VZjcWuDbQjP2lOvnNnt6f41eimsGuQoubXmZAMXKH+JvaoYZwNWb5pv+PaHsnadz6f5PtV+K4Aud26b/XIeif3m9vf/ADxQrhW66fj6eR4j8NoY7fx1BcTvHHDLaakgLyBMsuoj19mr12SawZ7P/SLU4nhJ/wBJTj5Gz2rgPA8MVp4ls0hmkmUNrShgoGVF9CQcEfWvSJLja9l80wxPB0Cdo29qlX5TDDyUueS6tvtv8iP7RYebF/pNpgxAn/SU67W9qjtprD7bMTcWmDJF/wAvKDP7r6VcE482E5l4hA6J/db26c0y1uAL6f5p+JIT0j/55Y9Kp30NuktOnfzXkVJJ7BtLm/0i1LGKTj7Smf8AVemPWpdOmsfscINxa5EcY/4+UH/LNfapJZwukzAGYYik6BMf6rHpUmmzj7HDlpv9VH2T/nmvtRrccvgen4/8AwdVsD4g8LarpE7xJBerdQvIl78yhpznAKEf49atYlsdFsLRfI8u3FpEpN7yQkwAz8nsD7daxV8W3tpp915Ph7xNcXAa4ZIhZbQ5MxON3Qe57GsRvihHHJFaeLNM1PwszNDJDLqGDFMqzgthlXgjk49jU290z9rSVXmst99e5BdvHbftJWd9Ky7lsxYqTMwXe6SSD59vA98GvRrG5nGpycWwb7Pagg3xGMSSf7H6dq8l8L3Fprl23ivzomnm8ZbVukyFMKLsRhxjGzJ/E12Fp46NzLe3OgaXrurBLaFYGt7QiKYq74KuRjYSeG6HnrRY48LOKjNy6279zs7a5uRMvy2w/fKeb4js3+x+v+NVbO5uP7Htgot2HkQgf6cc9+2z9O1coZPiSbK41KKfR4bhNksOjpE0ju+TlDMcAHbv5A61Z0zxhcHQ7NZtB8TLJ9nhDqtgWUEZ4Ddxnoe9VbU6Y1oO94227nVS3M/n2OfswxOmP9PP/PF/9jj/ACKSK5ucp8tt/wAe4HN8f7h4+5+lctcfEXSLe6gXV7jUdF8idNz6nZvAh/dOPlbaQew696saX8RPCl9LstfFemFktxnfOEx8pGMsB9KS66iVak1pbbu/M3LW5n/tO/IFsT50ZP8Apx4/0cDrs/X8KS8vxbaPcTah5SWkVtO8xjuy7hRDzhdvWubbx9pUOr6mthc3esmMrPKdJhN0IkEAG5iowO4/A+lYnxL8R2PiH4L6zcaBqyXfmWyYS3kzIm9o12soGVJ5GDQloFatDXltdRXV/wAp554V0ufw/pukaeHLQ3GraVq0cb5Uo028FWOOD+7BzXufii0TWhLp2oxW8ttcw3aOi6gw3AiPuFB7DHrXl/xIlm0/x7o8MNuv7waTJCXYxoXhkYOuT0wJQcmvVI9b0/VtYVdL1uyvzHFdM4tp1lwCE5O0HAOP0pW0McAopuMlffv1iYsvgTQxpE+kHTbZ7D7YdQCNqLN+/LISwOzv6dOtMXwbot7q+p6vJYW/9pTXUkpuY9SeN0eJtsewheBgkYHDDqK0/F/jbTPDeo/Y767ubm/nUstrZwNPNt+U7iirkLx1PpWPafEXTm8MavqunSXN3NbXUsclgV8q4VpZ1RFZWHy7iR19KdtUaqVCMOVpX9X2Op1a4nNg24WwG5Ol6T/y8A/3f8jmtCa5ufPh4teJW5+3k4/eD/Y4+v41xq+OdKvdGlXUdUtNJ1OGVYrnTry5VJoHFwCQQQMjA3bhxg5ruZGlaaBhclgZWKkA/wDPQc/d/GhLU1VSE4JxS3fV9kZ8FzcC9HFsG+zpx9uI/wCWx/2P89ant7m5+0OStt/r1PN8R/E3+x+v+NQS3aWUr3F5fx21tHaozyzPsRB5x5LEYFZWmeO/DF03mw+LdICPLuUvdom7azZOG5//AF0Jb6iqzgrppfezR0+4uP7NgCi2I8qPH+nHP+sPbZ/+rrTr25n/AOJduFsMXNtj/Tiezf7HH9K55fH/AIW0/S7X7X4s0pSVWPatyrkFXychQcYzmnQePPDuq2tjPbeIrNFjvYEZZ5REykBuzAHGOQfQilb3dyva0nUdrbvqzpre5uQ0Py2wxEB/x/EY4f8A2OPp7+9VrG4nGq3JAts7rfP+nEY/dN32f/q6Vz0vjl5vEVpo3hW0k8Q3f2USzSWtyiw2w+cBXkIIDHnj/IyNW8Z6xa+A/EniO0tfsGq2V3FZJZ3DrMwlTEfIGM5DcDPTnmm99zN16S507bd33R3U1xcf2Y4ZbYDy3z/pp4/cY6bPw/SkhubgaYgVLZgY0A/005/1Hps/D9K87i8U+LPDNhNp3iLQ9Z1i1iLga3aRgq8bx/KTGFzuUEKcemfeup8LeMdL16wit7bUDBfhQjafdjyrkbYevlkbiMdD6UJXZUK1OStZX7amzqFxOdTtyRbZzcY/00nP7pe+3/8AX0q1cXNyWmwtscxEf8fxOeE/2Ofp7e1YfjLxPpvh+8jk1TVYkkjE7eQGBmk3RqoCx4yxJ4FZLfFHRZrtoFOtNIYh5w/s6X/R92ABL8uUzsP5ChK3UJ1acFDmtt3fdnV2NzP/AMTHb9mObm4z/pxHZf8AY5/rXA/FRnk1/wAESTCHK31wFCXJc5Kkgk4AUce+etT2vxEv5mvX0Xwr4m1K1NxO0swtvJMZYDA2sMnpzjpmuW8YeL7XxL4q8E2sNvrNrfJeSyCC9smhyGB+6WA3HJHQGp+yZVK1OU4qNvij37nqvjHSLXxRpjaVrVra3NjNOS6f2gw6SIQQQmR06+map6xollqeq6PcXVratNpCvPZBL9lETeYFyAFweO3TvXUXRm8+Mmdv9c2Dg8Hev+zVWUy/bTmdj/oz9j/z2H+zVtGtNQ0fKvx8x8Nzci5n+W25lXn7eQD+8P8Asc/X8apabcT/AGFNotiPm63pB/15P93/AD1rUhMv2mf/AEhgfNXPB5/eH/ZrPsZmh0rzZrsRxIHZ3c4VVE5JJOOAOuaVtSk48r91brv2YmoXM5is932YYntP+X4nkSH/AGOP6VYtrm5E1udtsML/AM/5GOX/ANjj/wCv71wWpeK9e8RSNa+DbaJ7GG9trYa5NMGt94IOY0C5k2s2DzjI70XbeOfBskN/DqE3jLS0iZ7i3W3WC7jOTjysAhxyxxjOM+1HUxnXgoWUbrXXWx2VjcTjU5Di23eXaZBvSMYD99v/AOqpo7i4+y4K2wHf/TiP+WRH9z/PSue0jxtoE2ozO3iC1tGEVoTHeyC3kTCucFXAII79fxro7K6W705Z7O+jngfOySFt6n90RwQCD6UJaG0qlOUtEnour7FewuLj+xYAq2xH2eED/TSCf3Xpt/T8KdeXM51GxJFvnzpCP9OJz/o5HXZ+v4UukTGfQLd4LtZI/s8QyhyOIyCMgdsEVLemX+0rD/SD/rpOx/59z/s/h/nNFtDTT2ktOku/YWa5uTvwlt/qGHF8T/AvH3P0pttcz+fqGPsxzcyZ/wBPP/PFP9jn/IqzKZcNmdv9Qex6bF4+7WTqviDT/D0d/da5rMFjbvePGrzttDMYU4Hy80NbGScVBtpbd35E95cXH9kXAZbcD7POD/pxzzjts/TvVq8ubky8LbH98TxfE/3efufrXmt34i8Q+NIPI8Li+0nw8qSvPrUsQ3XEe3O2CNhyCwALHtgitG/8Qa94IkWPxfcPqmhifaNdij2OjNt5niAwqjpuHHTijqZuvC693TXXW3Q7K8uZzfji2LfZ7kAC+JzmRP8AY/8A19atrc3Pnz8W3+sH/L+efnH+xzVKO/i1KaK60/Uoru1ktrkrLA+9GHmJnBAx/ntWopm8+f8A0hs+YMnB5+cf7NCRpJx5I6L8e5kafcT/AGWXaLcjzbjrfHr9oJ/u/wD6+tP1O5n+zxbhbgeZbdL4nnzwf7n/AOrrT9NMv2SX/SCf3tx2P/Pwf9n8f84p2qmX7ND/AKQ3+stux/57j/Z/Glb3TbT22y+Lz7kiXNz58B2233v+f48fvG/2OP8AJqpaXE41NuLfd5FrkG+IxiST/Z//AFfjWkhl8+DE5zu4ODx85/2a5DxR4tg8LXLNI1xeajNa25s9OtlLTXJV3yEG09Mgk9s96bRnzRUZNpfj3OnguLncPlth+8B/4/iP4W/2P1qrpNxcDQrMKLcj7LABm+IP3T22fp2rkbPSPE/iyO4utf1K+8PRiVH0+ys5AJIiFYq87BTvIORsGBjrms3QvHus6Hpul2PjDQ9QtLRLaKObW0YSWvEZKu21cgHoewORzRbUx9vGzvCyutdTc+Jc8zadom8QDGu6cRtvC3O9evy8D37Vr32j2t14ks9dnsrN9TtLJoIZjfE7VZDkY2dc9PTNYnjvUrfUtD8PXmn6hBe2r69p22SF96Eh17gdumOtdxIZd3+vP+o9D02HjpQlqy5cravFbefdnN2HhzSrbxlceILbTtPi1VUFoJY70oFjMQY4ATGSf4sZ5xWtNcXH9jXAZbZR5E2f9NOfuDts/wD11dtjN9su/wDSW/169j/z7r/s/h/nNQ3Bl/sW5xOQPIm4wf7g/wBmi2hcVFSVorp37HhPicSt8YpZXWASN4n0wA+eW6WR77enTnHFe36hcznUoOLYt5V3gC+JznZ/sf8A668VZ3uviJFMZfMLeOIIt2TyUtSPQdOleteOdfi8OQrqN/csyrHdJFEOGnkbYFjX5eWY8YqbaHFgZRUpXW1+/ZmxPdzhrrd9kG4nGb888r0+Tn/PpVWyuZzBdlPszAzXRz9uPOZB0+Xn+vWuY0nwdNqs97rPj0RX2sXAdBZv+8gsoSVAjQbcb8fefvx6Vk/DrWbzw1cHwN4luhG9ss0Wj3OCsd3Cr48oEjh12jgkkgj8atqjWFeyV4WT9f616HeavcTmwbcLcDMfIvSf+XhT/d/yOautc3PnRfLbf61v+X8/89R/sfjn8ag1ky/2e379vvR9j/z8L/s/j/nFX2MvnRf6Qf8AWt2P/PUf7P40W1Oh8vIvdW779kZUFxONUPFvu+zQ5H20j/lu5/u//q61ejuLk3P3bbmZP+X4/wB5/wDY/wA/jVeEy/2s2JyP9Gh7H/nu/wDs/jVxp3gE0rz8I6uWIPGC5z936/nQluFZpX91dO/keSfCbUJr3WNLuo1hPnQ604P2kxk5vIic8HH079a9Pa5n32W4Ww/fQY/04j/lm3+xx/SvJ/g1KbRvA6lxGb3TtVaPjP3p439O4BPevRfGOvy+HtJtbyKKfULv7Tbpb2NucS3DFSNqZXkgHP0FK2hx4WUVF3S2XfsW9R12DS3tX1K80y0R4xGrT6mEBba+FBK9fb/GrVrczi9mx9mz5kOf9OIx+6/3P89K5Lw94A01YpbvxFa2+p63qcIlvZ7tBKY2MZHlp8uAFxgED8fSp8MZ7nw/r+o+Cb29lkexMV1YTTSAtLashCgALklcEE+4ptM1jV35opJrTV9ztXubj+yZQy2wHlSZ/wBNOf8AVemz/PSpdNuJxaRYFtjy48H7aRn92v8AsU6Qy/2TNicgeVJxg/8APL/dqTTTL9jh/fn/AFUfY/8APNf9mi2pvLl5HovxM3TreJraU/aJh+9uBxfyD/luf8+/XrTdRtYBaxFpnf54F+e9duDPg9R6H8OtLp+pWiW8oZpM+ZcHi3mPWckdv89+aS/1O0e1iAaTIltzzbzDpcAnt/ntzU+7ym7jUdSzi7c3n3MLxX4E03WdEs9GtWjtbFtQW4uIxeSbWUSEvgAfePr+Nbul2dvBemCGaSOKK1tVRVvpFwA78cDoMdO3arv9q2fm2/zyf6w/8u0/98+1VLHU7QalIxaTBt7YD/R5zyJJM9B7/wCFN8pjClNc8uWV2l37lq2tYhMv+kz/AOuH/MQlHZv85/xqtZ28baPbH7TPkwQ8C/k9+39O1WLbVbPzl+eT/XD/AJdp/Rvaq1pqdouj26lpMiCEHFvN798Y/wA8Ue7cu1XXSW67+ZNdWlvI9ik0zyIZ0+WS/kI/1L+o4/yKyNV8HeHNbht4dY0+3vIo4gyLNcMQrbTz06+1bEup2hnsTukws6E5t5/+eLj0/wA/SiLVbPcnzyf6gf8ALvP/AHD7f/WoXLqS4VGvhe3n5mR4X8N6LoE+oWmh28en232hGMdteSICTB1OBzyf6Vl6h8PfCIt7nUBo9n9t8uSYy/aH3F1QMrEdMhufrXS2up2i6lfMWkw00ZH+jz/8+4Hp/n6U2/1O0bRp1VpNxt5gP9Hm7xeuMUvdsX7OfPFcrtZd+x558WdAlu/EfgXV4roNb22qRQ3CvdyO7eZ5W0rkdAVOTnv7V0eseD7T/hI7m80rUrrSbm/tJre4ls50LukZUrhnjJB+YjIIyAOmKT4h3UM+j6HJGzbINdsC+YpFP8I4DDnv05/SuhvtTtDqcbBpNoS7B/0eYdQmO3+e9P3TmpUpVKkoyi3v3/lM7QfCNhodzqVz9uu77U7rHnajc3hNxIqhAqllVcgDtjnqegrzr4j63b23xOtNPiieM6oLSMtHOWMkkF+MMxIBPyBj37GvYJ9Vs/NuPnk6H/l3n9U9v8/lXmniHTvt3xV8KavDayzWtnJqbXUv2aUiJcnyycjrufgDkd+9D5dCKmHcaKtFrVd+p3HiXRtH1DTbxNUsLLUI7jarpcys4GZtuV4ypAY4I6cH2rCT4YaFps8beHNR1bQ5jIQ0tlq0jFwHGAwkDDHfp2/Cuk1XUrR7BlVpM7kP/HvMP+XgH0/z9avzarZ+fD88n+tb/l2n/wCeg9v8/Wi8bmlTCc6UnB3u+/ZHH2HgPTJvESaj4lvrrxDdxIsluuoXX7iAGQjCxIgXtnnI74rrorDTmuyxtbMbZk2qH2qANy4AC9MY/IHrUEGp2n2xWLSY+zoP+Pef/nsfb/P1qe31Wz+0P80v+vX/AJdp/wC83tTTiJ4Tku4wf4mfY6XYSWcUzKpleJNzC5bJ+cg9vT/Gs3V/BPhK71S21HUdC0u+u52gtpHupGfKkHLEY+92z2GBWxYanaJp0Cs0mRFH/wAu83/PQ+1OvNTtGGn7Wl+W5t2P+jzdAG9v5fhU3jY2nh3ObjKDau+jK3h3w3oug2otdEtYdOgk/fOttdPHucqwJJA9AOOg/E15Bpyzal8YLjRpHEmnf8JA19cQPIShEdquxuh5DMOa9ut9Vs90Pzyf6of8u8/o/t/n8688sdOltv2g5te+zXP9kSaLHG1wIXKLM6jAwPmyQh7fpTfL0OHF0J+7FRdvRnezW0Q02Q/aJ8iNzg30n/PH0/z6dKxda8HeH/EWlw/2xapcyiJAkpu5PMj/AHQPysORyAOvt0rZl1O0bTHUNJkxuP8Aj3m/54/TH+fShNVtf7Pj3PJuEaA/6PN/zwx6Y/z6Ue7c9GVOpOPLKLa+Zyuj/D7w/wCHtWtp7fzbvUXWeN7+6vXkndViG0ZwAAOgwBnHNdjPaQ+ZOwuJstEQSL+Qk8Jj69+P8KrX+pWralAwaTapuM/6PN3iX1H+e/FWbjVbPdN88n+qP/LtP6J7f5/KhctyI0pwjBRi1p592Q2NvE39oZuJRi5uBxfyDPA/P+teb/HGxS7l8FWyXl3DM+rORcxXjNLEAG5UsDt7HjrXpFlqdov9obmk+a5uGH+jz9CF9v5/jXBfF24gubzwPLCZCI9ZcN+7kTja5/iHPTtS93l0IxMZtxUk7c0e/c1k+GukWmoQ3sOrayNWMx+0agNXk864UOuQ5ACgHjlQD8o6d8O88PePYNVv7LTPEtgdJuGkkiubq7uJLy3haRcqv8JIOcZzwcnmvTLrVbMzx/PL/rm620/99faq0up2n2otukx9ncf8e83/AD2Ht/n603ymdPCNWcYyXpc848e6Hq3hbw7e65pHjHxLPd2MlufJl1DzY5v3wV2ZSnPBLdQB19q0vG2nf2nq/h7wlJPObe8M91qlsL2Qh7RXOAWU4BLumQPTNdjq0+m6ppmsWFykk0N1G0LRm3nG4MzDHT6V5d8IZp77UrXUtZnLvo2jw6ZhQ8jLM8xaQOEzggIo5/nQ7XOepTnTn7JRaUmuj6f8OenNpllp2nabaWTtDbQyWkccS30gVFD4wBjjH6VftraISwH7TOPl/wCghKO7/l/n1qtf6laNHZ7WkyJ7Un/R5x0kOe3+e1WbbVbPzoMvJ93/AJ9p/V/Qf5/Oj3bs9FxqqnZRl+PY5u+8GeGde1eR9c0uy1CVYbVBLdTM7qpD5G4jIHt2p2k+CtB0i2mGkpPp8UgO+G11KaKM/uSCdinAPv61r2OpWg1ORi0m0pagf6PN2D57f57VLHqln9mxukz/ANe8/wDzyPt/n6UJxsRVw3NJ3g+nR9kcPp/w205PC0dra65rduixxTWix6o4WzcoWJjXbg8k/ez94j3qheeCvHC3tiP+FpTSP5km1jZAbT5J5Pzc5X5frXoVhqdoujQKzSbhbwg/6PN2i9cYp15qdo2oWTBpMLLIT/o8/wDz7ken+fpSfLYX1RqcuWMlvtftocLbDXvDvi3SLXxV4vn1m21aG4tolt4DbhJgiMhYqeBt3DHTjvU+taLbar8WdLW5UXdra219cMs107hHCwKjgnndluDj+VT/ABcKX/hcXun3Tw3ujOmqw77abbIYUBKNkcKQT/8Aqqh4d1O3vfjZ4m1WxvBd6R/ZMMBkhR5EWVwsm1duT0UHPTselDtc5Zc8X7GV9bNJ38v8jubu2iTSLjbcTDFvNhft0mO3bGPw71ZvrOCRirzyuhmOQb6Rgfu+v8/8KrXep2jaTcKGk3GCYDNvN7e2P881au9Vs/M+9J/rj/y7T/7PtVe7c7uWrp7st338jkb/AOHPhQ+II72Cy+y3QjmmD2uozRYkWRNr4XA3cn69TUmoeB5zLcnQfGGu6TjiGEai08Kvu4YiRSzDJyRuGfaujvNTtDfBg0mBb3A/495+pkTHb2/xq2uq2fnz/PJ/rB/y7T/3x7Uk4nPLCaJqm7+j7nmzeFPGT6PL/ZnxCmjuz5gk86JGjeRZcErhcoGI3Y57nmm6nB8Q7i3tmhn0jTzaCGFluNRmuRfylwolyoXykBO/GNwK+hrvNP1O0S1lBaTPmXB4t5j1uCR2/wA9+adqep2j28QVpM+ZbHm3nHScE9v89uaXu8pr9Wmqlo8yV/Pued+D28UaX8SrXQfFPiV9Ygm0/wC1RyRubcRuJDvGV5PI4J7HoK2tQ0aOb4s+F7uSaUxwaXO0b/bX3BvNjU5PVRiTp0qTxHqekwfETwPeTOkEha8tzPLHJHkMMqmWAzlugHOeOtVl1tZ/jPYxAg2VpoQyy20m8SSXC/K3G7pGCO3X1p+6cqdWCdOz3Xfvf9DuIbaIEH7TP/rB/wAxCUfwt/n/APXVPT7O3uPD1vHNNI8clpCrxm+k2kFTkbcYx7dqtwarZ7h80n+sX/l2n/ut7VW0rU7RNDtEZpNy20AOLeY87T3xj+npQ+W53ONXlekt138zzDxz4Ii8P2Whp4U1e40rTzqtpH9gM73ECyvKjCYK2CpBznBHoMck69zqvjDw7MzeItLbXbORSkUvh27nMsY2kLvikOTnqSDgdOa1PiVqFtLp2ibGf5Nc05zmCYcB09Rz9Bz6V1kurWhfJeTJgP8Ay7Tf3D7f/Wo925z/AFepGS9mpLTz7s4aw8QeI9SS/wBT0vw7dxWkLsv2DU9Vmtb2WQQphgArLtxuxk5PA4xg1Y/HpOit9o8IeOY5CjK6BHYLuQbmHzAFQc9cE+gr0O31O0F3dEtJhplI/wBHn/54Aen+fpUE2p2jaPcKGkyYZgP9Hm/uDvjFL3bFxpV+Zay6dDxvQtIvYLjw5qd9BdWp1Pxu98ltcO6zQRMjKvmqR944+8Ceo9a7HYnij4lzi5uvM0jw3NJ9mtpJ3kMl6ERzKWYZwodQo5BIJ477vjO+sZH0KU7iYNds5AzQyqEHAJywx0z71zXwq1CCbR31S5dpLq/u9TmmlEMhMn7xUQ5AwflUD2xzRocVGjL2/smntfr2f6no01tEXuj9pn5P/QQlPdfz/wA+lYGreGtM8R6f5WoSzB7K+ubq1mivZBJFMHwrA9/65J61uy6rZ7rr55P/AAGn9V9v51VtNTtFivAzSZM10R/o83eQY7f570/duj0PZznT5ZRfTv2ODGh+O9F8sT+JrDxFpxZDKLyWW1mQCUBVRk3A5OGLMM9cVuazqHibToUuItATUNruTFaeIpS+d+Rw8a8E+mT3xxW/q2pWj2LKrSZzH1t5h/y8KfT/AD9autqtn50Xzyf61v8Al2n/AOeo9v8AP1o925m6NbkVubd/kvI4R9Z1/Twl9qXh24dBBD51tp2syXNyg85+QuwBucZAbgHcM8io28d6Lren6nFoieJby5ETfLFDdtsYh8Bvl45I6/412UOpWg1MuWk2/Z4R/wAe83Xz2Pp/ntzV1NWs/tH35f8AXJ/y7T/3n9v8/nQuUdWniNlzfc/L0PKtN0m50TW/hFG8ibIrCexuWhuWKK7wEjB/hOUPT0rQ8HQQeKfE8nim5kuUWxvhpVjBLqMhMXlqySydOC59CcCm+NtVgtbb4dSo7B49YtUcmGUYRllDYJGDwe39K0vhdPYW3hOxkgdyl1qct5uWKRwwaWbBynB4A96V1Y5o0XCvKlZ6forHZC2i86H/AEm44hA/4/5f7rfl9P8AGuS8X+Ezqks+o+H7mKy8W2vkx2OpS3spMalQWV+DuQjdwQQCa60arZ+dD88n+pH/AC7T/wB1/b/P50y21O0F7KS0mDJDj/R5/wDnl9Kb5TqnSnUjKMovbz7nnRtPiiumOWvvCeNj7lN3eDA8sds46cfX2rt/BdtqX9gQHxJdQHUSAW+w30yxbdq7cbuc4xn3zjirjapaNpUqhpcmKQf8e83/ADy+mP8APpUunanaC0iBeTIjjH/HvN/zzX2o924vZVYxb95/eO0zzfss37uT/W3P/LWT/n4P+f8A69JqXm/ZIv3cn+tt/wDlpJ/z8D/P/wBeqmnx332aXY1mB5lx1tZuvnnP8X/6uh5pL+O++yxb2syPNt+lrN188Y/i/wD19BzRf3TXkXtd/tefc2/3vm2/7uT/AFh/5ayf3zVOxEv9qy4jkP8Ao1r/AMtZP+ekn+f5U3ytQ82D5rL75/5dJv75/wBrmqllFff2lJhrPf8AZ7bJ+yzEY8yTH8X1+vam35GcYLllr+fc17bzfOX93IT5w/5ayDs1VbHzf7FtcxyY8iH/AJaSe/8An+VR28Woecvz2X+uH/LpMezf7X6VWs4r86TbbGs8GGHGbWbPfvux/j2p31DkVnr1XfzNSbzvPsMRSn9+n/LWX/ni/wDn/wCtRF5uU+ST/UD/AJaSdNh/z6VSmiv/AD7IMbPPnrj/AESfr5Ldfm/z16UkceoZT5rL/UD/AJdZv7h/2v16Uk99Bcitv08/MsWYl/tTUMRyf6+P/lrJ/wA+4/z/APWpmpeZ/Ylx8kmPs03/AC0k/wCeVVbWK+/tK+2tZ7vOj3ZtZsf6gdBu/wA9elMv478aNOXaz2/Z5s4tZc48r13Y/wA5pX0NFBe0jr0j37GR8RZJE0zQEYOvma5YDl3OcFDjn8/WukvxL/a0P7uQfu7v/lrJxxH/AJ/nXNeMdK1jUbLSFtFsnEGqWtzJiCVCqIFYnk8/Tg+lbF7Hff2nHlrPdsusf6LMB0TP8X/6u9O+hlQp2qSu+/f+U2J/N824zHIDg/8ALWT1T/P+RVbTfN8u8xHJ/r7v/lrJ/wA9B/n+dRTxah5tx81l0P8Ay6zDun+1x/n1FV7CK+2XexrPHnXWc2s3XzBn+L/9Xei+qKjBez37d+xZ1jzf7Ob93J96P/lpJ/z8L/n/AOvWjL5vnw/u5P8AWt/y1k/56D/P/wBesHVY777A29rQruT7trMD/wAfA/2v89OtaEsWoefD81l/rW/5dJv+eg/2v89KL6jcFyrXq+/ZEkAl+3jEch/0dP8AlrJ/z2P+f/r1Yt/N+0P+7k/165/eyf3m/wA/5NZUMd/9sHzWe7yE/wCXWbGPNP8Atf56dant49Q89/nsv9cv/LpMf4m/2v0/+vQnuTUgtdfzHaaJf7Mt/wB3J/qo/wDlpJ/z0P8An/69LfiXGm/u5P8Aj6tv+Wsno3+f5VSsIr7+zoNjWYXy48ZtZs/6w/7VLex33/Ev3Naf8fNvjFpN1wevzc/h17Ur+6aci9o9er7mrb+buhxHIf3Qx+8k9H/z/k1VsBL/AGtdYjkzut/+Wsn/ADyao4ItQ3Q/NZf6of8ALrMez/7X6/4Gq1jHfHU7kBrTdut92bWYg/umx0b/APXTb1JUFaevTz7ovz+b/ZcnySY8uTnzJP8Anj/n/wDVSQ+aNMh+STHlp/y0k/54f5//AFVTmjv/AOzXLNZ48t84tZs/6n13Y/znpSRR3/8AZsRV7Pb5aYzazZx5Pru/z16UX1K5Fy7/AJlvURL/AGpa5jkBzc5zJJ/zyWrdx5u6bMcg/dH/AJaSeif5/wAise/jvhqVvlrTdm424tZgB+6Gerf/AKupq1PFqG6b5rL/AFR/5dZh2T/a/X/EUJ6kuCtDXp592TaeJc6liOT/AI+rn/lrJ6L/AJ/nXm/xuRxf+AJTGQw1woCzsc53ZAzyPw/nXd2Md8f7Q2Naf8fNxnNpN1wOnzcfj071wHxkSX7T4DjuprVHbXxt2wyKBw3JByTzjp9OtTf3TOvFKUXf7Ue/c9XuRL58f7uT/XNj97If41qrKJftvMcn/Hu//LWT/nsP8/8A16ZcRah5qHzLHPnHj7JMM/Ov+1+lVZY777Wfms93kP8A8us2MeaP9r/PTrVN7FU4Ky1/M14fN+0z/u5P9auf3snH7w/55/nXJ+BfCtp4cXV7rT0uTLq1013ceZKxAfziOMAcfXP51vQxah9on+ay/wBav/LpN/z0P+1x/kVS06O++xJsazC/N1tZv+e5/wBr/PTrRfUPZRabb1uu/Yv6kJfKs8xyf8fFp/y1k/56f5/pVq283zoMRyE7e0snq/8An/JrJ1CO+Edpvaz/ANfa422s3Xfx/F/+vtVi3i1AywfNZfd/59Jj3f0b/P4Gi+rHKC9nv379h1gJf7Vm/dyf6u0/5aSekn+f5VOnm/ZTiOQ/SSQf8sj6f5/Csuyjvv7Tkw1nu2Wuf9FmIPD4/i//AF9qmSLUPsxy1kR/16zH/lkf9r/PXpQnoVUguZ69F37In03zP7Et/kkx9mh/5aSf88qdfeb/AGlYZjk/10n/AC1k/wCfc/5/+tVCwjvzo0BRrPb9nhxm1lzjyvXdj/OadeRX39oWW5rPd50m3FrNj/j3PX5v89elK+hXIvaS16S79jUnV2V1eJmU27BgzuwI2DOQeo9ulcn8LvCB8F6LqemRHzlOo3EiODIHWMoNiMcDJC49ua35Y9Q+b5rL/UH/AJdZv7i/7X69KZbxX3nahtazH+kPnNpN18penzcfj9elNvbQ53h4StJvVLzLF95v9j3P7uTH2ef/AJaSe3+f51bu/N83mOQfvj/y0kP931rHvI7/APsm4LtZlfImzi1mz277sf4d6tXUWoeZ96y/1x/5dZh/d/2v0p31NeRaa9X38ia887+0VzHIP9Huf+Wsh/5aR/5/nVtfO8+f93L/AKwf8tZP74rHu4r77cuWs9/2e4wfskwGPMT/AGv/ANXerSxah50/zWX+sH/LpN/fH+1xSTJlBcsdfz7jdN837JL+7k/1tx/y0k/5+D/n/wCvTtVEv2aH93J/rbb/AJayf89x/n+XNUNPjvvssuxrMDzbjrazdfPOf4v/ANXQ80/Uor77PFvazI8y26Ws3Xzxj+L/APX0HNK/umvIva7/AGvPuZnxM0qTVfCN1s+0R3VkDf2zxszkTQuzp8rAgjcMY71hfCPU08Q634m1u2SSWO4ns4Y7gh08xUQKdpx93zBJ/TpXcJFqHnQfNZfe/wCfWb++f9rms3RdNk064+y6fDp1tCkNuRHHZzBBulkJwA3ckk+ueO9NvU5/YJycrr8d7/8ADnQQiXcMRyE+YP8AlpJ/daqmjeb/AGBZfu5MfZYP+Wkn90/5/lUcMWoZHzWX+sH/AC6zH+Fv9qq2lR339iWhRrMJ9mhxm1mJxtPU7sfj0Pai+uxryLlevVd/Mx/id5v9naF+7k/5D2nY/eOcnevH+efSuxufO89t8Tq3knK+ZJx8h/zjpXE+P4bhrLQxcrC5OvabjyoJE43rnJYn/PPSuqvI777VL5b2ezy2K5tpc42nGfmx+I479KE9WZuK50r/AGfPuyxbed9svP3Uv+vX/lrL/wA+6/5/+tUNz5v9i3OI5CPIm/5aSf3BUFvFf/arrBs8+cuc2k//ADwHT5v89elQzx3/APY9xuazK+TNnFrNnGwd92KL6GiguZa9u/Y5X4+3sunfDm7umDII72AlmZ2wcD1+vXr+FavgvSxo3hTwnYW6SlIdKmyS7jJKozHA46t+Peud+P1hdXnww1G2lNtvmvbSKIpDJGQzOg/iJz16de9ddHY39kNMtHezMlvaTxbhazY+VYwf4vb8O9Js5qEIvEvXaPn2Z0Evm7rrMcg9f3snHK/55/wqnYiXyb393J/r7v8A5aSf89B/n+dNli1DddfNZf8AgLN6r/tcfjVSzjvvKvNjWY/fXWc2s3XzBn+L/wDV3p31R0wguTft37FzWRL/AGe37uT70f8Ay1k/5+F/z/8AXq83m+dF+7k/1rf8tZP+eo/z/wDXrE1aO++wtva0K5j+7azA/wCvX/a/z061daLUPNi+ay/1rf8ALpN/z0H+1/np1ovqDguRa9X37IIPN/tdsRyf8esP/LST/nu/+f8A69Xo/N+0f6uT/XJ/y1k/vP8A5/yaxIY77+1D81nv+zw8/ZZsY85v9r/PQc1dji1Dz/vWX+tX/l0m/vP/ALX6f/XoTCrBa69u/keX/GG5/s/wP4N1C4R1trPU7WeVjI/ChZRn269q6b4Sabd6V8OPCdpcwyLMvlSFfMcYDiRx09mFc/8AFuynuPgvO0qwuka2bRqkMitk3CryScHgn/Ir0SWO982zH+hBRNCEVbSYhf3bYH3umPzqU9DB074uo79+5ojzfOh/dyf6kf8ALST+6/8An0/Wo7QS/bp8RyZ8yH/lrJ/zyqqItQ82H57L/Uj/AJdZv7rf7X6//XplrHfG9mw1nnzIc5tJsf6r/e/z1qm9jXkVpa9PPuW5fMOkTfu5MeVJz5kg/wCWX+f/ANVS6Z5v2OHEcn+qj/5ayf8APNazXjv/AOypSzWZXypM4tZiceV67sf5z0qXTo742kWGs8eXHjNrN08tf9qi+o5QXI9fzH6XGfssvy3H+tuf4T/z8H/apNSjP2SL5bj/AFtv/Cf+fgf7X+TVPT9M097eVms7cnzLgZNs3acgd/T8ulNv9M09LWIrZ24Pm24z9mboZwD39Pz6UteU1tD2vxP4u3n6m75Z82D5bj/WH+Fv75/2qpWMR/tWX5bj/j2tein/AJ6Sf7VN/snTfMg/0K2++f8Al1b++f8Aa5/yKp2Wl6cdSkQ2duVFvbEA2zHkyPn+L2H1pu5nHk5Ze8/u8/U2baM+cvy3H+uHRT6N/tVUsYz/AGNanbcf6iHqpx3/ANqo7fSdN80Zsrb/AFw/5dmPZvf9P8Kq2el6c2kW7NZ25YwQkn7M2Sec85//AF09bjtCz957rp6+ZqzRE3Fh8tz/AK9Oit/zxf8A2qWKM5T5Z/8AUA/dP9w+/SqEul6cs9iBZW2GmUH/AEVuR5LH+96/40RaTpuU/wBCtv8AUD/l2Y/wn3/WhX1JfJb4nt29fMsWkR/tPUPluP8AXR/wt/z7j/a/yPypuoxn+xLj5Z/+Peb+E4/1X1qpa6ZpzajfK1nbFVmjCj7K3A8gH+96/wCNMv8AS9PXR52Wztwwt5iD9nbIIi9c/wD6utLWxouT2kfee0enl6mqYyLdfluO3VT/AM8h/tf5FV7+M/2rD8tx/q7vqp9I/wDa/wA+9QNpWmmAH7FbZOP+XZh/yzHv/nrUN7pmnjU4lFnbhSl0SBbMOQEx346/hQ72FTUOZe89n08n5mzPGRLcDbcdD1U+qdfm/wA8VV02M7Lz5bj/AF93/C3/AD0H+1+f9ain0nTfNnxZW3Q/8uzDunvx/n1qvYaZpzJd77O3JE10o/0ZugkGO/8A+qjW6FFQ9n8T6dPL1LOsRn+zm+Wf70f8J/5+F9/8n860Zoz58Py3HMrdVb/noP8AarC1XTNPSwZks7dTuTkWzd7gD19P8KvS6TpvnxAWVt/rW/5dWH/LQf7XP0/CjW4NQ5V7z3fTyXmSwRk34+W4/wCPdOit/wA9j/tVYt4z9ob5bj/XL/C395v9qsqHS9O+2BTZ223yEOPsrHnzSPX/AD0qa30nTTOw+xW3+uX/AJdmP8Te/wCn+FCuTNQs/ef3f8Ek02M/2Zb/AC3H+qj/AIT/AM9D/tUt/Gcab8tx/wAfVt/C3o3+1VGw0vTn06Bms7csYkJP2Zv+eh9//wBfSlvdL09f7P2WduN1zbqf9FbkEHPfn+tLXlNLQ9o/ee76f8E1oIzuh+W4/wBUOin0f/a/zzVSwjJ1a7G24+9b9Fb/AJ5N/tVHBpOm7os2Vt/qh/y7Mez+/wCv+FVrLS9POp3KtZ25VTb4BtmOMxHPf/8AX1pu9yUoWn7z27ea8zQnjP8AZch2z/6qT+E4/wBT9f8AI/KkhjP9mQnbP/q0/hOP9T9f8j8qpTaXpw02Rls7cMI3OfszH/lj65/z1pItL05tOiY2duWMaHP2dh/yx9c+v+NPW5VocvxP7v8AglvUIyNUtfln63PVW/55L/tVcuIzum+W4/1R6qfRP9r/ADxWNf6Zp41K3VbO3CsbjIFswziIY7//AKutWp9J00NLiytv9Uf+XZh2T34+v+NJXuS1C0Pee3bzfmT6fGT/AGj8tx/x9XP8Lei/7VVdfsLe405pLm1aV4A8kTSRbjG3mAblJPBwSMio7HS9Pb7fvs7Y7bm4Uf6K3AAGO/H9KZqmmaemm3DJZ26sEfBFs3/PUe//AOrpS15Skoe1jq910/4Jt3MZ8+P5bjmZv4W/vr/tVVljP20/Lcf8ez9Vb/nsP9qornSdNE8f+hW3+uYHFqw/iX3/AE/xqvJpen/ayos7fb9nc4+zN180D1/z0qnczpqFl7z+7/gmvBHm5nwtwcSr0Vv+eh6/NVLS4z/Z6fLP/H/Cf+e596bDpOm/aJh9htv9av8Ay6t/fPbPH0/CqenaXp72KM9nbk/Nz9mb/nuR6+n+FLW40ocr957rp5PzNDUoyIrP5bj/AI+LT+Fv+en+9+X9Kt28JMkB23GCMcKc9X/2v881jX+l6ckdpss7cEz2qn/RW5Bfn+L/APXVm30nTfNgzZWx+X/n2Y939+f8+lGt2ElD2fxPr08vUdYxn+1ZvluP9Xafwn0k/wBr/PtU6Rk2p+W479FP/PI+/wDkVl2Wmae2pyqbO3KhLUgG2Y9Q+e/PT8amTStNFsT9its/9ezH/lkff/PWhXsXU5OZ+89l08l5ljToz/Ylv8s//HvD/Ccf6r60t7GRqVh8tx/rpP4W/wCfc/7X+R+VULDS9PbR4Gaztyxt4ST9nbJJi9c//r60680zT11CyVbO3CtLICPsrcjyCfX1/wAaNbD9z2kvee0unl6mtLGfm+W4/wBQf4T/AHF9+lR2sZE+o/Lc/wDHy/VW/wCeKf7VVJdJ035v9Ctv9Sf+XZh/APf9aZbaXpzTX+bO2IW4cD/RW4HlKf73+etDvdGa5OV+89u3p5li+jP9j3Py3H/HvMeFPt71cu4yJPu3H+uPVT/s/wC1WNeaXpy6VcMtnbhhBMQfszZB4xzn9e1W7nStMDEfYLXmY8/ZmGPu/wC1+n+NPW4Pk01e76enmS3kRGor8tz/AMe9z1Vv+eif7VXFjPnT/Lcf6wfwt/fH+1WNd6Xpwv1UWdsFMFwcfZWHIkTH8X1+lWl0nTfOn/0K2/1g/wCXVv74/wBrj/IpK4pKHLH3n93n6iabGRZy/Lcf624/hP8Az8H/AGv8mnarEfs0Py3H+ttv4W/57j/aqhp+mae9rKWs7ckSTjP2ZugnIHf0/LpS6npenJbxFLO3BMluOLZuhmAP8Xp+fSlrymvue1+J/F28/U2EjPnwfLcfe/un++feqdpEf7Vk+W4/1Fr0U/8APST/AGvy/pTE0nTfOg/0K2xu/wCfZv759+f8iqtrpmnnU3Q2dvtEFsQPszHkvJnv7D603fQiKhyy95/d5+psQxkkfLcf6wdFP91v9qqujxn+wbI7bj/j1gP3Tj7p/wBqoodJ03IzZW33x/y7Mf4W9/8AP4VW0rTNPfRLR3s7cubaEkm2bJO055z+vejW4Whyv3nuunr5mhcxE32mfLcf8fI6Kf8An3f/AGv8j8qneM5Hyz/6j+6f7h9+lZVxpmnLe6cBZ2wDXADD7K3I8hj/AHvX/Gpn0nTcj/Qrb/Uf8+zf3D7/AK/jQr3YSUPd957dvN+Zetoj9su/luf9ev8AC3/PBf8Aa/yKhuYydFuTtn/1E3RTj7g96rwaXpxuroGytiFmUAfZW4HkA/3vX/GoZ9L05dIuGFnbhhDMQfszEg7B3z/+qjWwJQ5l7z6dPL1M74m+H7/xB4aFhpiv539oW07CYlF2RlHbknrgcCt/UkJ1WA7bj/VXZ5Vv9j/arGll8Pt4jl0Jbe3/ALTSAXpiFo4HkkBd2c4+8Dx+NW7/AEvTxqUCiztwrR3RIFswyRsx3/8A1UO5FGNPn5lJ7Pp5PzNiWMhrr5bj8VPqvX5qpWMZ8m9+W4/4+Lr+E/8APQf7X+femy6Tpu65xZW3HT/RmHdffj/PrVSz0zT2ivN1nbkie5Uf6MwwBIMd/wD9VGt0XDk5PifTp5epd1mM/wBnt8tx96P+E/8APwv+1/k1eaM+dF8tx/rW/hb/AJ6j/a/yfzrD1bTNPSxZks7dTmPkWzf891Hr6f4VdOk6b5sWLK2/1rf8uzf89B/tfp+FGtwahyL3nu+nkvMIYydXb5Z/+PWHop/57v8A7VX44z9o+7cf61f4W/vP/tVhw6Zp/wDaZQ2dvt+zxNj7M3XzmB7+n59Kux6Tppn/AOPK2/1q/wDLq395u2f0/wAKFcKqh/M/u9PM5jxfpl/qXwxit9Itrie+P2J40wQDi4Uk5JwAADziuuljJksvluP+PiHorf3G/wBquN0y+sD4h0zw9JpNszT6ONRN0YmzlZwm3bnnOc7s+2K6R9L05Xs8WdsAZoQf9FY5BRvf/wDXSV+UTVN1qklJ7vp/wTTEZ86H5bj/AFIP3T/db36VHaxk30/y3H+sh6K3/PL/AHqqDSdN82H/AEK2/wBSP+XZv7re/P1/wpltpenG8mDWdsQskOB9lbvF9f8APWqd9AtC0vee3bzXmXJYz/ZMx2z/AOqk6Kcf6r61LpsZ+xw/Lcf6qPop/wCea/7VZj6Vpw0uVhZ24YRSEH7MxP8AqvXP+etS6dpenm0iJs7ckxxkn7M3/PNfelrcJKHI/ef3f8Ei0+eZbaUDTrxv3lwciCLH+vP+126f/Wpt/PM1rEP7OvB+9tzkwRf89x/td+n6dKsaYv8Aosv7q3/1tx/An/Pc/wC1Samv+iRfurf/AFtv/Cn/AD3H+1/ke3NKz5dzXmXtdl8X6k/2mbzYP+JZfcyH/l3i/vn/AG6qWU839pSMNOvDm3tuBbxE/wCsk5+93/XHNae395B+6t/vn+BOfnP+1VKyX/iazfurc/6PbdUT/npJ/tf574ptPuZRlHllov6fqOt7mbzl/wCJZfH98P8Al3i9G/26rWlxMukW4/s69IEEPzC3iwevfd/+vvWlbr+9H7qA/vR1RPRv9rpVSxX/AIk9r+7t/wDUQ8hUz3/2v896dnfcfNGz0W6/XzCWeYz2P/EtvRiZTj7PEc/uX4Hz/jRFczZT/iWX3+oB/wBRF/cP+3+tTzr+/sP3Nt/r16pH/wA8X/2qWMcp+7g/1I/hT+6f9rrQk9dROUbbLb/PzKVrPMNSvj/Z14SZo+BbxZH+jjr834/r1pl/cTNo04OnXig283zGCLA/ddc7s1Zs1/4meofurf8A10f8Cf8APAf7X+T703UR/wASW5/dwf8AHvNztTP+q/3qVnbc0Ul7SOi2j+XqI1zMIAP7NveCB/x7xD/lkP8Aa/z161Dezzf2nGTp14Nsd1wYIsnhP9rt+meK574jXNzaweFvsrNCs2t2kUvkBFDIVGVcg/dPp0JPPcV1F8v/ABNYP3UA/d3XRE9E/wBr8v0zQ723M6VWMptWWif5eo+e5mEtxnTL4cH/AJd4h3T/AG/8/nVewnmVLvGnXjfvro8W8XH7wcfe7fp2rQmX97P+7t+h6InHKdPm/wA8+9VdNX5Lz91b/wCvuv4E/wCen+9+X6Zos7rUcZR9nsun5epV1WeVrBgdOvF+ZOWgix/x8D/a/D9OlX5rmbz4f+JZfcyt/wAu8X/PQf7dV9YX/iXN+6g+9H/An/Pwv+1/ke3NaEq/v4v3Vv8A61uiJ/fH+1RZ33ByjyrRbv8AJeZnQXE32xW/s28P7hBjyIif9cefvVPb3M3nv/xLL4/vl/5YRf3m/wBuiFf9PH7q3/4906on/PY/7VWIF/ftmK3P75f4E/vN/tU0n3FUlHXRf18zNsLiZdOgH9nXjYij5EEWD+8P+1S3s8zDT/8AiXXgxc25GYIueDwPm71Npq/8Sy3/AHVv/q0/gT/nof8AapdQX/kHfurf/j6t/wCBPRv9r/PtU2fLuacy9o9Fu/63FguZi0P/ABLL7/VA/wDHvF6P/t/5/AVWsZ5hqlyRp14SzW/AgiJH7o9fm71owL80X7q3/wBWOqJ6P/tf549qqWK/8TW7/dW/W36on/PI/wC1Tad9yFKNp6Lb9V5kU1xMdMcf2degGNxkwRY/1Pru/H9etEVxMNOiH9nXpAjQZEEWP9T67vx/XrVi4X/iWS/u4D+7f+BM/wCp/wB7/J9+KSBf+JbD+7gH7tP4Uz/qfr/k+/FOzvuVzR5dkVr+eb+0rcnTrwFTccGCIE/uh/tdqtXFzMGm/wCJZfD90f8Al3iHZP8Ab/z+dM1Bf+Jpa/uoOtx0RP8AnkP9qrc6/NL+7tx+7PRE9E/2v88+9JJ33Jco2hotv1fmULGeZf7Q/wCJdeNm5uDxBFxwOD83b/8AVTNVuJm024B068UFH5aCIAfvR/tVZ09R/wATH91b/wDH1cfwJ6L/ALX+feuY8d+IZ9Iv9E02Kws5YtWkmheVtoMW1g2QBnPTHOKWvLuN1IxqRbS3R1VzczefHnTL4fvm/wCWEX99f9uq0lxN9rLf2bef6hxjyIs/64c/e/CtG4X98n7q3H71uiJ/eX/aqrIv+nf6q3/4936In/PYf7VU0+5NOUbLRf18x8NzN9on/wCJZfcSr/y7xf8APQ/7fFUtOuJlsUA068b73Igi/wCe5/2vw/8ArVqQr/pE37q3/wBYvBROPnPT5qpaWv8AoCfuoOr/AMKf89z/ALX+R+dFnfcalHlei3X5PzItQnmaO0zp14v7+1PMEXPz9Pvd/wBe9Wba5mM0GNMvjlf+feI93/2/8/lTdSX91Z/urf8A4+LX+BP+en+9+f64q1brmWH91bn5e6J6v/tf549qVnd6ilKPs9l1/L1Myynm/tORhp14cx2vAgiyOH/2u/645qaO5mNv/wAg2954z5ER/wCWR/2v89etFiv/ABNZ/wB1bn93a9UT0f8A2vz/AFxU6r/ox/dwHg9VT/nkf9r/ACffihJ2epdSUebZbL8kUrC4mXRoANOvGAt4fmEEWD+6653Zp15PMdQsidOvARNJwbeIE/6Oenzfj+vWpdOH/Eltv3cH/HvDztTP+q/3qdeJnUtPAityfOk4CJ/z7n/a/wAn34os7bj5o+0lotpfl6hLczYb/iWX3+oJ/wBRF/cX/b/WmW88wn1D/iW3hzcOTi3i4/dLwfnq3KPvfu4P9Sf4U/uj/a61FaL+/wBR/dW3/Hy/RI/+eSf7VDTutTNSjyvRbfqvMp3lxM2k3A/s69ANvN8xgiwOnP3v/wBVWru5mEn/ACDL4fvj/wAsIh/d/wBumXy/8Si5/dwH/R5uqp7f7X+e1XLpf3n+qtx+9PRU/wBn/a6U7O+4+aOmi3f6eZQu55vtysdNvRi3uBj7PED/AKxOfvdv07VaW5m86f8A4ll9/rB/y7xf3x/t1Hdr/wATJP3VuP8AR7joif8APRP9r/Parar++m/dW/3x/AnHzj/apJPuTKUeWOi/p+pk6fPMtrKP7OvD+9uDkQRf89z/ALXbp+nSnalPM1vEDp14v7y2OTbxf89x/td+nv34qXTF/wBEl/dW/wDrbj+BP+e5/wBr/I9uadqq/wCjRfurf/W238Cf89x/tUrPl3NuZe12XxfqOS5m86D/AIll997/AJ4Rf3z/ALdVbWeb+0mb+zrwkwWox5EWfvyc/e7/AK45rSVf30P7qD7391OfnP8AtVTtF/4m0n7q3P7i26qn9+T/AGvz/XFU0+5nGUeWWi/p+o+G5mLD/iWX3+sA/wCPeI/wt/t1W0qeZdEtANOvGAtoPmEEWD8p5B3ZrRiXn/VW5+cdVT0b/aqro6/8SKy/d2//AB7Q87Uz90/7VDTvuPmjyvRbr9fMinnma904/wBnXgIuAQDbxc/6O3A+b8f161O11OrKRpt6CIMj9xF/cPP3qzPFeo/2TFpd0sFm7HUra3COFG7zQIzjB7b93pxyRW264I/dwf6n+6n9w8/e60JO71Jc4uystv1ZXguJvtd0f7NvSTMOBbRcfuB1+f8AH9etQT3EzaPcf8S68AMM3zGCLA+Qf7WauWy/6Xd/urb/AFy/wR/88F/2v8n34qK6X/iTXP7qA/uJuSqZ+5/vUrO25SlHmWi6fl6nCQ3nl/HzU1ktZklk8NRqkTxorkibPCgkdPeu01Ceb+0oWOnXgIiuuDBFk/c/2u36dq891+D7N8fdJvwyBZLFbJkQALlkmcZwcH7nrXpGoL/xNLf91bj91ddET/Y/2vy/TNKz7nNhJLnlouv/AKSPluZt11/xLL7j/p3iGOV/2+KqWc8yw3n/ABLrw/vro8QRcfvBx97t+natORfmuf3Vv+CpxyvT5qpWC/ubz91b/wDHxdfwp/z0H+1/ntmnZ3Wp0QlHk2XT8vUg1aeZrEg6deLzHy0EWP8Aj4X/AGvw/wDrVda5m82L/iWX3+tb/l3i/wCeo/2/89OlQ6yv/Evb91B96P8AgT/nuv8Atf5HtzV5l/ex/urf/Wt/An/PQf7X+R7c0Wd9wco8i0W7/JeZlQzzf2oW/s68ObeEbfIiz/rm5+9+H/1qupczeef+JZff61f+XeL+8/8At1DCv/E2b91B/wAe0PVU/wCez/7X+R7c1eRf3/8Aqrf/AFq/wJ/eb/aoSfcKso9l0/TzPI9Dv5pPjLaxfY5W+z+GlQLHEhchrhGyRuxjng9a9Ne4mZ7P/iW3nE0J5gi5+Rv9qvHfBkp/4aFvYSIiX0KJUVguOBExxzjPBNe0Sr89l+6tz+/h6on9xv8AapL4dzOnOPtKi0+KX5jftM3nQ/8AEsvv9SP+WEX91/8AbplrPML2U/2beEmSHgW8RI/df79Wwv72L93B/qh/Cn91v9rrUdqv+nXH7q3/ANZD1RP+eX+9VNPuXzRtLRbfr6lZ7iZtLl/4lt6AY5OTBFj/AFXruqXTZ5vskQGnXhxHGMiCI5/dr/tU6Vf+JVN+6gP7qTkqmf8AVf71S6av+hQ/u7f/AFUf8Kf881/2qVnfccpR5Hov6+ZiXE40jQtQ1K/1G4gsrX7VLM4t4X2qs5ycAEn8Pw4qnDq9rqs8tjY6rcT3NsLGaWM2sS7UllDRtkgA5BBx+B4qLxFZWuu+Ctb0iK/srea9S6iR5J48KTMcEgDOPp+HFZGheH4dG1vUNSl1PT50vINMt1jjnTcpgZUZjnscZ9h1qdOUput7eyirc3Zd2egfYrvzYP8ATrnmQ/8ALC3/AL59v8/SqllZ3R1KQC8uM/Z7Y7hDb85kk45/z68YqCz8Q6Rdazc2CTLHNZMhkaWSJUcOzFSjYww+U5NPs7uw/tOVjdWoU29uMm4ixne+e30+neqaQoOo4Ssl/wCAruXbayuzMuL64/1w/wCWNv6N6j/636VWs7O6OkW5F7cKDBCQPJt8Dr7Z/wA81NBe6f5ozd2n+tH/AC8Reje1VrK8sF0i2DXVqGEMWQbiLIPOeMZ/zzRpfcr95rot19leZZls7oT2Oby5OZ0A/c2/H7luf8/zois7vKf6dcf6gH/U2/8AcPt/9emTXenmax/0q1IE6k/6TDwPKb29f85pY73T8pm7tP8AUj/l4i67T/n1oVtdSX7S2y2/lXmMtbO5OpXwF5cAiZMnybfLf6OP8/8A16Zf2d0NGnY3twyi3mOPJgAP7r6Z/r6c0W13pv8AaN43n2oPmp8xuYfmHkDpx6/5zTdQvLBtHuAt1aljbygATxEk+XxxjP8An1paW3NF7T2kfdXTouxyXxPtLhY/CRa8mIOv2YGY4hglR/dHP0PH4112oWtxHqKF72cAR3Z3tFbjaAEz7fX9O9cz8Q7izaw8PGO7t/k1qxLASo3GV67eg9zx261qeLhDqNtc2thqNjbzzW13Gk0jwyIhITGVIwQeRj8qNLGFH2iqTsu/RfyljVtUtrHUvslxrE4nntprqMLbQsGji2F2yoI4Hbqe3es3wT4j07xQdRTQ9YuZmhElxIDZxJhJW3Rt8yjqATgcj2rhZ/hoJ/CK6XceIrCLUYdSlu1ubW6VFS3lK+ZCpABwQTwAFz2ra8K+HJ/D3i/XL/R77Qf7JvtkP2eecCWKG3whK7RtJO4Y6DkUaXRMKldQ9+KW3Rdju9VtLlbBi15cMNycGGAf8vAHp/n6VoTWV358I+3XP+tb/lhb/wDPQe38/wCVZurXdg1gwS6tWO5OBPEf+W6+3p/nFX5b3TvOixd2n+sb/l5h/vj2/wA/Snpfc3ftOVaLd/ZXZEMNndfbAPtlxnyEO7ybfp5x9v8AP0qe3srszv8A6dc/65ekNv8A3m9v/rfpVWG80/7cGN1a48hBn7RF180+3+fpU8F7p3ntm7tMeav/AC8RdNze3+fyoVu4pqprov8AwFEFhZ3R06Ai8uFBijwPJtz/AMtD7f578Ut7Z3QGn5vLhs3NuB+5txgkHnp/P8aj0+8sF06ANdWoYRpkG4iB++fb/P0pb68sG/s/bdWpxcwE4uIjgYOT0/z3pacu5dqntHot39lFq3srstD/AKdcf6of8sLf0f2/+v8ApVaxtLo6pcgXlwCDb5Pk25z+6bHUY/zzzU0N7p+6LN3af6sf8vEXo3t/n8qrWV3YDU7pmubXaxgwTPEAf3Zzzj/Pem7X3JXtLT0W38q7olms7r+zHJvbhh5b8eTBz+5+mf8APrSRWd0dNiIvbhR5aceTBx+5+mf8+tNnvLA6bIBdWpYxuMfaIv8Anl6Y9f8AOaIbywGnRA3VqGEaDH2iLI/c+n1/zmjS+5X7zl2X/gKDULO6GpQA3lwSTcYPkwDGIhnoP89uatXFld7pv9OuP9Uf+WFv6J7f/X/WqV/d2B1K2K3VqVU3GSLiIgfuxjoP89uatz3un7pcXdp/qz/y8Reie3+fzoVrkv2loaLb+Vd2RWNndH+0MXlwuLm4B/c25yQBz0/l+FcF8ULSWPxF4KeSeeVzeXCqTHGNvyn+7wfx/Diu6sbuwX7fuurUZuZyM3EQyMDB6f57VxfxOmt5NT8HPBLE8a6jMHZZY2Ufu2xnHQ4z14qdOUyxHPzRutOaPRdzsdYu00/WdJsLvVLlLvUbiVLaP7NCfMKYZhkDAwozzgelc1L420T7Pa3663eyWdxZtOJ009GEUfn7d0mE/drkHlsdPSpfipoNn4v0JbOw1e0sNSjuDJbXguo1MR3BW5XkAqWHB9OwrD8SeGZLiPRtI0e/0NPDunWoV7S5uQPtTLIMCQoOVyA2P4uc8cU3YhSxC2iv/AUel29pcvNKyX9wymRCCIbc5Bc47Y/Lj8Kp6dZ3RsUK3lwo+bjyYD/y3I9P8/Ss/wATeKdM8M6Bf6tcNb3CWrRkwwXEWWzLtwoxz1rTtZrG2tYo3u7bLIJMNNEpAeTcAQRkHDf5FOyuaKpK7p2XNo7cq2MrxZqlroK6OusavLB9tu7aGAvBBgvuJ5IHGAOrYHrW7bWd0ZYMX9wQV7Q25zy/qP8AP5V5hcQ6f4z8c317qEtlJpGj40OCEyxgyPMoFy7AjqoYKD0BXPOK0vhhqthpF5eeDtQvi0+mvvsZriaHE9md2zDYwSvQ59vwWl2Y+3rNaxXK20nZbnZWVncnU5ALy4zstcsIYOch8dR/nvU0dndfZs/brg/9sLfn90fUf5+tVrK7sBqczG6tdpS15NxFg8Pnt/nvU63unm2Obq1yR/z8Rf8APM+3r/nNCtbc7KntOZ6LZfZXYjsLO6OjQML24VTbwnHkwED919M/19eafd2l0uo2P+m3BYzSYPk24K/6Of8AP/16i0+8sF0e3DXVqGFvECDPFkHy+eMZ/wA+tLeXdgdQsSLq1IWWTJFxEcDyD7ev+c0aW3Hap7SWi2l9ldi1LZXWG/064/1BP+ot/wC4vt/9emW9ndGfUMXlwMXDg/ubfn9yvPT+X86WS90/5sXdr/qT/wAvEXXaPb/69R2t5p6zahm6tQDcOR/pEPI8pfbnn/OabtpqZr2nK9Ft/KvIbd2d0NJuCb24YCCY48mDnp7Z/r6Vau7K7EnN9cf64/8ALG3/ANn0H/1v1rhvF3xB0nSpZdOhtrjUTFbySX8tmUdbGJigEj8cj5s4Bzx2rsU1bSb21try0vbV7W5PmwuZohvQ7cHGPr+OR2NFlczVZylyK11f7KFu7O6F8oN7cZ+z3B3GG34/eJxx/n04q0tld+dP/p1zxIP+WFv/AHx7f5+lUrq70/8AtBWF1a4EFwMi4i670x2/z2q0t7p3mzf6XaffH/LzD/fHtSVu5cvacsdF/wCAruU9PtLk2spW8uFHm3HHk2//AD3Iz0/z24p+pWd0LeLdeXDDzLbgw2/ecc/5/HiotOu7BbWUNc2oPmznBuIv+e5x29P/AK3FO1O7sGt4gtzak+ZbnAuIv+ewz29P/r8UtOXc1/ee12XxfyruW0srvzoP9OuPvf8APG3/AL59v5/yqra2dydSYC8uN3kWp3CG35y8nHT/AD37VYW907zYf9LtMbuf9Ii/vn2/z9KqWt3Yf2m7G5tdpgthn7RFjO+TPb6fTvVO3ciPtOWWi/8AAV3LsNld7h/p1wf3g/5YW/8Adb1H+fyqrpVndNodoy3lwqm2gIAhtyB8p9s/19az9e8X+HfDk9lFrd/Ha/a8SQu2CjL8wzuCkAZ4/CtGxmsbbSrWKS7sy620PK3MRDfKeQccg8HNDSuQqrleKtfTSy8zI8d2/l6DardTSyyvq+miB2hizG/nR8jaMZxn73HrzUeoeJ9Ms57uO41u6V7SaHT5h9ijO2eZP3a8LyDkcjp3INHj2/i/sG0W0mtnifWNNWciaM7U85DnjpyB1z39zWRr3g7StQ+I1h4hbU7WO0gtw9xZrdR7Z7hAfLkIA2nGT154GDQrXMH7aM24xT26L+l/T6mn4T8W6Z4l1OeHRdT1K4LTMPMGmKsZKQ4bLsgUEEYxnn610E9ndDR7gm9uGAhmyPJgwfkHtn/PFcLoXhg2/j6HWLvUvD8VtZNcIgsBFbvciWJNolA+UhQvv83vXcXF5YNpFwBdWpYwy4H2iLJOzjjGaVlY3pOs2uaK6fZXY85+Ik8qfETw/CHfzY9TsITKViz88Vz2X5c4b07c16RqFncjUoQby4yYrrBMNvxjZnoP89q8g8QyWd78VJCl0my21/Shv8yMogNs+eQMY569MnBr1y+u7A6lbsLq1wIrrJFxFgH5MdB/+vtRpY5sBz88rL+bouzLktld7rr/AE644/6YW/qvt/L/ABqpZ2dyYrzF5cLia6B/c256SDnp/L8KsSXunbrjF3ae3+kReq+38v8AGqlld2CxXebq1BM9yRm4i6eYMdv/ANfanpdanZD2nJsun2V2HataXS2JLXlwwzHwYYB/y8KOw/z9KutZXfmxf6dcf61v+WFv/wA9R7f/AFvwqhq93YNYMEurUndHwLiI/wDLdfb0/wA4q417p3mx/wCl2n+sb/l5h/56D2/z9KNL7g/aci0W7+yuyKsNpdf2mR9suN32eE7vJg5HnNx0/wA9+KupZXf2j/j+uf8AWr/yxt/7z+3/ANb9KoQ3dh/ajMbq12/Z4hn7RFjPnNkdPT/OKuJe6d5//H3aY81f+XiL1b2/z+VCt3Cr7Tsv/AV5Hhui2V1B8ebXUd5EDRwWRcqm4M9lIwwOhHyjr+Ne3PZ3W+zzeXLZmhA/c2/B2Nz0/wA968R/tG2kvrHUI22H/hLbKy3OyqSsds0b4z/CCevvXtct5p5ez/0q1OJ4Sf8ASIuBsbPb/PeoVrHLh+d1azS+0+i7k4srrzof9OuP9SD/AKi3/ut7f/X/AEpltZ3X22UC8uQfMhyfJt+f3X0/z9aX7bp3mxf6XaY8of8ALxF12t7f/X/So7a80/7bOTdWuDJFz9ohGf3X0q3budP7yz0W38q7ivZ3X9lSk3tww8uTjyYOf3X0z/n1qXTbO5NpEftlwB5cfHk2/H7tfaoJLywOlzAXVqWMUgA+0RZP7r0xn/PrUmnXlgLOIG6tciOMY+0RDHyL7UtL7hL2nI9F/wCAoi0+8sUhljluIVkMtwArPCDzOcDHX/PHFSam0As48nH723zxF/z8DPb/AD34rzc/C7RtSstTn1CzTUNZuhMranc6l+9WZXKiRQFwvPOB1q8i/EHT9AtNPuJfD9/5C28X2yW/kWSUiX5dyhcDnGeenNCtymTlOFS846X6NN79kYfhXxhdar8ZP7R8yCPwtqkkmmW8rCMtNLbZZCp6Dd5jYPQj6V6zZPANUlBOALe24xF2kk9R/nvXGax4b1ZfCvhrT9ITTG1XRZYzbXUt7sRSoKM4ULlc5z3qnoSfEHQ2udNS60rXJiImh1O8vmhZIdzbUdAp+YMWI56A57UHJTc6KlGcb37ep6Mk1pA6vPJHEnnL8zmFR0buRj/P0qCyaA6PbjIJ8mEHiI8jOeg/z3rz/Q/htZbobnxPbRa7qzSh7ie51NvKkkyx3rHjavbHoOO9VbfwFqllZxDwr4ivdE02ZEmltIb1JFMjEncoZfkHT5RwPxp312OhKta/Kun2keoTPAJ7D5iP36Z4i/54v7f5+tLEYMp2xAB0i/uHjp/9evP7XTPiDpd7ZJB4o06/slmDIuosPNLmNusiAYUDIHHetPf49N9bSx3HhtLdINrwefId/wApx83VSOeB60JrsO0+VXj07rz8zqLQxHUtQPzFRNGc7YuP9HA9P8/Wo9TktotCundwipbTszHygFAi69Pb/JrzOz8A6vDIL6y8Q3Ufi6CcyT376jvt5XaMnb5JXGzBA9eMVp+JdO8X6/4WbSNak0OPT5CDeT290/mPAiq7hUIwrOV29eKSatsTKVWLTcNbK2qfTyPP/BWtW+saHcAQvFM/jW31ARTABkgmZdmM9c7W9q95vmg/tWHByCl32i54T2/z2ryX4nyeII/F1j/Zml7LW7k0tIb37SJIYZIZG2o5xznzF/U84ON/UvE/jKS7ezbwy1tqbNLDDeRX6T2qo+0PKQdrNsG04x83PpQtjnw0nRk1NNvXbXoejTtAZZz6g9ovVPb27f415do2tjVvjzqccFt5On6fZXmnqrspMswkjklcj7v8QxjsK6dZfH9tc3E0174Y1AJaqiQlniE0gZcuzD7pYYO3kDHFcPCs3hzxv4QudfutPt7jUbzWptSuLSQmGMsFcDcQCcBQPwpu2hliJz91NNJNX7fgeq6u0A05sHB3R9ov+fhfb/P0rRlMHnxHsJW5xF/z0Ht/n6V5beXPivxlA2q6frp0Hw2J9tnBbyA3FzGZNqzMzLwC2GC44HNTSeB/EQaKb/hNNXOqLKwS7OoIVVNw+Ux7NuM/Nu60XV9jrVSpUgnGGl31S6LuehQtAL4DP/LunGIv+ex9v8/SrFuYPPbtmZTnEX95vb/636VwPhuz8d6ZqEkN1r2k6nAyJ5b3blZYo/NPUoAGOfpgVah1D4iieUrp/hY4mBGdVlXd8zcj5P8AOaasOrNwXvR/X8jqdOaA6Zb5OT5SdRF/z0Pt/nvxS3zQD+zsMR/pVuDxF6N7f571wsPi3xhp9strN4Nl1BkjTbc6fqsfkyDfkY3gNx9Oo9KS98Z+K7m402CDwVe2u66tgtxd6lEY0PQllU5wASeD2paco/bx527Pd9H/AJHocDQBos8YiA6Rej+3v9f0rzK18QWdz8ereOOR47KGzfTXDOgWS7VFf5Vxt4UkZPvV628QfELSbdTqXh6w1gxkwq2m6mIpJBhir7XG0JgkY65+tcffx6roFnpvjXXLW1hvtJ1dtT1C1gmBdo7pFjAGP4o1A+uccUSsclarOabgmkt/S/8AmezzmEaZIOhEb9BH/wA8cen+frRF5P8AZsIIyTGh5WP/AJ449P8AP1rgZ9X8QeNbN10Zm0vwmHbfdtdeXdX8SoQfKG0+WjADBPJ6dDWVpPw51nS9PMeleMdYgtZCJfL+3oxJ8vKnlT0GBjocYour7HYp1JRvCN16pfmeo6g0B1O2weCbjtFz+6X0H+e3NWp2gLS45zER0i9E9vb/ADzXnVrpnjjSNViX/hJLPV7fbcFE1GQeYXMYz+8QDjgADHrWjJqPxGbzy+neFwfKOANUlO7hOPu+n8qI2CU3FQUo9PJ9X2OssGgP9o5Yn/SrjGRF6L7f57Vw/wAWTH9t8FFJMAatKCnyAco/PA/nxzUlnqXxEH23y9O8Ltm5n3Z1WUYJAzj5OR/Oua8fXnimXWfB0Guadp5T+0ne3ksL0ybpdjZiIcDBJ+6ehxSfwmVWqnON01rHfTqeyXLQGePnOJmPIi/vr7f5/OqsrQG8Iz/y7vxiLH+uHt/n6VyU+v8AjHWtWto9K0hdEtIyZJZtXuFcu5bGxBGx4+6xPHSqVrpnxIfU5VuvG2gxL5T7GFhvDL5gzkbhg5we9U7dio1GlpG9v607/Iyf2kdbs7LwFqGlKkkl9qcimBY0Q4WKXzHckDgAAdPX0re8U+I20n4V2N1awXF1q19p1vaWcUSqztcSKNuCozkYLfVa5/WPCGvtb+Lta8Va3Y6rdzaFNYRLAvlJCWJJKpzuJKjkY+8ani1i9Hhz4Q2cHklZp4pdguPmKx27AN0+QZY+tTfU4pup7Z6WbSS1XkjrfDmg2Hhnw1pdjbtI0xntJbqZ9heaZnzI7bsnJOTgnjoeKxPijpk1uml+KvDdrc3HiHS5IkMMDAm4tTK3mQhFUg5znJHAz7V2GoXV55VoGjhUCe1x/wATAHkPwPucf096sW93fCWE+TCML/0EQMcv/scf/X96NNT0p4Zuio6aea7HHaP8SPCMuqXYu9TXTXh+zRNFqEaWzbl37tocDIB4z+ddLomt6LrOnvNpF/a3kSEqz27wsFPlH2/z9agSM3epu13p9hcOsVsuJ7pH2DD9CUOPf096x5fC6w6gdY0KG20XVynlvcW92pSRPL+7JEU2sOMDpgmhPQJ066k72ei6pdPU6nTzCdFt8nJNvD1Ef/PL6Z/z60t68H9o2GDwZpO0X/Pufb/P1ritRk8c23h2O70/VbW8MSQOLKKCFTNGQAyDpghScc8Y71W1r4l3lnqVkLnwZ4rWTc8qLGom3gxlMApkZ4J+g/Gi6sUpP2kudW0fVdv69Cv8Y9V/s/xT8PFi+aGXUisiYTkmNEH3R23mu61bW9M0HTtb1TU5HW0tp3dyqxMxHlIAAAOSSccV434zvtR8Va/ovii+tNUstA0e7svs8N2BEwYyDz3Knkj7gDHHSuz8VT3+q/EbRNHcwGwW4uNWliNyriSSGOMICxXgZf05P0ournHSnJqdl2tqurS/QueCtJEXg3VNR1WSeTUddgluboSiNSoKgJFj+EKuBj8RVfw9YN4Q8fReGNOW5l8K3ds8+nRyFZTazIQZU3kEkEfMAWOOTXY313fNpdz5kcQ3QTbj/aAzzjPGz9O9YXxI0nWdf06FtIktrPWrK8FzZ3TX+4I42gg4UfKw4PrT6m1TDyjCLjum+q8jp7t4DqKgHINvccYi5/eJ6D/Paratb+dNz1kB6Rc/OPavPrXx1cW2ptpvi5bXS9ZtrOVpXm1FI7e4Dy/K0LHJYHZnBAPPpW2vjzSPPl/4nehZaQAf8TyMZO8dPl5/yaE0VzRlCLuvvS6mtprQG0lyc/vbjtF/z8H2/wA9uKdqrQC2hwcfvLbtF/z3Ht/nvxVbT7q8NpIUjhdTJOc/2gO85P8Ac/8A19adqd1em3i3RwqPMt+RqAPInGB9z/8AV1pXXKdXs5e16fF3Xcnk1Cwg1fS7KRyLi8aQwjZHg7CWbnGBwc89apX2p2OjrqOpXrOtpZWUE8xjjjYqivIWIGMnA/8Ar159488SX6/FHwfaraKqabOsk8huMhvtMjRoFfAxyvXFaPj+HUta8Q+HfDdxtt9K1dRJePFceY4S1beEJwAgZpFHem2jgVdpVVppZLXrf8Tb8E6RDe2V7q3iBHurzX2/eWk6qFtrUh/KhVW+78rbjjux6VlfDi/Gi3t14H1C/wDtcdpbRXmjTSRqJZ7Ns8OTnBjI2gcHA6V3Md5fl9zQwA+YD/yEQMfK3+xXGeKNAvPEXhTTZNPFva6zYRQT2F4Lxd6uFPykbRlSMgqTgZpdRPBSpxU42urdVre9zR+I0Sy6RpTRbdsOtabJJkxg7fMReBjnkj/Oa6qU2+/5eR5JAJWL+4fb/wCvXkGs/Ey18TaTpcE2ieIU1e31exa7Vbb9zDPHLGGQSZCgkHjOB8w+tdhq/jnULC8Qah4N8S2VtIrr9ofbJFGgU/M5j3FRjsaE0iaeJhOW9tOun5nWWzwfa7vk8TL2h/54KPT/AD9aiuDAujXPY+RNwBF/cHtmuX0DxzeapE19a+E/FDQXEmYyTEhLBNgADspwQud2Pb3qLQ/H1rrmnanaBV0+/tPOguLG/vlhnjOAoOwryCSAME5JA4ourHTGpFzSuunVGBbrDN8SvFgyxH9vaIQMJyBCM9Bj+nrXpd+8B1O3AJIMV32i5+5joP8APavH7XXTeXfiDX1EbQP4ssYBItyGUmERxgg4+YHP3q7nxT4z/s7XIbG3tjqmsiO4xp1lfq8u1gDvclQqL8vUnJyMCjQ5sHaMnJ7O/Vf3lodJr+raZo2m6lqOoyiK1hUu7bYiTyvAAHJ9h/jWB4W8YaLrOpXulQC9h1HbcXawXlosDPE0nDDcoz0OQOmPrVW28OX1/fprHi5rTV9Ri2zW0P2gRQ2D5BKquD5jDIBc9dvAFQ+LfCsXi3T5xNFDb6hBcXD2+oRXo86A+aCQp28g8jnqCTxTvrsdEI1ZU+aKXTRtf56HX6y0I09iDg7o+0X/AD8L7f5+lXmaDzYvaVj0i/56A+n+fpXnk+neOo7OZb7xXaPArxiEpFFvK+auN5I5bdzxx39qtM3xHsdQcxXmgavbPJmL7TcG2eEhxuz5akHJ59gKE1fYqfNGmm49X1T6LsdXC0A1Zhnj7NDxiL/nu/t/nvxV6NoPtGc/8tVPSL+83t/n8q84EfxGvdRllXVtC0mcQRKkER+0IV81sMzOAc5ycDpwfatLTfFXiix222ueGr6/v4p1WW8025hEEwBOJEDMCM5bjHH40K3Ymc3J/Da/9fL57nFWVgsvhHw1NDGrlPHRmmPGQvmun8yvtXscjQCSy+Yj9/D0EX9xvb/PevM9EivbfwFYteWgt421+K8QTXK+YFe9yuUGezevGc1par8RZf7Vh07w7pFxr19bzRecbK8HkQOqkbJJioVW9hnoR1qVaxnFezq1G+uu/e/T9DqfEfiLRPDltDd6zdpbxeVtRdsZeRgrfKigZY+3Xn6VH4O8RaP4mtpNT0e4aa0M0aZZI1KssWCCpGQR71heHPD2ox6xFrviY2mq64YFEMj3Sqlgu1sxxALgdeSeScetQ6r4Uu5tcn1bwxdx6Frg8qPzobxWhcbM4ki2gNk4yevaqb8i1Gs05WVrd1fdHbyGAaVMM4Iik6CL/nl9M/59ak01ofscPPWKPtF/zzX2rghdfEmDTXtni8MXaIJFN019JCZF2cMYwpCnbjjJ6YrqPCWqate6LDLe6athMAqGKTUVJIVVAYEL0IGR7GjS441PaJxSt66fiaOlzyfZZv3y/wCtue//AE8E/wB3/P6UmpTyfZIv3y/6237n/n4B/u/5/Sq+nWKPbSk3dyP3lwONQcf8tz/n360l/YotrERd3J/e2451B/8An4H/AOv260teXY6OWn7X/t7su5s/aH32xE43CQn2Hzk/3ao2M8g1WXE6jFta9z2kk/2f8+9O/s+Pzbf/AEy6/wBYf+YjJ/fP5f5NVLKyjOpSL9ruQBb2xz/aEgP+sk/zjt1703fsZRjT5Zf5LuadtPIJlImUfvgep9G/2aq2M8h0a1HnLjyIRjJ7Z/2f8+9Ftp8fnL/pl1/rh/zEZB2b/Of8aq2ljG2j27G7ueYIeBqD479v6dqet9h8tPX1XReZoz3EgnsP36D9+nc/88XH9z/P60sU8gKfvl/1AHX/AGDx93/PrVWWxjWex/0y55mQc6jJx+5f8v8AIpItPjyn+l3X+oH/ADEJP7h/zikr66Ccadvl2XmSWlxJ/aeoHz1/10fc/wDPuB/c/D/OabqM8n9iXA81cfZphjP/AEyx/d/z+tQWtkh1K+H2u5G2aPkag4z/AKOOp7+mfwpl/YoujTt9quSRbzHBv3P/ACy7j+nfpS1tsaKNP2kfSPRdjI+IMkj6RopMqsBrWnk4P+0g/uj/AD2roL2eU6pDunUkx3eT65Ef+z/n2rmfH1ukejaSouZ283WdPXm8aTHzIcjPT/eH0rdvrFBqca/a7k5S75+3uTwE6H/Ofwo17GNCNP2svn0/umrPPIZbgmZTkHnPXlP9n2/z34rxp4RsvG+kRW1/5DyWery3Ss+4ZjEv72PIUEb149OBnFdVPp8fnXH+mXXQ/wDMQkPdPz/z6VXsLFGS7zd3IxNdj5dQkHSQfnn9ab1toN0qU6XK/IdqJFvoyQQNHHBEIo4404CKJ1wANvAGB+H5VqzXEn2iE+cuRKx69P3gP93/AD+lYmq2KJYMwurk/Mn3r9z/AMvA/wA/rWhNp8f2iEfbLr/Wt/zEZD/y0H5fX8aNb7FONLkS830XZBBPIL4ATKP9HTv/ANNif7v+f0qxbzyC4ciZeZ1PXr8zf7PvWdBYx/bAv2u5H7hDn+0JAf8AXH/P61Pb6fGZ3/0y6/16/wDMRkH8Tf5z/jQr66CqRp6/5ITTZ5P7Mt/3y/6qMdf+mh/2f8+/Slv7iT/iW/vl4urbv6Bv9n/PvVWwsUbToCbu5GYo+BqDgf6w9v8AOOtLe2KL/Z2Lu4Obm3HOoSHHB/L+lLXl2NOWn7R+r6I0beeQNFiZRiIDr04f/Z9/89ud8RaQnifTtc0W7uESG8S3jZiC23EZIONozjHrWxb2Ee6H/TLv/VD/AJiEg7P+X0/xqtY2SHVLhftVwArW/I1CQH/VN1P+cdKbvfYjkptT9O3mix8lron2e08qC3igdI4k4VFEGAANvTHH+c0+GZzpkIMy/wCrTjP/AEwx/d/z+tVprGMaY5+13XEbnBv3x/qfT/PpSRWMZ02M/a7rmNDgX74/1Hp/n0o1vsUoUlGy/In1CeQ6pa5mU5Nz36/ul/2f8+3WrlxPIWmzMpzER168J/s+3+e+ZfWUIv4lN1dszG42t/aDnGIh7c/16GrFxp8e6b/TLr/VH/mISHsn5/T/AAoV77EuNO0PTsu7H6fcSf8AEx/fLzdXHf1C/wCz/n2rz/41MJx4Him8uZf7e3bWGQPlc5+768967axsY2/tD/S7gYubgcahIM8D8/61wPxlgED+BcTSSK2v7SXunkKna/Qn7v8AXrU/ZIrRp88fWP5nqVzcSGePMy8TMevT51/2aqyTyG9x5ykfZ37/APTYH+7/AJ/Si50+MTx/6Zdf65v+YjIf41/L6/4VWlsY/tRX7Xc/8e7nP9oSE/64f5/Wqd+xVONOy/yRbvs3VhrMUsiMkkMm8Ebsj5z028/pXjPw3f7XqXw0MrB/s/hqaSPJ+4wuFQHgemeteu3NhH9m1T/TLvhGP/IScZ5b8/8APrXjf7P+km5Y38lxKI4dGs7dNtwyFS0rOQCOg4+7+NDvc4K8Ie3jby/Q9q1K4k8qz/frxcWnf0k4/h/z71at55BLARMowvXPu/8As+/+e2ZqFiix2mLu4OZ7Uc6hIesn6f0qxbafH50H+mXQ+X/oIyDu/wCX+fWjW70PQlGn7P7+i7DbGeQarNiZeI7THPTAk/2f8+9TpO4tjiZRjPf/AKZEf3fw/wA5rPsbFDqci/a7kAR2nP8AaDg8h+p/zj8amjsIxbZ+13XHrqEg/wCWR/z+lCvZ6FVI0+Z+i6LsiTTp5P7Etx5q4+zQjGf+mWP7v+f1pb24l/tKw/fr/rpO5/59yP7v4f5zVSwsUbRoG+1XIJt4TgX7j/ll2H9O3SnXlig1CyH2u5O6aTk6hISP9HPQ/wCfSlrbYfLT9pL0l0XY5740pc3fw0137OweaG1WdcHldjRsSPlHQCksNQiufjBfwCdTdWmkzSMc9pGtwP4fRT2/KrnxAskTwV4gZbq4YjSrjhr52H+p7g9fp/hXN6LopPx18S3X2uQwx6PBEWW7fcGcbgGfqThOnuKHe5wyVPnt3S/O56FfTyDSLkeco/0eYYye+P8AZ/z7Vcu55GkyZlP74nr/ALv+zWVd2KLpNw32u5OLeY4N++O3b+nerV3p8fm/8fl0f3x6ajIf7v8AnP8AhVa32Ovlp6er6LyHXk8h1NGMyFvs9xz35kT/AGP8+1V9e0jTfENld6frVtaXlnJJkxyrnBLY3KdmQcE8jBFJeWKC/C/a7k5t7g5/tCQn/WJ/nHfrVpdPj8+f/TLr/WD/AJiMn98fn9fxpK/YmUKXLH/Jdzi/Dvgm00s+do+ta3YQQ+dBFZx37yW8arLt4jkRhzjP1546VX1qx+IGnRKbDxVperxSyw/LqNl5LwHzh5YVoxhlU4Y5GTg46112n2KPayk3dyP3lwONQf8A5+D/APr9+tO1KxRbeIi7uT+8thzqDn/luP8APt1pfZ2FLC0XUtFta9PU838VaJcaL4Y0651nU21TX77XtOku7rpGNlwQqRrtG1BnOPUk966q6vIm+MejW6t/pcGiSSls8BGuYgvb1Vux/Gj4j2EEfhOa6luZHW0lhucS3jSL8lyp6Edf/wBdVINMiuPjVdTRXUhWw0S2tZH89lYNJcNIBv6j5Rn2FHU8+UYUqnJFvVr9b/od3DPICMTKP3gOcn+63+zVXR55P7Ash5y4+ywDGfRT/s/596ILCPcP9Muv9YP+YhIP4W/zn/Gq2lWKPodoxu7kE20BwNQcD7p6D+nam732PU5afK/VdF5mL8TJnOl6GTKDt17TcHPA+df9n/GuwvLmR7mRvPQgxMOCcY2n/ZriPiRapFpWjKLidt+u6aCWu3cr868gn7p9x/Susu9OjFw4F5dkCI8nUJM/dP6+34UK93oZctPnXp282TW1zL9su/8ASF/1y9z/AM8FH9z/AD+tc14w8K6J4o0+OfXrK3vJ7KGbyHcsGXMfTIXkdwDxnng81uQWKG7uh9sueJl6ajJ/zwHX+WfwqCawjXR7hvtdzxDMcG/f+4O39O9LW2xp7OlJpNdui7HBfGG2svC3wmWPS4IYNO0zUbOZbeDjgSISRlRknuT35PrWt4Ei1AxrrWsyj+1taF1dzA4yse2NYkwqADEYTPXnPNXPiT4MTxd4YuNH/tSaBZrmJ3eS6eYbVCsRtPGTjAPataXSobOeytIru5McVvcxqTqDk4UIB27+nem79jGjSj7bme1nb7mbMs8ha6zMpz1568r/ALNUrGeQw3uZl5nuu57yD/Z/z7U6Wwj3XX+mXX/gxkOeV/P/AD6VUs7JGhvP9LuRia6Hy6g/P7wfn/XrRrdaG8I0+T7ui7FnWZ5P7Pb98vWPv/08Kf7v+f0q81xJ50R85eJWPX/pqD/d/H/OKyNXsUWxLC7uTzHwb9z/AMvC/wD6/wBauNp8fnRf6Zdf61v+YjJ/z1H5fX8aNb7CcafIvV9F2RHDPINWb98o/wBFh7/9N3P93/P6VfjuJBcZ85f9chzn/af/AGff/PbHhsU/tMr9ruf+PeE5+3uD/r2/z7daux6fH9oP+mXX+uT/AJiMn95+/wDX/GhX7BVjT1/yXkcJ8T7+7s/gvNc2kqGaBLJ0BOPmFyu3+H1I7/nW74F0q58N+GNH0+6ntmvhdLcXcsS7RJNJvd2OF55OM9OOKp+IfCY8U/Dr+y01KS2e4itm3vdPIi7Zg3+r4H8PTt1rpHsUEln/AKXc8zQjnUJOPkb8v6dKnW2xEqUPrNSb8+xeE8nnQnzl4hA69Plf/Z96jtbiT7dP++UYkhPXp+6/3KgGnx+dD/pl1/qR/wAxCT+6/wCX0/xptrYxm9lH2u5GJIemoyA/6ruf846VTvpoVy07S9Oy7k8s8g0mYCZceVJxn/plj+7/AJ/WpNNnkFnD++Ufuo+//TNf9mqL2CDSpT9ruuIpDg6hJ/zy9P8APpUum2KG0iP2u5GY4zxqDj/lmtGt9hyjT5H/AJIp6fqNqlvKGZ8+ZcHiKc9Zz7f57802/wBRtWtYgrPnzYDzFOOk4J7f57c1paZI32Wb91N/rbn+KT/n4Pt/n60mpSN9kh/dTf622/ik/wCfge3+frS15TXmj7XZ/F3Xf0Gf2naeZB80n3z/AMsbj++faqdlqNqNSkYs+Db2wH7q47SP6D3/AMK3vMbzbf8AdT8SH+KTn5z7VSsJHGqy/upz/o1r0aT/AJ6Se3+e1N3Moyhyy0f3rv6EFvqdp5q/NJ/rh/yxuPRvQf8A1/1qrZ6jappFurM+RDCD+6nPr7Y/zxW3bSMJl/dTH98vRpPRvaqtjI/9i2v7qYf6PB/FJjv7f57U9bj5oa6PddV5+RVl1K1M9iQ0mFmUnMVx/wA8W9v5fyoi1O0ynzSf6gf8sZ/7p9v/AK1aM0j/AGjT8RT/AOvT+OT/AJ4v7f5+lLFI2U/dzf8AHuP4n/uHnp0/Skr6kuULbPbuvPyMe11C2XUb5i0mGmjI/dXH/PAe2f8APpTb/UbZtHnVWkybeYD91OP+WX0x/nnitOzkb+1NQxFP/r4/4pP+fce3+fpTdRkb+w7jMc3/AB7Tc7nx/qvpS1saqUfaR0e0eq7ehxfxC1CFtO0ERlyF1qxLkxTcAFP7w9fx9K6O91G2OpxNuk2hLoHMU/cJ7f571H4r0M69b6OTNd2x0/UIL8AF2WXy41OxgR3HQ9uDyK1L+Rv7Vi/dTD93d/xSccR+3+e9PWxjQsqjbT1v1X8voQz6naebP80nQ/8ALG49U9R/P/Cq9hqNsiXYZpMma6P+quD1kHt/nvW1PI3m3GYphwerSccp7f5/KqumyN5d5iKf/X3f8Un/AD0Ht/nvQ73RcZQ9ns+nVdvQy9V1G2ewZVaTO5OsU4/5bg+n+frV+XU7Tz4vmk/1rf8ALG4/vj2/z9aXWJG/s5v3c33o/wCKT/n5X2/z9a0ppG+0Q/upwPNb+KT/AJ6D2/z9aNbg5Q5Vo931XZeRiQ6la/bA26THkIP9Vcf89T7f5+tTW+p2nnt80n+uX/ljcf3m9v8A6/61agkYXw/dTn/R06NJ/wA9j7VYt5G+0P8Aupv9ev8AFJ/eb2oV9SZyhro/vX+RiWGo2qadArNJkRJ/yynP/LQ+3+e3NLe6jbMNP2tJxc27H91OOx9v5fhV/TZG/sy3/dTf6qP+KT/nofalv5G/4lv7qb/j6tv4pPRvb/PalrymnNH2j0e76r/IrQanabovmk/1Q/5Y3Ho/t/8AW/Wq1lqNsNTuWLSYY2+P3U/aI+gz/njitq3kfdD+6mP7odGk9H9v84+tVbCRhq11iKbO626NJ/zyb2pu9yVKNp6Pbuu68ijNqVq2myKGkyY3H+pn/wCeP0x/n0pItStV06IFpMiNB/qZ/wDnj9Mf59K0Z3b+ypP3c3+rk53Pj/UfT/P0pIXb+y4v3cw/dp/E/wDzw+n+fpT1uVzQ5dn96/yM2+1G2OpW7BpMKbjP7qfvEPUf578Van1O03S/NJ/qj/yxuPRPUf8A1v0qbUXb+1LbMcwObnq0n/PJfarlxI+6b91MP3R/ik9E9v8AP5Ule5LlC0NHt3Xd+RjWOo2y/wBobmk5ubhh+6uD2Ht/P8a8/wDjPdwzP4FaIuQmvjOVkXs3Zhk/h+PNeoafI2dSxFN/x9XP8Unovt/nvXL/ABI8Pz+IYdAmSRoE0fUDqL71kdpAGKhF445YZP8AXilryk1bSnFKLvePVd/Q6G51O08+P5pf9c3WG4/vr7f/AF/0qtJqNr9rLbpMfZ3H+quP+eo9v8/Wtu6kb7RH+6m/1zfxSf319qqyyN9sP7qb/j2f+KT/AJ7D2/z9abuFOULLR/ev8jPvdTtTa6kN0mSp/wCWNx6t7fz/AJ15R+zrqtm+g3e1pP3dtZwthJGG9S2fuZ9R1/CvbJ2dotQAjm+Y4+9Jx8ze38/515X+zZaJZfDycxxyNK99MsjLuGdsqgdBzT1ucs5RdeNk/v8ATyO9v9RtnjtArScT2p/1VwOj/T/ParNvqdp5sHzSfd/543Hq/oP5f41Y1KRvKssxT/8AHxafxSf89Pp/ntVq2kfzoMRTn5ezSc8v7f5/OlrdnXKUPZ7Pr1Xb0MKy1G2GpStukwyWoGIp+wf0H+e1TJqdqbYjdJn/AK4z/wDPI+g/z9KtWEjf2rN+6mP7u0/ik54k9v8APap0kf7Kf3cx+jP/AM8j6D/P0oV7MupKHM9Hsuq7LyMiw1G2XR4FZpMi3hB/dTn/AJZfTH+eOKdeajbNqFkQ0mFlkz+6uP8AngR6f5+lX9Okb+w7fEc3/HtDzufH+q+lLeyP/aVhmKf/AF0n8Un/AD7n2/z9KWth80faS0e0uq7ehzPj3ULV/BfiBEL7n0uccwzjJMXqR/8AW/Cs/wCH1/Zzah4x1KUuLybV5bV9sUrLsgiVFwVB9+9dD8QpG/4QfxF+7mH/ABKbj+J/+ePXp0/Ss/4TQLB4UurqISSDUNTv7wsrvjLOy9hj+EU3e551RxdeOj27r/I07zUbVtKuFDSZMEwGYpx6e2P6etW7rU7TzPvSf64/8sbj/Z9R/wDX/Spr6R/7Huf3cx/0efnc/t7f571cvJGMv+qmH749Wk/2fUU9bndzQ00e76ry8jGu9RtTfq258CC4H+quP+eieo/z35q0up2nnTfNJ98f8sbj++Papr2R/wC0V/dTj/Rrnq0n/PSP2/z3q4sj+fP+6n/1g/jk4+ce1JXJlKHLHR/eu/oc/Yajapayhmkz5tweIpz1nPt/nvzS6nqNq9vEFZ8+ZbnmK4HSce3+e3NX9Nkb7JL+6m/1tz/FJ/z8H2/z9adq0j/Zof3U/wDrbX+KT/n4Ht/ntzS15TXmj7XZ/F3Xf0OX+IQh1jwF4itIA7v/AGdcSgFJVxsLNnLDHGOn9aj8ILHFr3ifVbh3Z5ruxtSQsjAbLWFsAKMgZdj/AJFdD4ukb/hDPEmUlH/EpvOrP/df2rnPhzdCbxR4vaNZWX7Tp4wC3a2jB5H0od7nmzip172emu/nb9TpYdTtcj5pPvj/AJY3Ho3oP8/nVbStRtk0S0VmfItoQf3U5/hPtj+npW3BI+R+6mP7wdGk/ut7VU0eR/7Ash5U3/HrBzuk/un2p63O/mhyvR7rqvPyOQ+It5BNpejNGXITXdNLZjlHG9fUZP4c/pXXajqVqt/cKWkyFYH9zOf4T7f/AFvwqn4j06PWJNHt7hLpUj1GC5BRnzuijMijlT3Qe+OnrWxNK7vuaObJgOSWfn5Dz0/+tQk7sh8vMpWduXuu78jMt9StRdXRLSYMykfurj/ngPb/AD9Khn1K1bSLhQ0mTDKB+6nH8A9sf55rXtpH+2Xf7qf/AF6/xyf8+6+3+fpUNxI39iXP7uY/uJuQz4/1Y9qNbFqUeZaPp1Xb0Ks+p2nPzSff/wCeNx/cHqP8/SoL/UbY6lAwaTAjugf3Vx32eo/z3rZuJHIOYpx+87tJ/wA8x6iq2pSMdUt/3Uw/dXnVpP8AY9v896HeyClKF1o9n1XZ+RBLqdpuufmk/wC/Nx6r7fz/AMKqWeo2yRXYZpMma5P+qnPWQe3+e/Nbssj7rvMU34tJxyvt/OqVjI3k3uIpgPtF3/FJ/wA9R7f570a3QQlDk2fTqu3oZ2rajbPYsqtJnMZ5inH/AC3X1H+frV1tTtPNi+aT/Wt/yxuP+eg9v8/WpNZkb+z2/dTZ3R/xSf8APwvt/n61eaR/OizFP/rW/ik/56j2/wA/WjW4OUORaPd9V2XkYEOo239ps+6TabeIf6qf/ns3t/ntzV1NTtPtH3pP9av/ACxuP7ze3+fzp8Ejf2u2Ipv+PWHo0n/Pd/b/AD9avxyN9o5im/1yfxSf3n9v8/nQrhVlDXR/evLyMHR9RtY9DtFZpNwhjHEU5/iPoMf54qV9Rtmezw0nE0JP7q4/uN7f57Vb0SRv+EfssRTf6iLndJj7x9qmkkbzLH91Mf38HRpP+ebe1LXlKnKPtJ6Pd9V/kUhqdp5sXzSf6kf8sbj+63t/9b9aZbajai9mJaTBkix+6uP+eX0/z9K1RI3nQ/u5v9SONz/3X9v/AK361HaSN9unxFP/AK2H+KT/AJ4/Sm7kc0LS0e3dd15GY+pWraXKA0mTFIB+5n/55fTH+fSpdO1G2FpEC0mRHGD+6n/55r7Vckkb+yJv3cx/dSc7pMf6r6f5+lSabI/2OHEU3+qj/ik/55r7Ua3HKUOR6P71/kZenQ3f2aXYbTHmXHWGXr559/8APfmk1CG7+yxbzaY8236Qy9fPHv8A57c1a0tJfss3zXH+tuf4G/57n/a/z+tN1JJfskXNx/rbf+Bv+fgf7X+T+dK3ul+0ftd/tfqS+Re+bb82fMh/5YTf3z/tVUsobs6lJg2m/wCz22f3ExGDJJ7/AOe1auyXzYPmuPvnHyN/fP8AtVTsUl/tWbDXH/Hta9Eb/npJj+L8v6U2jONR8stf6uFtDemYDNn/AK4D/UTejf7VVbOG8/si3KmzC+RDjMMue/vj/PFalukvmjBuP9cOiN6N/tVVsUl/sa15uMeRD/A2O/8Atf59qdtQ9o9deq/UbLBeGex3fZM+emP3E3XyX680kUN7lObP/UA/6mX+4f8Aa/8ArVanSbz7D5rn/Xp0Rv8Ani/+1REkuUwZ/wDUD+Bumw/7XShLcTqO2/T/ADKFrBd/2lfYNpnzo85gmx/x7g8c/wCfpTL+G8/sacsbTb9nmziGXP8Aqvrirlmkv9p6h81x/ro/4G/59x/tf5H5U3UVl/sS45nx9nm/hbH+q/3qSWm5oqj9pHXpH8hjQ3ogXBs8ZH/LGb/nkPf/AD9KgvobwanFk2m7ZdY/cy44Ce//AOrvWgUl+zrk3Hbqjf8APIf7X+f0qC+SX+1octP/AKu76o3pHn+L/PvQ1ohU6nvLXo/yYs8N6Jbjmz4B/wCWE3qn+1/n8qr6fDd7LvabTia6zmGXqJB7/wD6u9aU6SiW4ybjoc5RvVP9r/PH4VtNSXZec3H+vu/4G/56DP8AF+f9aLarUmNR+z37fkU9VhvPsDbzabdydIZf+fgD1/z9avzQXvnwjNnzKw/1E3/PQf7VQawsv9nNzP8Aej/gb/n4X/a/yfzrRmSXz4fmuP8AWtj5G/56D/a/z+tFtQdR8q16v8kZkEN59sHNpu8hP+WEuMecfep7eG9+0PzZ/wCuUf6iX+83+1ToEl+3jDXH/HunRG/57H/aqxbpL574Nx/rl/gb+83+1TS3FUqPXUy9PhvP7Og2m02+VHjMMuf9YfelvYbz/iXbjac3NvjEEvXB9/8AParGmpL/AGZb83H+qT+Bv+eh/wBqlv1l/wCJbzcf8fVvj5G9G/2v8+1S17pp7R+0evVjYIb0tDzZf6oH/UTej/7X+fzqtZQ3h1S5ANpu3W+7MMuP9U3vWnAku6HBuP8AVDojej/7X+efxq2CS/2td4M/W36I3/PJv9qm1qSqjtPXp+qIJob3+zHLGzx5b5xDLn/U/XH+fSkihvBpsRU2YHlpjMMuf9T9f8/SrVwkn9lycz48p/4Gx/qf97/I/KkgST+zIeZ8eWn8DY/1P+9/kflTt7xXtPdKl/DeDUrfJtN2bjbiGXH+qHqatTw3oabmy4iJ/wBRN6J/tf5/Kk1BJf7UtcmfrcdUb/nkv+1VudJd02Tcf6o9Ub0T/a/zx+CS1JdR2hr0/VmdYwXn/Ew2m04ubjOYJeuF96ZqsN5/ZlxvNpt2PnbDLn/Wj3q5p6S/8TH5rj/j6uP4G9F/2v8APvTNXSX+yrnmf7j/AMDf89R/tf5/Wlb3SlU/ex16okuYL0Tx82f+uYf6ib++v+1VaSG8+1nm03fZ3/5Yy4x5w9607lJfPjybj/XN/A399f8AaqrKkv23rcf8e79Ub/nsP9qm0Z06mi1CK3vWuJ1Js/8AWqP9RN/z0I/vfzrjfhbpNzp/hRxAYAs95czESxSMwJumXqpx/DXeQLL9pmINxkSr/A3/AD0PX5qw/CFpc2ugRxTCZXEs7YVTghrpyDw3uPx/OnbUwbbqqXRfrYsahBeeVabvsn+vtcYgl6mT6/8A6+1WLaG9MsHNnyv/ADwm9X/2v8/nRqSS+VZ/Ncf8fFp/A3/PTj+L8v6Vat0lMsGDcfd4wjer/wC1/n+atqzolUfs9+/5GVYw3h1OXBtN2y1z+5lI5D+//wCvtUyQ3ptuTZ4/64y/88j7/wCfpT7FZf7Vmwbj/V2nRG9Hx/F/n2qdEl+ynBuO/RG/55H/AGv8j8qEtGVUqPmevRfkjPsIbz+xoCptNv2eHGYZc/6r64p15Dd/2hY5NpnzZMYglx/x7k88/wCfpVjTll/sS35nx9nh/hbH+q/3qW9SX+0rDm4/10n8Df8APuf9r/I/Ki2hXtH7SWvSX5HP/EOG8HgXxIXNptGkXJOIZQf9T2yf16Vz/wAAJ72++EmisBbARG5jzJFIzN8zNkkHH8Vdn4y0671TwrrVhamY3F1ps8MYZWALNFgZO7gcjmqfw40OXw74PtdIeOeKezHlyhQSN/kJu6EDrnmhrVHHe9TnfRfqX7yG8/sm4LGzK/Z5s4hlz29/896tXcN8JOtn/riP9RMP7v8AtUl8kv8AY9zzcY+zzfwN7f7X+ferd0kvmctcf649Ub/Z/wBqnbU6faba9X+hnXkF4L9ebPd9nuMfuJgP9Ynv/nvVpYL3zp+bPiQf8sJv74/2qS8SX+0Uy1x/x73HVG/56J/tf596tqk3nT/Nc/6wZ+Rv74/2qSRMqnux1/q5j6fDd/ZZdhtMebcdYZevnn3/AM9+adqcN39ni3m0x5lt0hl6+ePf/PbmptNSX7JLzcf624/gb/n4P+1/k/nUmpI/2eLzGugPMt8bY2Jz54x/F0zSt7pq6lqu/wBrt5mP4whvx4P1/As2U6Zd7sQyggbXyRk9a5L4L+bqFnqWr2zwONSuY590iSOMK7RKBtI4xGOv4V3XiwOvg/xFuafnSrsDKN/df/arif2fbWW3+H2ipiUFraKTKKSCGuJ2HQj1oa1RxKbdZvy/VHfwwXpYc2ePMA/1E391v9qoNJhuP+EetCv2bd5EBUmGXG3aevPXpz0rRhSXI5uP9YOiN/db/aqpo6S/2DZc3GPssH8DY+6f9r/PtVW1Opz9169V+pDPBd/bdO3G0z9oGP3E3/Pux55/z9KleG9yObP/AFGf9TL/AHD/ALX/ANan3KS/btM+a4/4+R0Rv+fd/wDa/wAj8qndJcjmf/Uf3G6bD/tdKSWrCVR+7r0/VlW3gvPtd1j7HnzlzmCb/ngP9r/P0qGeG8Oj3BY2hXyZs4hlz9wd84q/bJN9svPmuf8AXr/A3/PBf9r/ACPyqG5SX+xbnBnx5E3RGx9wf7VFtNwVR8y17fkNuIb0ZwbP/Wf88Jh/yzH+1UGoQ3Y1KDJtN3lXeP3EoHGz3/8A1d60Z0lwcm4+/wB0b/nmP9qq+oJL/alvlrj/AFV31Rv9jP8AF/n3oa0QUqj5lr0f5MJYb0NdYNnx/wBMJvVf9qqlnDeeTebTaDE91nMMvUSD3/z3rVlSUNdc3HvlG9V6/NVKxWXybz/j4P8ApF1n5G4/eD/a/P8ArRbVBCp7m/b8itq8N39hbebTbmPpDL/z8L7/AOfrV1oL3zohmz5lYf6ib/nqP9r/AD9aj1lJf7Pbmf70f8Df8/C/7X+f1q+yS+bFzcf61v4G/wCeg/2v8n86Lag6j5Fr1f5Ix4Ybv+1Dzabvs8P/ACxlxjz29/8AP1q7HBffaCM2f+tQf6ib+8/+1UcCS/2u2DP/AMe0PRG/57v/ALX+f1q9Gkv2g/Ncf61f4G/vN/tUJBVqPv2/QydHhu/7CsyhtNvkRY3Qy5+8e+cVK8F4XstxtP8AXQ4xBL12N71JoiSnQLLm4x5EX8DY+8f9qpZVl8yyw1x/r4eiN/cb/a/z7Ure6VOo/aT16siEN750IzZ8wg/6mX+63+1TLaC8+2zYNpnzIc5gmx/qvrV0JL5sPNx/qR/A391v9rpUdokpvp/muP8AWQ9Eb/nl/vVTRn7R2lr0/VFR4b06VKWNnjypM4hlz/qvripdOhvPskWDaY8uPGYZenlr71LKkv8AZM2DPjypP4Gx/qv97/P6VJpiS/YoeZ/9VH0Rv+ea/wC1StqOVR8j1M/TrOwa2mLRRE+ZcD/Uv/z3OO/p/hTdQs7BLWIrFED5tuP9S/8Az8DPf0/wp+nOy20o+x3B/e3JyLZP+e59/wDPSm6g7NaxD7HcD97bnm2T/n4Hv/8Ar6VPu8pteXtfifxd/Mu/YdP823/cxf6w5/cv/fPvzVOys7D+05FaKLAt7Y48lzg+ZJnv9Pr2q75j+bAPsV1zIR/x6p/fPvVSydjqUrfY7g5t7bj7MhP+sk9//wBdN8pnFz5Ze8/v8yxbWOn+cuYYv9cP+WLnjDe/6VVs7OwbR7cmGIsYIc/un6857/8A66t28jmZR9iuv9cB/wAeyHs3vVazkZdHtv8AQ7k4gh5FsmD175//AF0/duF56+89119SWWz08T2P7qLBnQH9w/TyX9/WiKx0/KfuYv8AUD/lk/XYff8AWllZzPY/6Fc/69Otqhz+5f3oilYlP9Cuv9QD/wAeyf3D7/rQuXUTc7fE9u/qQ2tnYHUr8GKIhZo8fuX4H2ce/r/jTL+zsV0acrDEGFvMf9U/B8r1zUlqzDUr/wD0O4OZo+BbJx/o468/560zUJGOjT/6HcjNvNybdMf6r1zS92xonP2kfee0evkTNZaeYAfJiycf8sXH/LIe/wDnrUF9Z2I1ONRFFtKXfHkuM8Jjv/8Aq71NLP5VuhktbhQWCAm3jGSYhgD5u/pUV67f2pEfsdwNsd3x9mQHonv/APqofLYVNz5viez6+RZnsdP824xDFjBx+5cd09+P8+tV9Ps7Bkuy0URxPdAfuX/56DHf/wDVVm4kYS3H+hXXAP8Ay7IO6e/v/nNV9PdlS7/0O4P767PFsnH7we//AOrtQ+W6Ji5+z+J9OvkRatZ2KaezLFEDuQf6l/8An4Hv6f4VoS2On/aIcQxf61s/uX/56D3/AEqhqzs2nsPsdwvzIcm3T/n4Hv8A56VoTSP58P8AoV1zKw/49U/56D3o924Nz5V7z3fXyRVgs7D7YFMUWPs6HHkv184+9T29jp/2h8wxf69f+WLn+Jvf9Kggdjeq32K4P7hOPsyE/wCuPvVi3kY3Dj7Fc/65R/x7J/eb3prl1FNz195/eU9Ps7BtNty0MRYxR/8ALF/+eh96de2liv8AZ22KIZubcH9y/TBz3/8A10ae7LpsA+x3J/dR8i2TH+sPvS3zMw07/Q7gf6Tbnm2Tng+/NT7vKaXl7R+8931Jrey0/dDmGL/VDP7lzzh/f6f5FVrKzsTqlyrRRbVa3wPJfj902e9WreRy0P8AoV1zED/x7Iez+/8An8KrWLt/alyfsdwcm34FshI/dN2zTfLclOdp+89u/mhZrKwXTHIhiDCNz/qnP/LH6+v+NJFZWDabETDEWMaH/VOP+WP19f8AHpTppGOmP/oVyMxvybdP+ePrn/PWkikZdNi/0O5OI05Fun/PHPXP+etP3blXnb4n94y/s7EalbqsUe1jccCFxn90uO9Wrix0/dNiGL/VHH7lx2T3/wA/jVbUHb+07cmzuBtNxwbdAT+6XpzVq4kcNN/oV1xET/x7IOye/wDn8aS5bktztD3nt382V7G0sG/tDdFEcXNwB+5fphcd/wD9VM1WzsV0y4ZYogQj4Pkv/wA9R71JYMw/tD/Q7g/6TcHi2Tjhfemaq7HTLgfY7gfI/JtkA/1o96Xu8pScvax957rqXLmx0/z48Qxf65s/uXH8a+/6VWls7D7WVEMWPs7nHkv184e/+elWrmRhPGPsVzzMw/49k/vr71Wldhdlvsdx/wAe78fZkz/rh71T5dDOm52XvP7yxDY6f9pnzDFjzVx+5f8A56Htniqem2di1ihaKIn5v+WL/wDPc+/p/hVtZ/LluGktLhUWRclrePA/eEd24qpprstig+x3B+9yLZP+e59/89KXu3GnPlfvPddfJjr+zsFjsysUQJntQf3L/wDPTnv/APr7VYt7HT/NgzDFjb/zxc939/8AP4VX1B2aK0/0O4H7+1PNsnP7z6//AK6s20jGaD/Qrrlf+fZD3f3/AM/hQuW7CTn7P4n16+RTsbOwOpyKYotoS148lzjh89//ANfapo7KwFsSYYsjn/VOf+WR9/X/ABqKxdv7TlP2O4O6O14+zIT0f3//AF1MkjNbH/Qrnnj/AI9kP/LI+/8AnrQuWzKqOfM/eey6+RBYWdi2jQFoYixt4T/qn5PleuadeWdgNRsgIogGmkz+5fkfZz7+v+NJp8jDRoP9DuTi3h5FumP9V65p14zHULE/Y7gYmk4NsnP+jnpz/nrR7tirz9pL3ntLr5E0tjp/zfuYv9Qf+WTjnYvv+tMtrOwabUMxRHFxIB+4fp5Ke/rXK/ETxddeF5vD6QaYJBqd5HYv58IUqrhRlMHlue9dXbsyz6h/odwf9Jfpapx+5T3ofLoYxnJprmei7+hBeWdguk3BEMQYW82D5T9eMd//ANVW7ux0/wAziGLHnH/li44+X3/Sq15IzaTcf6HcjNvNybZOOnfP/wCqrV3Iwk/48rofviP+PZB/d96fu3LvPT3nu+voV7yzsPt4UQxYNvcHHkuOfMTHf/8AVVpbHT/On/cxY8wY/cv/AHx78VWvHYX6t9iuRi3uOPsqA/6xPf8A/VVpZH86cfYbriQD/j1T++PekuUmTnyx95/f5mfp9nYvaykxRE+bcD/Uv/z8HHf0/wAKdqdnYJbwlYogfMth/qX/AOe4z39KTT3ZbWUfY7g/vbg8Wyf8/B9//wBXSnamzNbxD7Hcj95bHm2T/nuPf/8AX0pe7ymt5e1+J/F38yPV9FsNS024sBsg+1wy2/mrA5Kbyy5xnnGc4/CsnwHoEGi6TpulXoglmtLGzjd1ichmDyZI6e1ZXxA8S6jofibwPDZBraDUdRa1uVntUKyIWxjvyCfauutmYao5+x3BzDbDAtkP/LSTnr3/AF703ynNBuU5vmd0u/dosw2OnhhmGL/WD/lk5/hb3qrpNnYPodmzRRFjbQE/uX67TnvVuGRiwH2K6/1gH/Hsh/hb3qrpLsuh2f8AodycW0HItkwflPOc/r3p+7c2vPlfvPddfUW4s7Bb3TQIogGuAD+5fkfZ29/X/GpnsbDI/cxf8e//ADyfrsPv+tRTuzXum/6HccXI4NsnP+jv05/z1qZ5GyP9Cuv9Rn/j2T+4ff8AWhct2Dc/d957d/NiQWenm7ugYYiBMuP3EnA8ge/r/jUM9lYLo9wRFGGEMxH7lzzsGOc1Pbs4u7r/AEK5OZl4FqnH7ge/+etQzyM2j3P+h3IzDNybdP7g75pe7YE58y959OvkTXFlp5BxDF/rP+eLj/lmPeoNQs7AalAqxRYMd3x5LjJ+THf/APVVi4kYA/6Fdf6zH/Hsg/5Zj3qDUGYalAfsdwMRXfH2ZAf4Pf8A/VQ+WyCk53XvPZ9fJliWx0/ddYhi9v3L+q+/FVLOzsGhvMxREie6A/cv/wA9Bjv/APq71clkYNdf6Fdcf9OyDuvvxVSydlhvP9DuD+/ujxbJx+8Hv/8Aqo926CDnyfE+nXyG6vZ2K2DFYogcx8+S/wDz8L7+n+FXWsdP86L9zF/rW/5Yv/z1Hv8A56VT1d2Ngw+x3C/NHybZB/y8L7/56VdaR/Oi/wBCuuZWH/Hqn/PUD1/z0o924Nz5F7z3fXyRRhs7H+1Cpii2i2hOPJfr57Z7+n+FXY7HT/tH+pix5yf8sX/vP7/pVOB2/tRm+x3HNtCMfZkJ/wBe3PX/AD0q6kjfaMfYrr/WqP8Aj2T+8/vQuUKrnr7z+/0KWj2dg+g2bPFEXMEWSYX67j3zUr2dgr2X7qIAzwA/uXP8DZ7/AP66j0Z2XQbP/Q7hsQRci2Qg/Me+f/11K7sz2X+h3H+uhPNsnPyN70vd5SpuXtJ+8931Hix0/wA6H9xFjyRn9y/Xa/v+tMtbOwN7MDDFhZIf+WL8fuvrUgkbzoR9iueYQf8Aj2T+6/v+tMtWb7bMfsVwcyQ8C2Q/8svrVPlM7ztL3nt38xj2VgulTEQxBhFJ/wAsXP8Ayy9c/wCetS6dZ2BtIiYYyTHGc+S//PNfeo3kZtKm/wBDueYpOTbp/wA8vXNS6a7fZIh9juTiOPkWyH/lmvvS9245OfI/ef3kemK32WX9zb/6257L/wA9z/tf5H50mpK/2SL9zb/6237L/wA/A/2vw+n51zXjefUNM+HPiS/sbq4guLeC8kjdYYwVYTnnPUf07V5n4m8S+IodF8ZyR6pd7rDTdGuLciNP3byOhZh6ZJPPfvRf3TGtiI0qrb1s79fP/I+gNr+ZB+4t/vnsvPznr81UrJX/ALWmxDbn/RrbqF/56Sf7X5/0qeK2uj9kJnmJLf8APvFz85qrY21ydSkAlmz9ntTkW8XP7yT/AD796bZcbcsveX49y9bh/NX9zbn96OoX0bj73Sqlir/2NbfubfHkQ84XPf8A2v8APtU9tbXXnL+/mP75f+XeL0aqtnbXJ0e2ImmUeRD/AMu8XHXvTvqPTX3luu/mWp1fz7D9xbH9+vVV/wCeL/7X+f0pYw2U/cwf6gdh/dPP3utMltrnz7DMs5zOmP8AR4v+eL0kVtdbk/fzf8e4P/HvF/cPNCe4na3xLbz8xlor/wBp6h+4t/8AXR9l/wCfcf7X4/X8qbqIb+xbn9zB/wAe83OBn/Vf71FpbXJ1K/AlmBE0ef8AR4jn/Rx/n/69Mv7a5GizkzTEfZ5j/qIhn9160r6Git7SPvLaPfsYnj63R9G0aWW3g8yLWtP8t1UZUlkBGQxwCCfzNb18H/taH9zbj93d9AvHCdPm/L+tYnjiOVNF0lZXJVtb07/WRIuPmTgbfr7/AK1N4wuZ9GtLvUJJpx9mtb2Td9jSTbhU6qpBI6Z5GPUcmi+hz0JJVZ3a69/5ToJw/mz/ALm3HB6Accp0+b/OT+FXTQ/l3n7i3/1912X/AJ6f73bt/WvE9R8f+Jbrw1B4mtQ88Yu7vRpYLVI4o5JW2CCYct3wMZPJ4bFWvh7D4tvfH2saPqmr6pJHo8cL3LQzRoBKyln3IVbzAzjBwwxRzaomFdSjZNdO/Y9f1gP/AGc37mD70fYf8/C/7X4fT860JQ/nxfuLb/WtwAvP7wdfm/z+tZmrW9yLBi0szDcnH2eIf8vA/wA//WrQmtbrz4f303+tbj7NFz+8FO+pu7cq95bvv2RBCH+3j9xbn/R06qv/AD2P+1Vm3D+e37m3P75eML/ebj73T/61U4La5+2KPNmz9nTn7PF/z2NT29rdG4f9/N/r14FvF/eahPcVS2vvL8SDTVf+zLf9zb/6pOy/89D/ALVLfh8ad+4t/wDj6t/4V54b/a/z7VHp9tcnTYCJplHlR8fZ4j/y0NLfW1yP7OzLM2bm2A/cRDnDc/5/Gpv7ppp7R+8t33LkCvui/c25/djqF9H/ANr/ADgfjVsQ/wDat3+5tzzb9VX/AJ5N/tVNb210Wh/fzH90P+XaL0eq1jb3J1S5Almzut8kQRHP7pu1NvUhWtP3lt590S3Ab+y5f3MH+rfnAz/qf978fr+VJAG/s2H9zAP3acgDP+p/3vx+v5Uya2uf7McmeZh5b/8ALvFz+59f8/nSRW1z/ZsRE8yjy0/5d4uP3H+f/wBdO+pWnL8S/EdqAf8AtS1/c245uOir/wA8h/tVbnV90v7m3H7o9AvHCf7X+cn8KOoW9yNTtwZZs5uMEwRDH7pe1Wri2ug037+Yfuj/AMu0XolJPUTtaHvLbz7si08P/wATH9xb/wDH1cfwrxwv+1/n3rkfiabz7R4MgtJTbG61poJVh6TJsdijgE7hlRx/+uussba5P9o4lmGLm4B/0eI84Xn/AD+Fcv4/aSz1bwBJMLiY/wBvuAqQoG/1Uo4A69e9K/umGKm4WlFq913O1uA5mj/c24/et0C8/Mv+1VaQP9tP7i3/AOPZ+dq/89h/tVxXxg1LWvCdlpviK0luZ7Gwu5Be2ixxR+cj4VTnB+65XjB61wPjG48TaFp3ho3/AIi1GLUvsQk1SITJDLMhm+5bAqRLLlsHBJ+UcAEVTZKrqGl1p6/1/wAMd58dXkh+GXiCRUiQrNbHcuAV/wBKXp83+PFd6IwsMXkwQBHiSQZwSdzhiclu5J/CvOPjtDcL8JfETNJcOM252yQRqf8Aj4U4OOQeO3eu805Z7rR9MuI5ZVSWxt3AEEZHOzoTyfxpX1M0/wDaLcytZdx+pB/Ks/3Fv/x8WvZf+en+937/ANKtW6v5sH7m3Py9wvPL/wC1/nA/HmPHes/8I5pdlNcG7ubqee3S0tIrRDJcyhiwRcA8kA4z+NO+HuvSeK9OF0iXdndW0zWt3ZzW8RkglXcSpBx2IIJAovqzplUhy8vMr69+xsWIf+1Z/wBzbn93adQvPD9fm/P+lTqH+zHENueD1C/88j/tfj9fyqtY29ydTkAlmzstOfs8XPD/AOf51LHbXX2b/XzH/t3i5/dH/P8A9ehPQ1qW5n7y2XfshunBv7Ftv3MH/HvDzgZ/1X+9S3of+0bD9xb/AOuk7L/z7n/a/H6/lUdhbXJ0WAiaYD7PCf8AURHH7r1p15bXI1CxBlmJM0mD9niGP9HP+f8A69F9B6e0l7y2l37HmHxyjL+MPhgkkUao+sxghABnmH0Jr1a2V/tOpfuLYf6TJ/Cv/PJP9qvM/jHbOviXwFLO80ogvBMAYkTaQ9vz8vXrXpUFtcm41HEswxcyZ/0eL/nitK+pw0H+8qK62Xcjvlb+yLn9zb/8e83JC+3+1/n3q5dB/M5htx++PQL/ALPH3ulcjrXiKa31D/hHtJs5ta1iWGQTwmIQxWaMu9XklCtgsFIVcc57d9Hw5rSeK9Ds9XsJ5o1uJW8y3NvHut5AQGibPOVI7+o9arm1NlWhKfs1JXV+5qXiv/aSZgtx/o9x0C/89E/2v8+9XFD+dN+4tvvjjC8fOP8AaqjeW1yL9QZZgfs9ycm3i4/eJ/n+VWltbrzp/wB9P/rB/wAu0XHzikmXK3LH3l+Pcp6aH+xy/ubf/W3HZf8Anuf9r/I/Onaqr/Zof3Fv/rbbsv8Az3H+1/n2qLT7e5NpLiWZR5tx/wAu8X/Pwf8AP/1qdqdtci3izLM37y24+zxf89xz/n+VK/um2ntfiXxefc8y+PLGPWfhqSFQjXB9zH/PRfc16hAr/wBszYhtz+5tuoHP7yTr83fv/SvIvj5P5fiX4cWcjs8/9rCflAp2+cq9F46161Bb3J1aXEs2fJtjkW8RyDJJj/PfvTvqcOHknOrqunfuXIg2RiG3PzjqF9G/2qq6OH/sGy/c2/8Ax7Qc4XP3T/tf59q5zxD4nn0HW7Cw+wavqKzYluZbKySX7JH8yh2VVJIJzxx0J56VteHpINS8OWt3omqfb9OMUccdzDbR7XK7lP3vmHIxzzxRfU39rB3hzK913/yMj4izz2thokluY4ZDrVhHmPALKzKGUkN0IJBHfNdVLvL5MUGfI9F/uHn73WuN+JcFwunaHvllbOuacBmCMYO9PTqfY8etcx4mufF0HxJg8N2d7eGHVDBqEN0FjUW1rGhE0e3uDgdx97pQnqyatRQcbtPTz7s9Xtg/2u7/AHFt/rl7L/zwX/a/H6/lUNyG/sa5/cwEeRNyQM/cH+1Xknwt8YazrnjeW21w3kWpXL3KtaW4jMVsIVVQZLdl3RkjGHLcnIxXrE9tc/2NcEzTMPIm/wCXeLn5BRfQulNTad1079jHPiCU/ES68MyWdoqppsepRzDqSWMbJjJGOAevY+vG1qAf+1bfMFuP3V30C/7H+127f1rzXWEvLX9oawmeR/Im0oWRYxqpVissijaOD9w9a9I1G2uRqUAMs2fKu+Tbxcfcz/n8qLszwsm5tNrS/f8AlLsgfdc/ubcfQLxyvT5qp2Afybz9zbj/AEi66BeP3g/2vy/rViW2ut13+/mH/bvFxytVLO3ufJvMSzLie6z/AKPEf+Wgyf8APTtRfVG0LcnxLp37DtZD/wBnt+5t/vR9l/5+F/2vw+n51eYP50f7i3/1rdl5/eD/AGv8j86ztXt7kWLFpZmGY+PIiH/Lwv8An/61XWtrrzov383+tb/l2i5/ej/P/wBanfUHbkXvLd9+yKkIf+1m/c2//HtD1C/89n/2vw+n51fjD+f/AKm3/wBavZf7zcfe/wA4rOgt7n+1CBLNn7NCd32eLp57/wCf/rVdjtrr7Qf383+uT/l3i/vPQmFW2vvL8fI8/wDCnjG4uvHU/hE2FmtvZ6VBdLNjLuxZSc/Ngf6wD8K7yUPvsv3Fuf38PVV/uN/tf59q8h8EafLN8atRu7aZm3aSkJKRodpQWzMCDxxu69a9ba2ud9l+9mbM8GP9Hi/55tUp+6RCXNOpeS+KXfuWAH82L9zb/wCpHZf7rc/e61Hah/t0/wC4tv8AWQ/wr/zy/wB6gW1150P7+b/Uj/l3i/uvTLW2uTeygSzZ8yH/AJd4jn91VNlaWl7y28+6FlD/ANlT/ubc/upOSBn/AFX+9/n9Kl01X+xw/ubf/VR9l/55r/tVXe2uf7JmJmmYeVJ/y7xc/uvWpdNt7n7JFiabHlx8fZ4jj92tK+o5W5H7y/Ep6cbIWswaWL/W3BwZYv8Anucfp/nFJqP2BrSMCSE5lt84ki/57jP6f5xWEfG3hzS7i+s7+e48y2uSk8sVl5sMfnS7490qqVGQynrx0rZ1K+05bVNt3bHbLBkq0HAE4z36f5PFLXlKjUhKr7rvr38zS3WPmQDzocFyD++i/vmqlkbI6pKzSxYNvbc+dF18yTP+fzrl/ih4zbwxptsNBtU1LXZC1xDZm2EgaBHzJISnQAEHJPfjIre8OanYamttqFrKr2t5Z2jwuEjAYlnOBuwc+xGfUU22ZQqwfPFPX/go1Ld7EyjM8OPNA/1sXTDVVsmsl0e2zNEGEEOQZY+vOasC4sraZftEsUOZQw3+SvGG55P/ANb9Kz7XVNKXS7SOS+tBI0MShWeDJK5JHXPH/wCunrcvmit31XX1L0xsTPY/voiPPXP72L/ni/8AWljexJTM8P8AqQf9bH12n/PrUM2o6YJ7H/TLbidc/Nb/APPFx6/5+tRy6tpNraSXc15arbwW+ZHDQnaAh9//AK/40K+pMpxUdX07+pJaGxGpX+ZosGaPH72LkeQP6/5zTdQeyOjXGJoixt5uBLH18riuU8MfEnwlrfiA2thfzNJfSj7N5lj5aybYBuwzKFGP8810Gu6xo9jo5W6v7SKSeOWGFS8GZHMeAqjOSc8f/XqbuxUa1N1I2l/L18ij46MA8P6aYXVkXWdOEhEqEKN6cnHv61sXxsv7UiIliKiO6/5ax46Jj/P5V5V4i1RNT1m/1u5ur638O6Nqmm2KgnbBNOso89zGMBimVXnI4zXVeOPiF4c8Na9YW95LNO0yz+YbWCOVYEcookkI4C5Vs4yRjgUXdjnoYimpyk3Za/lb8ztZv7PWSdVkgCgZA8yL1T/E/wCc1W077CqXhMsQJnuj/rYgTiTj/P5VLNf6YzTSJeWrxsPlcNBhgdhHfuBn/Jrk9V8c6Xol2LKGy1DWb25kvJBBpdvDcPGglUB3APCknGfbim73RuqkVSvft+R0mrtZNp7BZoid0fAlj/5+F/p/nFaErWInixPDgysD++i6bwK4yDxz4a1jRy0d/BaXqjfNY3RgjuLcJcAtvTPGACT7e1dTJrOjNqMdsuo2RuFPnGPzLfcEZwQ3XocfT8KLu4vbU3BWl1fXyQsLWRvgxmiwbdOfNi/56n+lTwPYmdszw4Eyj/WxdNzVSXUNMhuw0t7aRoIFBLSW4GRKSRyfT/OKsxX2mxzZa8tAHlVlIkt+RuY56+/+eKabFKrB3Sf4kOnNZDTYAZogREnWWPvIaW+NkRp2Joj/AKTbk4liPY5/z+dR6Vd2EtjbIt1bF2iUgF4OcOSe/wDn6VzMnxI8G3Wr6dplvq/+lC9iiJazKR7k3Kw8xkCHnoc4NS2+UudaEKj5n1fU7KB7EtFmeHmIE/vovR/8B/nFVbFrL+1LomaLaxt+fNiGf3RzV+BYg0WFBAjAyiREdH6Hoev+eK5I+OPCOneL7rS9Q12ztp0WF3eRF8qJlQqY2kxtD8g7c9PenJsiVanBS5nutPvR0E72R02T99EWMbj/AFsf/PHP8/8AOaIXsl02L99ECI0/5ax/88c/z/zmnytA2lM0ZV1aJ2RkERDDycZBHX/PeiI2402PzHhj/dIT5phT/ljjufX/ADmnrc1548nNfT1Ib9rL+07YrNFhTcc+bGcfuhj9atzvYhpcTw8REj99F1wn+J/zmq15LaSXMFzHcWpgHnFm823/AIkCjjPqO1XHMMwkeNd6vEdpEcRByE9O3Hb/ABoV7k+0hLlSey7+bKlgbIf2hmaIf6VcEZliHGFxXMeOjB/wkHw9MMilP+EgIYrIjD/VSYzjpx68V2On2/zXwkjdA9xOys8cQG0gYP04PPtxXHfECW0/4SD4dC3uoZW/4SAlliZDtBjk6he/Pfipu7HJj6keVxvrodhObDzIh50JUykEGWI8blqtN9gN7uMkJ2274JkiOD5o/p/nFXrkRCaMFSCJSeY4v7y+n/6qqyGE3pGOPs78bIv+ew/z/wDWqnc66drI88+O11GPCY0+zkikfUNRhttm9GyNzv8Aw/7g/wA4rr/Bslo3gzw8ZJYw50u1yDJGDnCDoeenrXOfFi1hv7jw5B0B1kSn5E5CQ3Dc4/z+lQWviODQvgVp+rEk3EejRJAFSIlpjhUAB5PzYOOuAaWtzhclHESk9rf5CaPd/wBvfES91Y3lu+laFdR6ZZRoyAPJKii4d+eSu4qDjjJ54qS6ks/DHxT0++EKJo3iCFLS4mh2OTfCRhFkD7u5TgsQc4HpW94d0Wx8P+GtLtYC8k8k9tcXVwyx7riZ5N0jnJyMk8DsODTfiLosuv8Agu/0/TJWgvzEstu6CNSJY3MiDdkYyygZ7Z+lGppKk3Q51pK9/wANjYsjZf2pMWmiwUtefNj54fP+fzqZXsWtjmaIk5H+uj/55E/z/wA5rD8Aa3beINMstSVoy01rZNIsSxlUkCuHUZ9GyOfxreje3+zuFKll6hUiOP3R/wA//XoV7HZKSk7rql+SINPeyGjW+Zogwt4eDLH18rmlvDZHULHE0WBLJn97Ecf6Of6/5zTtOMJ0W3yMk28P8Ef/ADy/P/PrTrtoP7RsshuZZMYSIf8ALDv6/wCe9Gtim/3kvn+RwHxuktobPS7iOQMI7G5l4dDws1qTjHfgn8K7O71LSNIsNZ1K/nC2dtI8sjI0bsEEScgAc8ntXnnxpvPtWpSaWsZaODwveXWdqDBMkQzxx/yz+tbPjJbPW9d0fw5LbfaFuNSOoTq2xB5EESMwyvXLFeOBS1ueXSm4uq1v/wAHQteB7P7H4c1TWb68zq+tpJezBmSN4QABFEASSFVcYGe/GKivinhj4kxXQvlPhfXrj7PNaoVk+z3u1RG6kfKiyYCn1Prmux1KSJtMu3IwxhnPCRcZx/n+VYfxP0WfX/Ct5a6OF/tWOdbuyL+WoE0ZVlJ29ehGDxyPenZ3NqtG1JcvxK7/ACNq8NkuoqfNiG23uP8AlrFwRImP8/lVpWsPOmHnQ4EgA/fRf3xXP+GNftvFGi6VrMUMkK3Vlcb1kSIYlWRFk/DcG5/LiugW4svtMiiaEu7gqAYCWG8Hpnn8KE2bOrBwi77+fmUdONktpLmaIHzbg8yx/wDPc4/T/OKXVDZNbRASxE+ZbHiWL/nuM/p/9finaaYTaS5Gf3tx1SL/AJ7n/P8A9al1RoRbRY4/e2w+5F/z3H+f58Ua8p0/8vv+3v1PIfjDHHqfj3QPKbeumJbSAqQwG++x29hXqtxe6Xp9xfX99cxx2lvawTTSB0baoeQscAZ4H/16828aiE+O/EMhHlmDS9OlU4UbsXxJPHFbPxHubq/v7DwlpAVbnxHDHDJKyRlIreNmabOOeQygdM5PPApapnlUZ8nt5L5febHw5srWKxn129uH/tjXJhcz+c0cbxQEMYYQCTgBcHHTJ6Vy/gWC08I+MY9AtoZ10fXLCK9sz5geOO6RT50YJJ25Ubj3zgV6jbrbRKiRRiOJGVUVUiwqhWAAz6DA/wAiuI8a2F5c+CNK1PRDKdT0VYL6JF8oB0CFZgQev7svjPfrTaaZvKkqVHmW8Wn+dyx8ShatpeitHIjKuuacGIkjOAXU84/rx611kjWO8Hzoc+RnPmxddhrkviJc29zonhye23iC41jTJlUpGDtZkIzjuAfpXZ3AhWZlC/diK8pF/dI/z3/Gmr3Z0cybT/u/qyvbDTxeXbeZCCZl582IZHkKfT1/zmo7hrJtHuf30RYwzdJY+uwYqxbND9ru+vEy/wAEX/PBf8//AF6iuTCujXIxg+TN0SL+4Pxpa2LXxL5fkeafESaOL4g+H3tZQYV1TT0kIdNq74rkEZHB4/DnmvR782Q1O3KzRYEV1z5sXH3Mf5/KvPr+SPUPiHq6Tn93Ya3oqrG6p8waNjnjgD569Ev2hOp245wYrr+CLn7np/n0panJgZ81SSfn+TJ5XsQ1zieHjp++i9VqnYmyWG8zNEP390RmWP8A56DH+fyq9O9uou3cqqdSzJEABlev+f61T097eSC8KkODPdYIWIg/vB3H9Pwqtbo6oNctvT8hmsNZGwYLLETuj4EsZ/5br/T/ADirzPY+bH+/h5kYf66Lp5gH8v8AOKqayYv7Ofbw2Y8HZF/z8L/n/wCtV4mHzYuOkjH/AFcX/PQH/P8AhRrcb+Ber/JGdC1l/arMZYsG2hGfNjxnzmz+n+cVejex8/HnQ481R/roum5qqQmEaswxx9mh42Rf89n/AM//AFqvxeSbjheTMnRIv7zf4/54oVwq/wCX6HiPw1uZtP8AG1ncXb7oNVvNVtFdugVBFtGTx0h+lexSGyZ7L99Ef38JOJYv7jZryO3v0tfDfg0qG81fGdxET8uNsjzqf89K9flMKvZcEfv4eiRf3G/z/OoV+U5qCaq1b92OD2PmxDzocGIE/vouu1qjtTY/bZ8zRYMkP/LWLn91/jU48nzofl6Qgfci/ut/n1/So7Vofts/cCSE/ciP/LL/AD/+urd9DfpL0/VEUj2TaXN++iLGKT/lrH/zy/x/zmpdNay+xwgzRZEcf/LWMf8ALNaSQwjSphjBEUnRIv8Anl+f+fWpNNMP2OHI/wCWUf8ABF/zzWlrccvgZhaTptnBoN5pdvo9mmnTm5jlgSeNVcGXBBAXngYz14zXML8M/B2nrFNb+FLOOTzIRlr9nBzMAQVJwRjHBBHQ16Dphb7LN+/T/W3Pcf8APwf9n8f8OlJqRb7JF+/Qfvbf0/5+B/s/j/nFK3uhKFOVSzgt/PucD4A8G6n4d8T315q0ttqsMSJYaTKbhA0Vorv8rAjg4Kj3A9KpyfC3Q7m5lito9SsSskV9GlrrHlxwSuzAsiYwp4PI5Ga9Zy3m2/79P9Ye44+c/wCx/n9KpWJb+1Zf36D/AEa17j/npJ/sf596bictPD0lTcXBO3r3PMPDvwl02C/S58SPe+JZo5VEJ1LUQViAJPAzzkgdePbmuph8NaHNo0SN4W0Zw9vErNiAEg5z/BkH9RXY2xbzl/foP3y85Ho3P3aqWJb+xrX9+h/cQ8ce/wDs/wCfejl1NY06aTSgt138zz6X4U+CN1oh8JWYDSqp/wCJk2SPLZiM59ecn0xW/Z+FdBt9gj8KaMB5Azu8hudhHda6qYv59h/pCD9+ndf+eL/7H+f1oiLZT9+v+oHp/cPH3f8APrQluHJTSvyLbz8zjNd8KaP4nLWOsaLbz2dpcxvFCl2kQjxb42gqAQvTgYGQB2rifin4K8OaT4T/AOEistCttPvtKa3mWW2usM6xug2YHQnJ+bGeK9jtC39qah+/T/XR9x/z7j/Y/D/OazPGOkwa74N1DTb+Y/Zp7aXcEcKw2oGGDt9VFJLQK1OMtIxV2l37Hl/hkNcfA7wlHfWUVzFca5DJNFLICJFkuWbDZ9QRz/hXdW3h3SdIgOk6boVnbWE1rdW8sMdymZ48Lw743N1OMknnjFM8W2FvpXhLw5p9gFS0ttX02KNA27aAUGSSM11N+W/tWH9+p/d3fcc8R/7Pf/OKbWhGFpxT5ZRT0ffszz8fCXwTDvQeEbVwibQX1JiTjaM5B5PJ/wAiuj8JaNpnh+CdNB0GxsQpuYd0NwgcqHHyl2BZunc89sV1E5bzbj9+h4PPHPKf7P8AnH51tNLbLz9+n+vu+4/56D/Y7/5xRbVFwp01DmUFf59jB1vS9LuklutQ8OaXcTyOpeaR4Wdj5wAy2zJ7fh7VNL4e0PzYgPCWhf6087bc4+cf7FamsFv7Ob9+v3o+4/5+F/2fx/zitGZm+0Q/v0P71u44/eD/AGP8/pRbUcoU+VPkW779l5nIR+HdENyFPhbRM+Shxtt+P3p5+5Uj+F/DtyJIpvB+iFWkClswg4LNnBCj8/8A61dDAW+3D9+o/wBHTuP+ex/2P8/pVi3LfaH/AH6j9+vcf3m5+7QoiqQpu/uL8TzuL4f+FbrQLSzl8Kaa8MYSRWFyqPu3EHLD5jwehJ9a6TUba3k0zTNOl0mxOnpc25W1aWIxA/McBNuByfStXTi39mW/79P9VH6f89D/ALP+ffpS35f/AIlv79f+Pq27jjhv9j/PvSt7ppyU1UdoLd9zg0+HemFIooG1u1gCZWC38QPHFGDuO1VHCgHt71raH4e0ex0q78PW/h7TzpUjxNNDJcK5kZozuZnYElj68be2K663LbocToP3Q9OOH4+7/nP5VbAt/a13+/UfNbc5H/PJv9mm46mSo0fffs1t590eer4R13R7S2tvCXiGbRPDyK5nsDLHNJHwZGMDsuVzkrhs9a108LaZNef2vqGm/wBs3rWy26Sarex3O2PZvwqlcA56nGe2ea62ct/Zcn75R+7k4yP+eP8Au/h/nNJCW/syH98p/dpxx/zw/wB38P8AOaOXUFQpL3uRb+Zy+s+GfD14GsLnwnootrnzQwi8lHwqAja6qCuD+fSseP4a6TZxGGxbXrWGOPCRQeI3VFAA6D8en19K77UC39qWv79Tzc9COf3S/wCz/n261buC26b9+h/dH054T/Z/zj8xRCVGk1B8i1Xn3ZwFn8MtBvba+jvdb8Q7PNmhaL+25WUqAMKefm6n61ieOdP8H/Du8+Hk1nbwWNnaauTNepEC/lrGw+dwCSc4Pv1Ar1LTy/8AxMv36/8AH1c9154X/Y/z7VynxEQS6z8PElZJEbxCwIOCP9VL1+Uf1pW0ucOMw8YJyjpt/WxoX/xA8P8A2RL6w1WPUo2cPDHZzedNJuYE5iVS6428kjriqnhnx1YeKrqZdIE4u4ICs9ndyCCeNmkDY2MMngZyP0rctfD+kaZq39oadYaba38shV7mG3jSRhvXqwQHng++Kq6r4e0fUdZN3qFhp11dfZmHnSwoz4Ewx8xTPc9+/wCFNpnTSjUSV7P7zlvFN7Nf/E7RbVZIc2NtqF5NEl2jlW8som4j7n+sOM1g6A39ofDf4XQXdqJrdbu1IX7Qo3FBMV4xxyAefSvTLfRNM0e31l9JtLCyeZcStBEiGTBbGSE5x/n0ry34ezvfaH8KdHSdYxb20urSEgHcI3aNUzjIOZCe/SixzzSVT34rX18j1jUb26MdpuhVcT2p/wCPxDyJOnT/APVVi2vbwTQH7OvC/wDP6g7v7e9GpFvKs/36f8fFp3H/AD0/3O3+c1aty3mwfv0Hy9cjjl/9n/OfyLas9GTj7P4V179jzOx8H6hp+qXUfhfW7zQrOaaK8mtbeS3dTLJuLNudSQOAAvRaVPDfiHQdSn1bwhcwma9LNqUOq3wkW5by/lZSq/uyMsOOOQMcCu/sC39qzfv1H7u07jjiT/Z7f5zUyFvsp/foOvp/zyP+z+H+c0KOhFSjTu7RWy6vt6nnltqXxIudDS1ttO0CwkEERS7e+85CFTAGzGckZznpn1qOf4p/ZHiHiDQddttWs5iJba1gM6zFodhaJ1G0jknk5wAOtehacW/sS3/fL/x7Q8ZH/PL/AHf8/rUl3NMl/ZKt0AryyBgGAB/0c/7H+f1otoSqMo1HZ3339PQ8k1LULnxbF428SnTrqy0mPw9Jptn9t/dzOUBdmMZ6AlgB9K6GX7XdfFmwuljX/Q9PvXYfaVO7etumN2Mdx9fwro/iFufwN4jJnBxpNweMH/liOPu/5/WsDSNTaX4263prSIPsuimRZCAN/mNCSPu/7HoKTVmcsacad1a97d+51N5eXX9k3AaAKPs8wJ+2JxnHbH/66tXd7eGXP2cH98T/AMfiH+77Ul8W/se5/foP9Hn449v9n/PtVu7LeZzOh/fHuP8AZ5+7VW1PQvHT3Vu+/kecat4IW41C9tUuryDQb/7RdXGjw3saxO5dchWA3KhyCUBwcfWorn4U+GFmM+iaHHo+pW0yy2l5bajloZA3ythiQwBwcH0r0O8Lf2iv79Dm3uc9Of3kf+x/n2q4pfzp/wDSE/1g7jn5x/sf5/SkomDo0lFPkX49/U81sX+Jj6WYUvfC/niWUtdF2XdiYbl2AEDccnP41WX4qRW9pd2/jOFtG1Gyuo4vlMjQ3AjnVi0b7OVwep7/AFFeh6aW+xy/v0/1tx6f8/B/2fx/zijWV8y0hEksTjzLYYYKf+W4/wBj/Pv0ot7pXsnGr7n83W76/f8AieNar4htPEcvj7XtJlW50+LRrW3M8bHG9bgyYyVGTgiuwi1Iy/FvQ1VGW7i8PbjH9qBUobiPB6YU8NnvwKufF6Db8LPEsduyIpspGKxADOHJ5wo9KxtI3t8cdJfzAAPCcHzcYX/SBx93/H8aOU4vZ8k9UtWn18z0SG9uww/0cD94D/x+oP4W9qp2E883h23gktlkhezhjYG8Qbl2kEYxkcHp2rVhLZH79B+8HPH91v8AZqro5b+wLL9+n/HrBxkf3T/s/wCfehrU9JuLi/dW67+Z4zr3hzxRo9votpdeIFbw3aazZrY2cciG4+aUEb5SP4BwDzjjPSus1rT/AIjAxxaN4otGg8ti0l9HC0wXBIXcoweODkZrV+JxP9m6FmZS39u6djp/fXn7vb/Oa6+VnL5M6kmA9x/cP+z/AJ9e9Cjqzn9jTTVo9O8u78zzK1sfild3s0d/4o0e3h35lewjQSbxENpG8EYxtU/j3q4Ln4k2XhyWK5/4RnUn2TbpRctA2xl7qBjIH5139sX+2Xf+kJ/r19P+fdf9j8P85qG4Lf2Lc/v1H7ibjI/55j/ZotoV7KPMrK23V9vM8q8X2us+Gl1jxHqk+mSPqGs6TO5tJzsh8ranV+TkEHd0HNb978QZtWt5rvwtoeq6ncQfaoV3NHHBKWxh1kYjeny8lRzniup8Y6DZeJ9CutJ1d1ltJ3G4KQCCEUgg7ODx1/8A11NJbR2Nxp9paPHHbQW91FFGpGFUBAAPl/z7UNWMqVBqSUdNHr12f9bHHTaF4i8Ry6ivjqa1n02TYY9L06+8uLPy7hK+A0g6YGccGs6Pwvr+hR3H/Cub+10mzLywyaddzCe2Cq+NyZyyueM4ODgmvU5S266/fofy55X/AGP8Kp2Jbyb39+n+vu+4/wCeg/2f8+1HLqjWFGm4axV9Ndb7HnRX4pQQyNqmqeGryAoqhBmMq/mja2VHPzc46YrUg8T+OrCT7NqvhhdUuUlPl3unXsUdu5Lg/MHO4YOcnHPWuw1kt/Z7fv1+9H3H/Pwv+z+P+cVeYt50X79P9a3cf89R/sfj/nFNLUU6ScE46avv2Xe5w9vqXjae7lMWnaDZTpbw4E+oPJ5n71um1cABsnnnFVrHxh4w0xJo9f8ACl3fz2sgaS90u7h8qZFBO9VYhsk7uMV2cBb+1m/fqP8ARYe4/wCe7/7P4/49KvRs32j/AF6585Ocj+8/+x/n+QkTUotKyev/AA3keRQ2l5ceDNJ1LWbRNOeDxDFrCQmdG2iS6YAbV6fLKT/StuP4o2V9dadFoun6rqrS7Jons1xGxRWGwySBVB/Ejir3i7w9c+K/hY2i2t7DBLcw22HkOAoWYMeiZ6A10Omafb6Pp2kadppit7O2kt0jjXAAAjbn7vUnJJ9SamzsJUpU6k4JabX16HHyR+O9el0v+0Z7HRtPMRe5hsLzNy6FGxEzsCEIyQSvPPB6VSXw94x0Z3t/A3iGO2tlaIC31aZLoRnyychyN3fGOgr00FvOh/fp/qRzxx8r8fd/z/Jlqz/bp/8ASF/1kPccfuf9ym46lqlCzvG7t3fdHlslr8XfsUm7xF4bSDY+VEIyB5fPb+7xXceB5vEFt4fgj8RSWt7fjBM1rOsSFNo2DaR1C4B9xWxIzjSJwJ1AMUmRkf8APL/d/wA/rUmmlvscP79f9VH3H/PNf9mi2po4xUW+VfezK0623W8p/tC5X95cDC3o/wCe5/2e/X3603ULbbaxH+0Lk/vbcfNej/nuP9nt19utO0/VrJLeVWnQHzLg9Ze85I7f5780l/q1i9rEFnQkS256y9BOCe3p/nNT7vKdlqvtfhfxdvMu/ZP3kH/Eyu/vn/l+HHzn/Z4qnZW3/EykX+0LkYt7bn7cAf8AWPwfl7fpV06zp3mW224X75zky/3z7VTstWsRqUjmdNpt7ZQcy9RI+e3v/hTfKZRVbll7r+7zLNvafvl/4mN2P3w63wHZv9n9f8aq2dru0i3P9oXQzBD8ovRx14xt/TtVq31iwEo/0hP9cD1l9G9qrWmrWK6Rbq06BhBCCMynkZ9v89qPduO1bX3XuunqTS222ex/4mNzzMo5vxx+5b/Z49P0oitOU/4mN3/qAP8Aj9H908fd/Sll1exM1iROmFmQn5penksPT3oi1iwyn+kJ/qAOsv8AcPt/9ahcuomq1vhe3b1IbW2zqN8P7QuRiZORfDJ/cDqdv4Z/CmX9rt0ec/2hdHFvN8pvAR/quhG38MfhT7XVrFdSvmadMNNGQd0vI8gD0/z9Kbf6tYto06LOhY28wAzL1MWPSl7tjRKrzx917R6eRz3j+2/4lWjH7ddPnWbDj7WHA+ZOcY/XtXQXtt/xM4l/tC5O5Lrn7aCeidPl7/rWL491C0l0LSnWePEet6eT/rCT8ycDI9ifw+lbd9q1k2pxuJ02hLoE5l7hMdvb/Gm+WyM6XtXUfuvZ9PJlme0zLP8A8TK7PB/5fgc8p/s8/wCfSq+n225Lv/iYXIxNdD5b0DP7wf7Pf9asz6zYGW4xcJyD3l9U9v8AP5VWsNWsUS7DToCZrojmXoZBjt/nvR7t0OKrcnwv7vIj1W222DH+0LlvmThr0Ef8fA/2fx/Wr8tp+/i/4mV3xK3/AC/D/noP9nj6/jVHVdWsnsGVJ0J3JxmXtcA+n+frV+XWbAzxH7Qn+tY9Zf8AnoPaj3bg1W5V7r3fTyRVhtv9NC/2jcj9whz9tAP+tP8As/j+tTwWn79/+Jldj98vP24D+Jv9n9f8ahg1exF4rGdNvkIOsvXzifSp7fWbATuftCf65T1l/vN7ULlFNVtfdf3FSwtt2nQH+0LoZiThb0YH7w/7P/6utOvrbb/Z/wDxMLk5ubcc3o44PP3eMfpSWGrWK6dArToGESDGZf8AnofanXmrWTDT9s6nbc27H5peAAfal7vKXar7R+6930JoLT5ov+Jjdj90P+X4Ds/+zx9P8arWVt/xM7kf2hcjabfkXoBP7o9Tt7fp0qzBrFgGi/0hP9UB1l9H9v8AP51XstWsl1S5Zp0CsbfBJl5xEw9Kb5bkpVrT917dvNCzWu3TZD/aF1xG5wb0f88fTb+H6UkVpu06I/2hdcxocC9H/PH02/h+lLLq9idNdVnQsY3HWUf8scen+fpSRavYjTolM6bhGgPMp/5Y49P8/Sj3blWrW+F/cNv7b/iZW4/tC5O43HJvQT/qh0O3v+vSrU9p80v/ABMbs/uj/wAvwOeE/wBnn6f4VWv9Wsm1K3ZZ12qbjJBl7xAdxVmfWLAtN/pCf6o95fRPb/P5ULluJqtaHuvbt5sgsbbd/aH/ABMbkYubgfLejngc/d5z+tcv48jaHXvh8EmkuHOvMVMl1u2/upOM4+X1z3xXU2WrWS/2hunUbrm4YfNLyCF9q5H4japanVvAU8HmSi117zpmijkfy4trgk5HAyRSXLY5sbGrKLXI+nQ7ae0/exf8TK7OJTz9uB/iXn7v61Wktf8ASyv9o3J/cOf+P0E/60cfd/H9as3GsWHnRf6QnEzd5f7y+1V5NXsTdFvPTb9ncdZf+ewPpTfLob01Wsvdf3Be2uLXUv8AiY3f3Sf+P4c8t/s8/wCTXknwj08Tv4JnS8nXyfDcpbFwE2FrwDA44HGcfjXrl3rFgbfUv36HIOBmXn5m9q8l+A15GIVuLiULBb6PZ2kYO/5WMzyMBgUO1zhrqr7eC5X93oer6hbbYrT/AImNyf39qPmvgcfP/u8Y/SrNvaYlg/4mV2Pl/wCf4DHL/wCzx/8AX96r3+rWLx2gSdCRPak/NL0D89v89qsW+sWHmwZuE4X1l9X9v8/nR7t2d8lW9n8L+7yKllbf8TKVf7QuRtS15+2gHo/X5e36VMlri3P/ABMbvjsb0D/lkf8AZ/z0qKy1ayXUpGM6bSlqAcy9g+e3v/hU66zYtbBTPHwMD/WD/lkfQf5+lC5bFVFW5vhey6eRXsLXdo8B/tC6GbeH5ReAD/VdANv4Y/CnXltjULIf2hcndLJyb4Ej9weh2/hn8KSw1axXRoEadAwt4QRmXqIselLd6tYtqFkyzphZZCTmXjNuR6ev+cUvdsO1X2kvdez6eRl+PbUDwT4hY6jdHGlXBAN4GDHyhweP0/CsDTNHdvjj4jvxd3CRLo9vF5gmCMSwJwW5zxH7Zre+IGq2MngnxAqzIWOlXAAzL18n6f8A1qpeB7mFtW8V6zPN+6uLtLSMtu6RWy8fKPV2P40/dueZVlVjXjGz1XY6G8tdulXB/tC6OIJuGvRg9OMbf071aurTMn/IRuz++P8Ay/A/3f8AZ/Wqt5q1i2lXCLOhYwTADMvfHt/nvVq71iwMn/Hwn+uJ6yn+77Ue7c9C1bT3Xu+noQXdt/p6r/aNyc29xz9uBP8ArE4+739O+M1aW0/fTf8AEyu/9YP+X8c/OP8AZ5/yaq3er2Jvlbz02iC4Gcy9TImO3t/jVpdZsPOnP2hP9YO8v98e1C5SZKtyx91/d5lGwtt1rKf7QuR+9uBgXo/57n/Z79ffrS6lbbbeI/2hcn95bj5r4H/luP8AZ7dfbrSWGrWSWsoadATLcHrL0M5I7en+c07UtWsXt4gs6EiS3PWXtOCe3+e3NL3eU1tV9r8L+Lt5md4103z/AAV4hX+0LhtumXT7Xut6nAc4KgDP+TWD4QRL7xtdsLqdW0/SdNtfMFyA2WLyEFscYyOD0roPGOrWL+D9eVbtVY6bdAAGT5iVf5enesX4b6rpsd74h3MFmNzYEyHfh1FpCMcDPBB/Pim+U4KlOtKonyvRrp6nYQ2mGH/Eyux84/5fgOzf7NVtKtt2iWh/tC6XNtD8q3oAHyngDb+narUOsWG4fv0/1g7y/wB1vaq2latYx6HaI86BltoARmXqFPtj/PFHu3O21blfuvddPU5v4kW+zT9E/wBOuH3a5p4+a7DY+deRxwR69q664sSkzIdRuyViK/8AH6P7p46fp+Fcr8Q7+3urDRUtmErJrenysFEhIRWUsenQDk4rrb3WtPe6lZbhCpjbBBl5+U+1C5bszftudLlfw9vNkNvbZurof2jcjEy8i/HP7gdfl/DP4VDPa7dIuD/aF1xDL8rXo5+Qdtv/AOup4NXsRd3RM8eDMpHzS9PIA9P8/SoZtXsW0e4QToWMMwAzKOSg9sUvdsaJVuZe6+nTyJri0zn/AImV2fnz/wAfwP8AyzH+z+v4VBf23/EygX+0Lk5iuuftoJ/g6fL3/WrFxrFh83+kJ/rPWU/8sx7VX1DVrJtShYToVEd0Cd0vfZjt7f403y2FTVa6917Pp5Msy2nzXP8AxMrv/wADgc8r/s8/59KqWdtuhu/+JhcjE1yPlvRz+8H+zzn9aty6xYbrr/SE595fVfaqtnq1ksV4GnQEzXRHMp4MgI7f570e7dBBVuT4X06eQ3VrbbYk/wBoXLcx8Neg/wDLdf8AZ/H9autafvY/+Jld/wCtb/l+H/PQf7P45/GqeratZPYsqToTmPvL/wA/Cn0/z9autrNh5sR+0J/rWPWX/nqPb/P1o924NVuRe69308kUYbb/AImjL/aFyMW8Jz9tAP8Arm4+7+Pt1q6lp/pH/ISu/wDWrz9uH95u+39f8apw6tYjUy5nTb9nhXOZeomY+n+frV2PWbD7QT9oT/Wqesv95/ahcoVVW/lf3ehS0e23aHaH+0LlcwxfKt6AB8x7bf07VK9rtez/AOJjc8zQjm9Ax8jf7PH9Ki0fVrGPQrNHnQMsMQIzL/ePtipn1exL2eJ0+WaEnmUcBG9qXu8pU1V9pP3Xu+g8Wn72H/iY3f8AqQP+P0f3W/2ePp/jTLa1/wBNmH9o3I2yRci+AP8Aqu/y/h+lSDWLDzof9ITiEDrL/db2pltq9iL2VjOmDJCR80vaLHpTfKRatZ+69u3mMktdulyn+0LriKQ4N6P+eXpt/wA9Kl062/0SI/2hdDMcZwL0Af6tf9mo31exOlyqJ03GKQDmUf8ALLHpipdO1axFpEDOmRHGDzL/AM819qPduOSrcj91/cSaWZfss3yTf625/wCWsn/Pwf8AZ/z9aTUjL9kiwk3+tt/+Wr/8/A/2f8/XiqWn/bvs8uz7Jjzbjr5/Xzzn/P5802/+3fZYt/2THmwdPP6+eMf5/Lmi/uh7Ne13+1+pvZl823+Sb/WH/lrJ/fP+zVKxMv8Aas2EmP8Ao1r0lkH/AC0k/wBn/Pao/wDiY+ZB/wAeX3z/AM9/75qpZ/bv7Skx9k3/AGe2z/r8Y3v6fj/Sm2Zxpe7LX+rm1bmTzl+Sb/XD/lrIOzf7NVLEyf2La/JNjyIf+Wj+/wDs1Fb/ANo+aP8Ajy/1o/57+jf59f1qrZ/b/wCyLfZ9j2+RDjPn57/h/ninfUPZaPXqv1NabzfPsMRz/wCvTpLJ/wA8X/2f8/SliMmU+Sb/AFA/5aP/AHD7f/WrPm+3+fZbvsmfOXGPtHXyW6/5/SiP+0cp/wAeX+pH/Pf+6f8APpST3E6Wm/T/ADLNmZf7U1D93N/r4/8AlrJ/z7j/AGf8/Tmm6kZP7EuPklx9mm/5aP8A88vpVK1+3f2jfbfsm7zk3Z8/H+oHT/P6U2/+3/2PPu+ybfs82dvnZx5Xbt/n0pJ6Gip/vI69I/kX7y1S8tYUu7Z5VjlSZBI7na6xqVYZXqDgg/0pL7zP7Vh+SX/V3f8Ay0k9I/8AZ/z3xVc/2h5C4+xY4/57/wDPMf5/+tUN79v/ALSiz9k37LrH+vx0TOf8/Wm3ohU6S5t+j/Jm1OZfNuMpN0PWWT1T/Z/z+VVdNMuy8wk3+vu/+Wsn/PQf7P8AnvioZ/7Q82f/AI8uh/57+qev9f8ACq9h9u2Xe37J/rrrO7z+vmDP+fzovqiY0v3e/b8i3rHmf2c3yS/ej/5aP/z8L7f5+taMxl8+H5Jv9a3/AC1k/wCeg/2f8/Wuf1X7f9gbf9k27k+752f9eP8AP/16vy/2j58X/HlnzW/57/3x/n/69F9QlS91a9X+SJoPM+3jCTf8e6dJZP8Ansf9mrFv5nnv8k3+vX/lrJ/eb/ZrIh+3/bR/x6bvIT/nvjHmn/P/ANep7f8AtHz3x9j/ANcv/Pf+83+fX9aae4p0t9SXTTJ/Zlv8k3+qj/5aSf8APQ/7NLfmT/iW/JN/x9W3/LWT0b/Z/wA9qz7D7f8A2dBs+ybfLTG7z8/6w/5/lzTr37f/AMS/d9l/4+bfG3z+uDj/ACPwqb+6aez/AHj16s14DLuh+Sb/AFQ/5ayej/7P+fzqpYeZ/a13hJic2/SWT/nk3+zUUH9obov+PL/Vj/nv6P8A5/yarWX2/wDtO5x9k3Zg3Z8/H+qOMY/z6cU29SVS0nr0/VGjcGQ6XJ8kuPLf/lo+P9T9P8/TmkgMn9mQ/JLjy0/5aP8A88Pp/n6c1Rm/tD+zZM/Y8eW+cefnHk/l/n0pIv7Q/s6Lb9jx5aYz52ceT+X+fSnfUr2Xu7lzUfM/tS1yk2c3PWWQ/wDLJf8AZq5cGXdN8k3+qP8Ay1k9E/2f8/lWLffb/wC0rfP2Tdm4248/H+qGc5/z68Van/tDdL/x5f6o/wDPf0T/AD/kUkyXS0hr0/Vk+n+Z/wATHCTf8fVx/wAtZPRf9n/Pemav5n9lXOUm+4//AC0f/nqP9mqlj9v/ANP2/Zf+Pm4zu8/rgZ/yfxpmqfb/AOzbjf8AZNux87fPz/rB/n+fNK/ulKn+9jr1Ru3Jl8+P5Jv9c2P3sn99f9mqkvmfbT8k3/Hu/wDy1k/57D/Z/wA/Wobj+0fPjz9i/wBa3/Pf+8v+fX9KrSfb/tZ/49N32d/+e+MeaP8AP/16pszp0tFqazCRzeLsmOWAP72T++3+zXl/wNSSC11W3VZAscVou1ZHGMPIOwr0SAagbmYN9jwZVB/1/wDfP+ef515z8K2mOoeJEshbhInhiYSGQ4Ill4yv9aL6nLUgvbxX9dD0rUjJ5VnlJv8Aj4tP+Wsn/PT/AHf89s1atjL50GEmJ29pZB3f/Z/z+dY2ofbvLtN32T/X2uNvn9d/H+fyqzb/ANoebD/x5fd/6b+r+n+f1pJ6s65Ul7Pfv+RJZNKdVl/dy8RWg4kcZ4k/2f8APbNTIZPsxwkx69JHH/LI+3+fpWVZfb/7Slx9k37LXP8Ar8dHxjH+fSpk/tD7Oc/Ysd/9f/zyPp/n8KE9GVOkuZ69F+SLOmmT+xLf5JcfZof+Wj/88vpS33m/2lYZSb/XSf8ALWT/AJ9z/s/5+nNZ9h9v/seDb9k2/Z4cbvOzjyu/b/PpTrv7f/aFln7Ju82Tbjz8f6g9f8/pSvoP2X7yWvSX5Ff4ieZ/wgviPKSgf2RcdZH/AOePXp+nSuT/AGdby41HwBf3s3mO82rXTZDsOPLQDoD0A/xrrfEUF7c6HqUE32PypbGVG/13QxDPXj8+PXiuO+AFtdW/wm0Z7cW2JzPK28S5zll/g46KPf1pt6nnTp/v4q/Q9GvhMdFumEcxUW8wJ8x8dvb/AD3q3dmTzeUmH749ZZD/AHfVaxLz7f8A2Vcb/se3yJs48/Pb8P8APNWrr+0fM/5cv9cf+e/+z6//AK/0p31O72W2vV/oWLwy/wBoplJ/+Pa56yyH/lpH/s/571cUy+dP8k/+sH/LWT++P9msS7+3fb1z9j3+RcY/1+MeYnr/AJ9atL/aPnTf8eX3x/z3/vj/AD/9ekmKVL3Y6/1cXTfM+yS/JN/rbj/lpJ/z8H/Z/wA/XinaqZfs0PyTf622/wCWsn/Pcf7P+e1Z2n/bvssuz7JjzZ+vn9fPOf8AP5807U/t32eLf9kx5lv08/r5wx/n8uaV/dNfZr22/wBr9Q8aJJJ4M8QZWUbdMu25lfsr/wCzXPfDdWTxJ4rRPMcLPpykh3XpaxegP/1u2a0PGi3zeD9c8xrJVGn3J/5bZPyvwM965r4TNdXF14ivrcoy3d9E4M/mZwv7sY2cfwf4U29UcnLao433X6o9OhMmRhJifMHSWT+63+zVXRzJ/YFl8k2PssH/AC0f+6f9moYv7QyM/Yvvj/nv6N/n/JqtpX27+xLTZ9k2/ZocbvPzjaevb+npQ3qdHslyvXqv1NG5837dpmEm/wCPkdJZP+fd/wDZ/wA/Tmp3MmR8k3+o/wCej/3D7f8A1qyZ/t323Tt32TP2gbcef18huv8A9b+VTP8A2jkf8eX+o/6b/wBw/wCfShPVhKl8OvT9WaNoszXV8Qk/yzKT+9k/54L/ALNV7kyf2Lc/JMR5E3PmP/cHtVa3+3/arrH2PPnLnP2j/ngOn+f0qGf7f/ZFxu+x7fJlzjz842D8P880r6BGl7y17fka9wZcHKTD953lkP8AyzHqtVtR8z+1bf5Jv9Vd/wDLWT/Y/wBn/PfFQT/2hg4+xff/AOm/9wev+fwqC/8At39pQZ+yb/Lusf6/H8Gc5/z6029EFKl7y16P8mbMpl3XWUm/GWTjlf8AZ/nVKx8zyb35Jv8Aj4u/+Wkn/PQf7P8Anvio5f7R3XP/AB5f+R/Vf88/4VVs/t3lXez7J/r7nO7z+vmDP+fzovqghS9zft+Re1rzP7Pb5JfvR/8ALWT/AJ+F/wBn/P14q8xl86L5Jv8AWt/y1k/56j/Z/wA/XisLVvt/2Ft/2TbmP7vn/wDPdf8AP/16ut/aPmx/8eX+sb/nv/z0H+f/AK9F9QdJci16v8kOg8z+12wk3/HtD0kf/nu/+z/n61ejMv2g/JNnzV/5ayf3n/2f8/nWFD9v/tQ/8em/7PF/z3xjzm/z/Lmrqf2j5/8Ay5f61f8Anv8A3m/z/k0JhVpef9aDtE83/hH7LCTY8iL/AJayf3j/ALNTSeZ5lj8kx/fwf8tZP+ebf7P+e1Zej/bv7DtNn2TZ5MeN3n5+8fTj/PFSyfb99nu+yf66HGPP67G/z/Klf3Sp0/3k9erNQGTzofkm/wBSP+Wj/wB1/ao7Tzft0+Em/wBZD0lk/wCeX+7VMf2j5sX/AB5f6of89/7rf59P1plt9v8Atk2PsmfMiznz8f6rj/P9KbZn7LSWvT9UXZTJ/ZM3yS48qT/lo+P9V9P8/SpdMMn2KHCTf6qPpLJ/zzX/AGay3/tD+y5t32PHlSZx5+ceV+X+fSpdO+3/AGSLH2THlx4z5+ceWtF9Ryp+49epNpit9lm+e4/1tz/BJ/z8H/a/z9abqSt9ki+e4/11v/BJ/wA/A/2v8/Xmqen6XZPbyloFJ8y4H3Je05A7/wCe/NN1DSrJLWIrAoJlgH3JTwZwD3/z25pa8ppaHtd38Xbz9Td2P5kHz3H3z/BJ/fP+1/KqVirf2rN89wP9GteiSf8APST0b/PbFM/sew82D/R1++f4Jv7596qWelWR1KRDAu0W9sQNkx5Mj56H2/wpu5nFQ5Ze8/u8/U2bdW85fmuP9cOiSejf7X/1/wBaq2Kt/Y1r89x/qIf4JMd/9r/PaorfSLDzR/o6/wCuA+5Meze/6VVs9Ksm0i3ZoFLGGEk7JR6++P8APFPW4Whr7z3XT18zVmR/PsPnuR+/TpHJ/wA8X/2v8/SliVsp80/+oH8En9w/7XT9KoS6TYiaxAgXDTID+7m6eSx9f8/SiLSLDKf6Ov8AqB/DL/dPv+vShX1E1C3xPbt6+ZZs0b+1NQ+e4/18f8En/PuP9r/I9qZqSt/Ylx80/wDx7TfwSY/1X1/z9Kp2ulWTajfKYFIWaMD5JuP3APr/AJ+lNv8ASrJdHndYFDC3mIOyXqIs+uKlXsaWh7SPvPaPTy9TVKN9nX5rg9OqSf8APIf7X+R7cVBfK39rQ/PP/q7v+CT0j/2v8981XbSbHyAfs65OP4Jh/wAsx7/5+lQ3ulWS6nEogXaUuiRslHQJjvx1/DvTd7CpqHMveez6eT8zZnRxLcfNcdD1ST1T/a/n/hVXTVYx3nz3H+vu/wCCT/noP9r8/wBc1FPpFh5s/wDo69D/AATDunv/AJ/Kq1hpVk6XZaBTia6UZSboJBjv/wDq70a3QoqHs/ifTp5epb1hW/s5vnn+9H/BJ/z8L/tf5+vNaMqP58Pz3H+tb+CT/noP9r/P1rA1XSrJLBmSBQdyfwS/8/AHr/np1q/Lo9h58Q+zr/rWH3Jv749/8/WjW4NQ5V7z3fTyXmTQK328fPcf8e6dEk/57H/a/wA/WrFuree/zz/65f4JP7zf7X/1/wBayIdKsvtgXyF2+Qhxsm6+aR6/5+tT2+kWBnf/AEdf9co+5Mf4m9/8/nQr6kzUNfef3f8ABJNNVv7Mt/muP9VH/BJ/z0P+1/n60t+rf8S355/+Pq2/gk9G/wBr/PaqFhpVk+nQM0CkmNCTsl/56H3/AM/WlvdKsk/s/bAo3XNup/dy9CD7/wAuvalrymloe0fvPd9P+Ca8Cvuh+a4/1Q6JJ6P/ALX+efeqtgrf2td/PP8Aet+iSZ/1Tf7X+e3FQwaRYFov9HX/AFQ/gmPZ/f8Az+dV7LSrJtTuVaBSqm3wNkveI+9N3uSlC0/ee3bzXmaFwrf2XJ80/wDq3/gkx/qf97/P0pIFb+zIfmn/ANWn8EmP9R9f8j24qlNpNiNNkYQKCI3I+WU/8sc+v+evSki0mxOnRM0CljGhPyyj/ljn1/z16U9blWhy/E/u/wCCXNRVv7UtcvP1ueqSf88l/wBr/Pfirc6vum+a4/1R6pJ6J/tf549qxr7SrJdSt1WBQrG4yNkvaIep/wA96sz6RYbpf9HX/VH+CYdk9/8AP5Ule5LULQ957dvN+ZY09W/4mOHuP+Pq4/gk9F/2v896ZrCt/ZVz89x9x+qSf89R/tf5+tVLHSrJv7Q3QA7bm4UfJN0AHv8A570zVNKsk024ZIFDBH52S/8APUe/+frS15Skoe1j7z3XT/gm5co3nx/Ncf65v4JP76/7VVZVb7b9+f8A4936pJ/z2H+1/n61Dc6PYCeP/R1/1zfwTD+Jff8ASq0mlWX2sr5C7fIc42S9fNA9f8/Wm7mdNQsvef3f8E2oFf7VN89x/rV/gk/56Hr838680+C1oVtvFV5mYPca1cKSEfok5AHB7Z/ya7uDSLD7TMDbrjzV/gm/56H3/n/OuI+FFhaT+HNTDwkrHrN8EDJJwv2npwfbvT1uc01D20dX93kvM7rUlbyrP57j/j4tP4JP+en+9+X6Yq1bo/mwfNcfd7JJ6v8A7X+fzrHv9KskjtCsCjM9qD+7m6F+e/8A+vtVi30iw82DNuv3f7kx7v6H/P50tbs6pKHs/ifXp5epJYq39qzfPP8A6u06JJ6Sf7X+e2KnRG+zH5rgdeiSf88j6N/n6cVlWWlWTalKhgXaEtcDZL3D57+349qkXSbIQ8WyYwTu2ynB8s478/57UK9i6ihzP3nsunkvMtaarf2Jb/NP/wAe0P8ABJj/AFX1/wA/SnXqt/aVh89x/rpP4JP+fc/7X+R7cVn2GlWTaPA7QKWNvCSdkvUxZ9cU670qyXULJVgUBpZARsm5/cE+v+evSjWw7Q9pL3ntLp5eptCLzHKO1wd0JGCj4I2DOfm6fpXA/AJGHwc8OENKAUueFRyP9ZJ6ECuwi02wt7lJvJVfLiL7tkvGFB9f/rVw3wOsLW6+EHhmSeIO/lXAzskPHmy/3Tj/ADzRrc86aj7eOrtZ9P8AgndXyt/Y9z89wP8AR5v4JMdv9r/Perd2r+Z964P749Uk/wBn1b/69Yt5pVkulXDLAoYQTEHZKfT3/wA96t3WkWAk/wCPdf8AXH+CYf3fU/pT1ud1oae89309PMnvEb+0U+e4/wCPe56xyf8APRP9r/Perao/nT/Pcf6wfwSf3x/tVi3elWQv1UQLtMFwcbJhyJEx39/8atDR7Dzpv9HX/WD+Cb++PekrkyUOWPvP7vP1DTFb7JL89x/rbj+CT/n4P+1/n6807VVf7NF89x/rbb+CT/nuP9r/AD25rP0/SrJ7WUtApIlnH3JRwJyB3/z35p2p6VZJbxFYFBMluPuTdDMAe/8AntzS15TW0Pa7v4u3n6jfGwceDtc+abnTroHMb/3X9TXI/AKV7vwRYXR8xGnRZGEasRn7VOOxHp9fSt/xppVknhHWWWBQRYXJB2y+j+prmfgXpkLfD/Qkuo1Yi0hdcpIcB7iZv4Tz1/wpu90clo+1dm9n0/vLzPT4VbI+e4H7wdEk/ut/tVU0dW/sGy+e4/49YP4JMfdP+1/ntUUOkWGR/o6/fH8Ex/hb3qtpWlWT6JaO0ClmtoSTsl6lT74/zxRrc6LQ5X7z3XT18zQuUb7dpnz3H/HyOkcn/Pu/+1/ke3FWHRsj5p/9R/ck/uH/AGun6Vk3GlWS3mnAQLhrgA/JMcjyGPr/AJ+lTPpFhkf6Ov8AqM/dl/uH3/XpQr3YSUPd957dvN+Zetkf7ZefPc/69f8AlnJ/zwX/AGv8/TioblW/sW5+ecfuJuiSY+4P9qq8Gk2JuroGBMLMoH7ub/ngD6/5+lQz6VYrpFwwgUMIZiDslPIQe+KNbAlDmXvPp08vU1rhHwfnuD+87pJ/zzHq3+fpVfUVb+1bf57j/VXfVJP9j1b/AD3zUE+kWHP+jr9/+5MP4B6n/P0qvf6VZLqUCiBdpjuiRsmHTZjqff8ADvQ27BSULr3ns+nk/M2ZUfddfNcfiknPK9fm/n/hVOwVvJvfnuD+/uv4JP8AnoP9r/PfNRy6RYbrr/R14/2JvVffj8aq2elWTRXe6BSRNcqPklHAkGO/+e9Gt0EFDk+J9Onl6l3Wlb+z2+ef70f8En/Pwv8Atf5+vNX2V/Oi+e4/1rfwSf8APUf7X+T781hatpdklizJAoOY/wCCX/nuo9f89OtXG0ew82LFuv8ArW/gm/56D3/z060a3BqHIvee76eS8x0Ct/a7fNcf8e0PRJP+e7/7X+frV9Eb7QfnuP8AWr/BJ/ef/a/z+dYUOl2R1MoYF2/Z4mxsl6+cw9f89uauppFgZ/8Aj3X/AFq/wTf3m9/8/nQrhVUP5n06enmO0NW/4R+yw9x/qIuiSY+8f9r/AD2qWVW32Pzzj9/B0ST+43+1/ntWXo+l2Umh2jvApZoYyTsl/vH3x/nipn0myD2eIF5mhB/dzHgo3vS15SpqHtJ+8930/wCCagVvOh+a4/1I/gk/ut/tf/W/WorRW+3T/Pcf6yHokn/PL/e/z9KqDSLDzYv9HX/Uj+Cb+63v/wDW/WmW2k2JvJlMC4EkWB5c3eLPr/n6U3fQztC0vee3bzXmXJVb+yZvmn/1Un8EmP8AVf73+fpUumI32KH57j/VR9Ek/wCea/7VZj6TYjS5WEC7hFIR8kp/5ZfXH+fSpdO0qyNpETAuTHGT8kv/ADzX3o1uOShyP3n93/BINOudtvKP7PuW/eXBytkP+e5/2u3T26U3ULndaxD+z7kfvbc/NZD/AJ7j/a79PfpW5ptlbC1m/cp/rbrt6XBH8qTULK2NrDmFP9bbdvW5A/lU68u4fWIe12+1+pS+1/vIP+Jbd/fP/LiOfnP+1zVOyuf+JlI39n3Jzb23H2EE/wCsfk/N3/Wuo+xW3m237lOZCDx/00IqnYWVsdTkJhQk21oenrJJmm79zKOIp8stP6uZtvd/vl/4l12f3w62IPZv9r9P8Kq2d1t0i3H9n3RxBD8wshz15zu/XvXS21nbmdQYUI89R07Yeq1pZWw0S2IhQH7PbnOPXdmnrfcf1inrp1X6mVLc7p7H/iXXPEynmwHP7lv9rn1/WiK75T/iXXf+oB/48h/dPP3v1rdksbVrjT8wIczp2/6YOabFZ2+6P90nNsG6d9jc0K+upP1mnbbp/mc/a3ONRvj/AGdcnMycCxHH7gdRu/HH40y/ut2jzj+z7oZt5vmNmAP9V1J3fjn8a3rSytv7U1AeSn+vjHT/AKds/wA6j1G0t/7DnPlJk2056f8ATEGlrbc1WIp+0jp0j+RmG6xAP+Jdd8YHFiB/yyH+1+P61Be3P/Eyib+z7kbUuuPsQB6J0+bt+ma6KSzt1txiFBggdP8Apip/nVe/s7caqmIUGI7zHHTAjxQ72WoqeIp8y06P8mZ893iWf/iW3Y4P/LiBjlP9rj/PrVfT7nal3/xL7k5muj8tkDj94P8Aa7fpXSXVnbrPdAQoAAccdOY/8TVbTbK28u8/cp/rrw9PSQYou7rUmOIp+z27fkYGq3O6wYf2fcr8yctZAD/j4H+1+H6Vflu/38X/ABLbvmVv+XEf89B/tc/T8Kt6tZ2/9nt+5T70fb/p5UfyrSnsrYT2+IU5mYHj/pqBRd33B4inyrTq/wAkczDc/wCmhv7OuT+4QY+xAn/Wn/a/D9Kngu/37/8AEtuz++Xj7CD/ABN/tfp/hWrbWVsb1SYUJ8hO3/TY1PbWdv8AaZB5KYE6gcdt7/4Cmm9dRVMRT10OZsLnbp0A/s+6OIk5WyGD+8P+1/8Ar6U6+ud39n/8S+5GLm3PNkOeDx97nP61tadZ2/8AZkH7lP8AVRHp6ykGi+srb/iWfuU5ubYnj1BzUu/KafWKftHp1ZmQXfzRf8S67P7of8uIPZ/9rn6/4VWsrn/iZ3J/s+5O42/AsgSP3R6jd3/XrXS21nbloMwocwqTx32yf4Cqun2dudXuAYUwWts8f9Mmptu+5CxFO09On6oxprrdpsg/s+65jcZNkP8Anj67vx/Wkiu9unRD+z7riNBkWQ/54+u78f1rbmtLc6S5MSZMcmTj/phn+dJFaW40qMiJARGnb/p3z/Onrfcv6xT5djDv7n/iZW5/s+5G03HBsgD/AKodBu7fp1q1Pd/NL/xLrsfuj/y4gY4T/a4+v+NaOp2duuqwAQoMG5xx/wBMVq3c2duGnxCgxCxHHfbH/iaSbvuS8RTtDTp+rOcsbnb/AGh/xLrk5ubg/LZDjgcfe4x+lM1S63abOP7PuVyj8tZAAfvR/tfh7dK3rCyts6l+5Ti5uccegWmavZ2/9l3H7lP9XJ29JgBS15dyliIe1jp1RQuLv99H/wAS27H71uBYgfxL/tc/T/Gq0l1/pZb+zrkfuHH/AB5AH/Wjn734fpXS3Vnbi4hAhQAzsDx23oP61Vms7cXZIhTP2eTt/wBNhVO+mpnTxFOy0M6C7xczH+zbviVf+XEcfvD/ALXH+RXKfDsXVloV3HfaVeJI+oXUq5sw25GuiVb73fP9K9HgsrY3VyDCmBMgHHT96wqjplnb/YE/cp1bt/08Efyou7ke0puXPbay+9f8AxtQud0Vp/xLrkfv7U/NYgZ+f/e5z+tWbe7zLB/xLbs/L/z4g55f/a5/+t7Vp6jZW3lWX7lP9fZnp6yHNWbSytmntw0KEFeePeT/AAFK7u9S5Yin7Pbv+RzFlc/8TKVv7PuTuS14+xAno/X5u/61Ml3m2P8AxLrvnjJsgf8Alkf9r8f1rUsLO3OqPmFDmOzzx1yJM1PDZ27WvzQoc8dP+mLH+dCvZ6l1MRT5np0X5I56wutujwD+z7o4t4fmFmCP9V1B3fjn8adeXOdQsj/Z9yNssnBsQCf3B6Dd+OPxrY060t/7DgPlJkW0B6f9MSakvrK2GpWP7lP9fIOn/TsT/OjWy1H9Yp+0lp0l+Rkz3Z2SbdOus+Q2P9BH9wc/e/WuX+E9nfeH/h7pei6tpVwl/YefFMFtxKMks4+bPo447V6JNZ2434hT/j2ZunfYvNNt7G2FxqQECcXMmOP+mKGm76amHtaT95x1S/yOevLrdpVwP7PuhmCblrIYHTnO79e1Wrq7xJ/yDrsfvj/y4gf3f9r9K0byztzo9yTChP2a4PT0K4q1e2dus2FhQDzyOB2+SjW+5p9Yp6adX+hzl5c/6crf2fcjFvcDH2EA/wCsTkfN2/TpVtbs+bKDp12cOB/x4D++P9r/AD0rSvrG2F8CIUBFtdY49JY8VaSytjPcDyUwJQBx/wBNAKSv3JliafLF2/q5ythc7bWUf2fcn97cHIsh/wA9z/tdunt0pdSud1vEP7PuR+8tz81iB/y3H+136e/StrT7K2FpLiFP9bc9vS5I/lTtTsrY20P7lP8AWWvb1uADS15dzX6xT9rt9r9TlvFkj3XhnVLePT7lXls541LWeACQ4GeayPheosfCmhQiwumxpllkG03nJZyc8jqT6c4x2r0lLO3+0W/7lOX9P+mjCqlpZ251RiYUJNvaZyOuZJM0301MVVhzOdulv/JkZsN3lh/xLbs/OP8AlxB7N/tVW0q526JaD+z7psW0PzLZAg/KeQd36966W3s7cuoMKEGVR07bXqrpFlb/ANgWR8lM/ZLc5x6qc09b7mjxFPlenVfqY09zuvdOP9n3PFwDg2I5/cNwPm59cfjUz3fI/wCJdd/6jP8Ax5D+4efvfrWtNZWzX+mAwof9KA6f9Ozn+dSyWduCMQp/x7bunfyzzSV7vUTxFP3dOn6sxLe5xdXR/s65OZl4FgOP3A6/N+OPxqGe63aRcD+z7rmGX5mshx8g77v/ANVdHbWNr9ruv3Cf68Dp/wBO4P8AOq01nbtolyTChPkTc4/6ZijW24RxNPmWnb8jMuLvGf8AiW3Y+fH/AB4gf8sx/tfp+NQX9z/xMoG/s+5GIrrj7EAf4Onzdv0ro7qytl3bYUGJcdO3lKar6lZ2w1OEiFBiG8I49NmKG3ZahSxFO606P8mZst381z/xLbv/AMAQMcr/ALXH+fWqlnc7Ybv/AIl9yczXJ+WyHH7wf7XGP0rp57O3D3gEKcHjjpylU7OzthBekQpxNeHp6SjFPW61CGIp8m3b8jD1a53WJH9n3K8x8tZAf8t1/wBr8P0q613+9j/4lt3/AK1v+XEf89B/tfhj8KvazZ2/2Bv3Kfej7f8ATyo/lV5rK28+EeSmDM4PHbzgP5Utb7g8RT5Fp1f5I5aG5/4mjN/Z9yc28Ix9iBP+ubn734e/SrqXf+kf8g27/wBavH2Ef3m7bv0/wq7b2dudVJMKf8e0Hb1uHH8qvpZ2/wBqI8lMecg6dtz/AOAoV+4VcRTu9P60OX0e526HaD+z7lsQxfMtkCD8x77v171K91uez/4l1zxNCebIHPyN/tc/1rW0Sytv+Eesz5KZ+zwnOPVzmpTZ2zSWIaFD++g7f9M2pfZ3KniIe0np1ZkC7/ew/wDEuu/9SD/x5D+63+1z9f8ACmW11/psx/s65O6SLgWIJ/1Xf5vx/Wt/7Hb+dbjyUwbcE8d9r/4CmWdlbG/lzCnMsIPH/TGqbd9yPrFO0tOn6mDJdbtLlH9n3XMUgybIf88vXd/nrUunXP8AokQ/s+6OI4xkWQI/1a/7Var2dudHlJhQnypOcf8ATEGptMs7c2cWYU4ji7f9M0pa33HLEQ5Hof/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shortened QT interval in hypercalcemia that results from shortening of the duration of the ventricular action potential. (Hypocalcemia has the opposite effect.) Note how the T waves appear to take off directly from the end of the QRS due to abbreviation of the ST segment. The slight J point elevation in leads V1 to V3 may also be seen with hypercalcemia in the absence of ischemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20633=[""].join("\n");
var outline_f20_9_20633=null;
var title_f20_9_20634="Neurologic disorders complicating pregnancy";
var content_f20_9_20634=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic disorders complicating pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Men-Jean Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Susan Hickenbottom, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20634/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/9/20634/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/9/20634/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy adds a unique and, at times, challenging facet to the management of neurologic disease. The pregnant state can affect many neurologic diseases, while certain neurologic diseases or their treatments may have a significant negative effect on pregnancy, labor, or delivery. This topic review will focus on the relationship between pregnancy and a wide spectrum of neurologic illnesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CEREBROVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease during pregnancy results from any of three major mechanisms: arterial",
"    <span class=\"nowrap\">",
"     infarction/ischemia,",
"    </span>",
"    hemorrhage, or venous thrombosis. Pregnancy and the postpartum period are associated with a marked increase in the relative risk and a small increase in the absolute risk of stroke.",
"   </p>",
"   <p>",
"    Risk factors for stroke related to pregnancy include cesarean delivery, pregnancy-induced hypertension, postpartum infection, and possibly multiple gestations. In addition, conditions unique to pregnancy can occur, which can present as either a stroke or a stroke-like event. These include eclampsia, peripartum cardiomyopathy, peripartum angiopathy, and gestational trophoblastic disease. Of these,",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    is the most common cause of stroke in pregnancy. Other causes are listed in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef60303 \" href=\"UTD.htm?5/44/5836\">",
"     table 1",
"    </a>",
"    ). The risk of stroke in women with",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Indications for antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebrovascular disease and stroke in pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=see_link\">",
"     \"Cerebrovascular disorders complicating pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MULTIPLE SCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS typically characterized by relapses and remissions of neurologic deficits. MS occurs with a 3:2 ratio of females to males and a peak incidence of 30 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During an MS exacerbation (relapse), patients typically complain of a progressive neurologic deficit developing over several days. Common symptoms of an exacerbation include those associated with optic neuritis (decreased visual acuity in one eye or ocular pain)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asymmetric numbness, weakness, or ataxia. Pain is rarely a symptom of a MS flare but can be a long-term complication of chronic MS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no accepted guidelines for recommending for or against pregnancy in women with MS. Each patient's MS history and current neurologic deficits should be considered independently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of pregnancy on multiple sclerosis activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there has been disagreement as to the overall effect of pregnancy on MS, a meta-analysis of 13 studies with 1221 pregnancies published in 2011 concluded that pregnancy is associated with a significant",
"    <strong>",
"     decrease",
"    </strong>",
"    in MS disease activity, while the postpartum period is associated with an",
"    <strong>",
"     increase",
"    </strong>",
"    in MS activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/1\">",
"     1",
"    </a>",
"    ]. The best individual report data come from the prospective PRIMS study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first report of the PRIMS study, 254 women with MS were followed during 269 pregnancies and for 12 months postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The mean rates of relapse before pregnancy, in the first trimester, in the second trimester, in the third trimester, and in the first three months postpartum were 0.7, 0.5, 0.6, 0.2, and 1.2 per woman per year, followed by a return to the prepregnancy rate.",
"     </li>",
"     <li>",
"      There was no acceleration in the rate of disability or disease progression postpartum.",
"     </li>",
"     <li>",
"      Neither epidural anesthesia nor breastfeeding had an adverse effect on the rate of relapse or progression of disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The second PRIMS report evaluated 227 women from the first series who delivered a liveborn term infant to determine clinical predictors of postpartum relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/3\">",
"       3",
"      </a>",
"      ]. Relapse in the first three months postpartum was most likely in women with an increased relapse rate in the prepregnancy year or an increased relapse rate during pregnancy. However, these factors correctly predicted presence or absence of early postpartum relapse in only 72 percent of women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the protective effect during pregnancy and the increased risk in the early postpartum period are combined, the net effect is no increase in the risk of exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Similarly, long-term disability due to MS is not altered by pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Stress, exhaustion, infection, and the loss of antenatal immunosuppression may account for the increased relapse rate during the first three months of the postpartum period.",
"   </p>",
"   <p>",
"    Pregnancy does not appear to affect the type or severity of MS exacerbation. The available evidence suggests that pregnancy does not increase the risk of developing MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/7,10-14\">",
"     7,10-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543013512\">",
"    <span class=\"h2\">",
"     Assisted reproductive technology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no definitive data, assisted reproductive technology (ART), which includes in vitro fertilization (IVF) and other similar techniques, appears to increase the risk of MS disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/15\">",
"     15",
"    </a>",
"    ]. One prospective study of 16 women with relapsing-remitting MS treated with 26 ART cycles observed a 7-fold increase in the risk of MS exacerbation and a nearly 9-fold increase in the risk of new brain lesions by MRI in the three months following ART [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/16\">",
"     16",
"    </a>",
"    ]. It is unclear whether one or more of the exogenously administered hormones (eg, GnRH agonist, FSH, progesterone) or the rapid changes in reproductive hormone levels in women undergoing ART, or both, were responsible for the increase in MS disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from earlier studies suggested that ART was associated with a more modest increase in the risk of MS relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The variably increased risk of MS exacerbation with ART in these reports may be due to differences in the regimens employed, such as use of GnRH antagonists instead of GnRH agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H478480\">",
"    <span class=\"h2\">",
"     Breastfeeding and multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data regarding breastfeeding and disease activity in postpartum women with MS are limited and results appear to be conflicting. However, the bulk of available evidence suggests that women with milder forms of MS are more likely to breastfeed (and forego disease modifying therapies) than women with more active MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the PRIMS study, women who chose to breastfeed had lower postpartum relapse rates than women who did not breastfeed [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/2\">",
"       2",
"      </a>",
"      ]. However, the most likely explanation for this finding was that women who chose to breastfeed also had lower relapse rates and milder disability scores in the year",
"      <strong>",
"       before and during",
"      </strong>",
"      pregnancy, compared with women who did not breastfeed [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Thus, the investigators concluded that women who chose breastfeeding had a milder form of MS before conception; breastfeeding itself was",
"      <strong>",
"       not",
"      </strong>",
"      associated with any impact on postpartum disease activity.",
"     </li>",
"     <li>",
"      In a prospective report of 302 full-term pregnancies among 298 women with MS who were followed for at least one year after delivery, the only independent predictors of postpartum relapses were relapses in the year before pregnancy and relapses during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small prospective cohort study found that exclusive breastfeeding for at least two months postpartum was associated with a reduced rate of MS relapses [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/24\">",
"       24",
"      </a>",
"      ]. The authors speculated that lactational suppression of menses led to a reduced risk of postpartum relapses.",
"     </li>",
"     <li>",
"      Another small prospective cohort study reported that the rate and duration of breastfeeding was less frequent among women who had more active disease prior to pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/25\">",
"       25",
"      </a>",
"      ]. In addition, there was no significant difference in postpartum mean annualized relapse rates for mothers who breastfed for &lt;2 months compared with those who breastfed for &gt;2 months. In accord with the PRIMS data, women with stable MS prior to pregnancy were more likely to breastfeed than women with more active disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these data suggest that postpartum relapse rates mainly reflect the severity of prepartum MS disease activity, and that breastfeeding is inversely proportional to the underlying disease severity.",
"   </p>",
"   <p>",
"    While MS itself is not a contraindication to breast feeding, maternal medications must be taken into account.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of multiple sclerosis on pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While evidence regarding the effect of MS on pregnancy is not entirely consistent, the available data suggest that maternal MS is associated with an increased rate of caesarean delivery and lower infant birth weights compared with women without MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study analyzed an inpatient database with an estimated 15 million deliveries in the United States from 2003 to 2006, including 4730 in women with MS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/27\">",
"       27",
"      </a>",
"      ]. Multiple sclerosis was associated with a small but statistically significant increase in the risk of intrauterine growth retardation (odds ratio [OR] 1.7, 95% CI 1.2-3.3) and cesarean delivery (OR 1.3, 95% CI 1.1-1.4).",
"     </li>",
"     <li>",
"      A report from Norway evaluated a nationwide registry of over two million births from 1967 through 2002 and identified 649 births among 461 mothers with MS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/28\">",
"       28",
"      </a>",
"      ]. Mothers with MS had a higher proportion of infants who were small for gestational age (OR 1.45, 95% CI 1.14-1.84). Mothers with MS also had more frequent induction of labor and operative interventions during delivery. This finding was attributed to MS-related neuromuscular perineal weakness and spasticity, and it supports the straightforward notion that women who have difficulty pushing during the later stages of delivery due to neurologic deficits may require an assisted delivery.",
"     </li>",
"     <li>",
"      A population-based cohort study from the state of Washington evaluated 198 women with MS and a comparison group of 1584 women who gave birth from 1987 through 1996 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/29\">",
"       29",
"      </a>",
"      ]. Women with MS did",
"      <strong>",
"       not",
"      </strong>",
"      have an increased number of pregnancy or delivery complications, stillbirths, ectopic pregnancies, children with birth defects, preterm births, or spontaneous abortions.",
"     </li>",
"     <li>",
"      A report from Taiwan identified 174 women with MS who gave birth from 2001 to 2003 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/30\">",
"       30",
"      </a>",
"      ]. Compared with 1392 healthy control women, maternal MS was associated with an increased risk of preterm birth (relative risk [RR] 2.3, 95% CI 1.4-3.7) and infants who were small for gestational age (RR 1.9, 95% CI 1.3-2.7).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spinal anesthesia has traditionally been avoided because of unsubstantiated concerns that it increases MS exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/31\">",
"     31",
"    </a>",
"    ]. The choice of anesthesia, if necessary, should be based upon obstetric concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/31\">",
"     31",
"    </a>",
"    ]. Mothers may need help postpartum and should consider the activity, stress, and fatigue required to care for a newborn infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment of multiple sclerosis in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy may affect the choice of therapy since some drugs used to treat MS are known teratogens, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73903 \" href=\"UTD.htm?1/12/1228\">",
"     table 3",
"    </a>",
"    ). Such drugs are contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception. Management of relapsing-remitting MS during pregnancy includes consideration of several disease-modifying drugs, including interferons,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    . The choice of therapy varies with the clinical setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the limited available evidence reviewed below, most authors suggest that women discontinue treatment with disease-modifying drugs for MS if possible when they are planning a pregnancy and during pregnancy. However, there is no clear consensus about this approach. Those who favor stopping disease-modifying therapies note that only limited evidence is available concerning their safety during pregnancy, and during which time the MS relapse rate is much reduced regardless (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Effect of pregnancy on multiple sclerosis activity'",
"    </a>",
"    above); disease-modifying medications can be started or restarted in the immediate postpartum period. Other experts note that the decision must weigh uncertain risks to the fetus posed by disease-modifying drugs for MS against clear benefits to the mother. Aborting pregnancy because of concerns regarding interferon beta,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    exposure is not supported by current data [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps the highest quality evidence regarding the use of disease-modifying MS therapies during pregnancy comes from a systematic review that searched the literature through February 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/32\">",
"     32",
"    </a>",
"    ]. The review identified 15 studies (4 prospective cohort, 5 retrospective cohort, and 6 case series) that evaluated pregnancies exposed to interferon beta drugs (n = 761),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    (n = 97), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    (n = 35). The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferon beta exposure was associated with lower mean birth weight, shorter mean birth length, and preterm birth (&lt;37 weeks) but was",
"      <strong>",
"       not",
"      </strong>",
"      associated with spontaneous abortion, cesarean delivery, or birth weight &lt;2500 g. The quality of this evidence was considered good.",
"     </li>",
"     <li>",
"      Interferon beta exposure was",
"      <strong>",
"       not",
"      </strong>",
"      associated with an increased risk of lower mean gestational age or congenital anomaly. The quality of the evidence was fair.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       Glatiramer acetate",
"      </a>",
"      exposure was",
"      <strong>",
"       not",
"      </strong>",
"      associated with lower mean birth weight, lower mean gestational age, preterm birth (&lt;37 weeks), congenital anomaly, or spontaneous abortion. The quality of evidence was fair.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      exposure was",
"      <strong>",
"       not",
"      </strong>",
"      associated with lower mean birth weight, shorter mean birth length, or lower mean gestational age. The quality of evidence was fair.",
"     </li>",
"     <li>",
"      There were no studies reporting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"       teriflunomide",
"      </a>",
"      exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later series of women with MS found that exposure to disease-modifying drugs for at least eight weeks during pregnancy (n = 61) was associated with a significantly lower postpartum MS relapse rate and a lower postpartum risk of disease progression compared with pregnancies not exposed (n = 89) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/33\">",
"     33",
"    </a>",
"    ]. The MS relapse rate was significantly lower for both the exposed and unexposed groups during pregnancy compared with the baseline relapse rate prior to pregnancy. These findings are limited by the retrospective, nonrandomized nature of this study.",
"   </p>",
"   <p>",
"    Acute MS attacks (relapses) during pregnancy are treated with intravenous glucocorticoids, which are not teratogenic (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3061?source=see_link\">",
"     \"Treatment of acute exacerbations of multiple sclerosis in adults\"",
"    </a>",
"    ). Glucocorticoids may, however, cause neonatal adrenal suppression, maternal glucose intolerance, and increase the risk of preterm premature rupture of membranes. Thus, short-term, high-dose regimens are recommended. There is no contraindication to restarting prophylactic treatment immediately postpartum. In addition, patients with a previous history of postpartum exacerbation may benefit from the administration of intravenous immune globulin (IVIG) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a primary or secondary progressive MS are sometimes treated with immunosuppressive therapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . These drugs have been associated with congenital malformations, low birth weight and prematurity, and should be avoided in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postpartum administration of intravenous corticosteroids or IVIG may reduce the frequency of exacerbation; however, these are investigational approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of neuropathies can occur in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Carpal tunnel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome (CTS) refers to paresthesias, hypesthesia, pain, or numbness of the thumb, index, and middle fingers, as a result of compression of the median nerve in the carpal tunnel. Affected patients often awake with burning, numbness, and tingling in the median nerve distribution, which is bilateral in 75 percent of cases. Patients commonly report shaking the hand to relieve the discomfort. The diagnosis is based upon presence of characteristic symptoms and objective findings and is similar to that in nonpregnant individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CTS is relatively common during pregnancy, with an incidence of 2 to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/38\">",
"     38",
"    </a>",
"    ]. In one large series, pregnancy accounted for 7 percent of cases of CTS in women between the ages of 15 and 44 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/39\">",
"     39",
"    </a>",
"    ]. The increased prevalence in pregnant women is thought to be caused by pregnancy-related fluid retention leading to compression of the nerve in the carpal tunnel; hormonal changes affecting the musculoskeletal system may also play a role. This was demonstrated by a study of 76 pregnant women with symptoms suggestive of CTS: 43 percent had abnormal nerve conduction studies of their carpal tunnel and these women were more likely to have edema than women with normal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms tend to occur during the last trimester, but can occur at anytime [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/41\">",
"     41",
"    </a>",
"    ]. In most cases, they gradually resolve over a period of weeks to months after delivery; however, symptoms can be prolonged for several months in women who are breast feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/42\">",
"     42",
"    </a>",
"    ]. In one series of 37 women followed prospectively from near term to approximately 12 months after delivery, symptoms remained in 46 percent and were more common in women with early onset of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/43\">",
"     43",
"    </a>",
"    ]. Symptoms may recur in subsequent pregnancies.",
"   </p>",
"   <p>",
"    Patients may receive benefit from splinting the wrist at night in a neutral position or slight extension. Wrist splints may need to be worn throughout the day in severe cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of carpal tunnel syndrome\", section on 'Wrist splinting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Corticosteroid injection or surgery to release the flexor retinaculum is rarely indicated during pregnancy since the disease has a better prognosis than idiopathic CTS and often resolves postpartum. In a prospective case-control study of 45 pregnant women with CTS and 90 controls (age-matched women with idiopathic CTS) who were followed for three years, the pregnancy cohort was significantly more likely to show improvement in severity and function scores (68 and 73 percent respectively) than the control cohort (42 and 39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bell's palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bell's palsy (BP) is defined as a paralysis of the facial nerve, typically involving all three peripheral branches, resulting in asymmetric facial expression and unilateral weakness of eye closure. There is a two- to fourfold increase in prevalence during pregnancy, especially in the third trimester or in the first postpartum week [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The cause for this increased risk of BP in pregnancy is unclear, in part because the mechanism underlying BP is uncertain. Perineural edema, hypercoagulability causing thrombosis of the vasa nervosum, and relative immunosuppression in pregnancy have been proposed as potential etiologic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/48\">",
"     48",
"    </a>",
"    ]. The clinical manifestations, pathogenesis, and diagnosis of the disorder are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=see_link\">",
"     \"Patient information: Bell's palsy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstetrical and neonatal complications are not generally increased among patients with BP, except there appears to be an association with preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/49\">",
"     49",
"    </a>",
"    ]. Long-term outcome appears slightly worse in women who develop the disease during pregnancy. A retrospective study of 77 women with pregnancy-related Bell's palsy compared recovery outcome in pregnant women to that of nonpregnant women and men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/50\">",
"     50",
"    </a>",
"    ]. All patients in all groups with incomplete paralysis ultimately recovered satisfactory function. However, more pregnant woman developed complete paralysis (65 versus 50 percent for nonpregnant and male patients). Pregnant women (as well as nonpregnant patients) with complete paralysis are less likely to recover satisfactory function than the other groups (52 versus 77 to 88 percent). The fact that pregnant women are less likely to receive treatment may also contribute to an apparent poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/47,51\">",
"     47,51",
"    </a>",
"    ]. It is not clear whether the risk of recurrence is higher in pregnant versus nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9655?source=see_link\">",
"     \"Bell's palsy: Prognosis and treatment in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment recommendations for BP during pregnancy are the same as for nonpregnant patients, except possibly during the first nine weeks before the palate closes, as corticosteroid administration may be associated with an increased risk of cleft palate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9655?source=see_link\">",
"     \"Bell's palsy: Prognosis and treatment in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Meralgia paresthetica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meralgia paresthetica is a sensory neuropathy that occurs when the lateral femoral cutaneous nerve is compressed as it penetrates the tensor fascia lata at the inguinal ligament. Symptoms include dysesthesias in the upper and middle part of the lateral thigh and are probably caused by the expanding abdominal wall and increased lumbar lordosis. Symptoms occur late in pregnancy, typically resolve within three months postpartum, and rarely require treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39061?source=see_link\">",
"     \"Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute inflammatory demyelinating polyradiculoneuropathy (AIDP, Guillain-Barr&eacute; syndrome) has been linked to a variety of infectious agents. It typically begins within thirty days of an infection with progressive ascending weakness and gradual loss of deep tendon reflexes and sensory loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIDP does not appear to occur with increased frequency during pregnancy nor has uncomplicated disease been shown to affect pregnancy, labor, or delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/52\">",
"     52",
"    </a>",
"    ]. There is one case report of congenital Guillain-Barr&eacute; syndrome in the neonate of an affected mother [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment in nongravid adults may involve plasma exchange or intravenous immune globulin. Neither treatment has been studied in pregnant women with AIDP, although aggressive fluid loading prior to plasma exchange may help to avoid hypotension. Maternal AIDP is not an indication for cesarean delivery, which should be reserved for the usual obstetric indications only. Consultation with the anesthesia service is important as these patients have some additional anesthetic issues (eg, need to avoid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , concerns about exacerbation of neurologic deficit, autonomic instability) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hereditary motor sensory neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary motor sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth (CMT) disease, is a spectrum of disorders caused by a specific mutation in one of several myelin genes that results in defects in myelin structure, maintenance, and formation. Affected individuals show progressive distal limb atrophy and weakness, often with gait disturbance and deformity of feet and hands. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An observational study including 108 births to mothers with CMT reported these patients had more operative deliveries, malpresentations, and postpartum bleeding than the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/54\">",
"     54",
"    </a>",
"    ]. Gestational age at birth and birth weights were comparable to those in unaffected pregnancies. It was not clear whether the increased prevalence of malpresentation was related to fetal disease, although the disorder typically does not present until later in childhood. Postpartum bleeding from atony may have been related to the effect of the disease on uterine adrenergic nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postpartum compression neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy has been reported postpartum in 1 to 58 per 10,000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/55\">",
"     55",
"    </a>",
"    ]. The true incidence is not known since most series relied upon patient surveys or medical record discharge coding. The femoral and lateral femoral cutaneous nerves are most often affected.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with significant femoral neuropathy develop weakness involving the quadriceps muscle group with sparing of adduction. In addition to muscle weakness, sensory loss over the anterior thigh and most of the medial thigh is typical.",
"     </li>",
"     <li>",
"      The lateral femoral cutaneous nerve does not contain motor fibers; thus neurologic symptoms are restricted to sensory changes. Lateral hip pain accompanied by paresthesias (burning pain) or hypesthesias (numbness and tingling) over the upper outer thigh is the classic presentation of compression of this nerve (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Meralgia paresthetica'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Peroneal nerve compression results in foot drop. It can be caused by prolonged squatting, sustained knee flexion, or pressure on the fibular head from stirrups or palmar pressure during pushing.",
"     </li>",
"     <li>",
"      Obturator neuropathies are an uncommon complication of delivery and present with medial thigh pain and adductor weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that appear to predispose pregnant women to neuropathy postpartum include fetal macrosomia or malpresentation, sensory blockade (can impair recognition of discomfort), prolonged lithotomy position, prolonged second stage, and improper use of leg stirrups and retractors. However, many of these factors are interdependent (eg, prolonged lithotomy position and prolonged second stage). The prognosis for complete recovery is excellent; however, weakness may persist for several weeks or, rarely, months.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of peripheral nerve syndromes involving the leg are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link\">",
"     \"Overview of lower extremity peripheral nerve syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MUSCLE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle disease affects women in the childbearing years. Pregnancy may influence the course of muscle disease, and vice versa. Experience with pregnancy in the setting of muscular dystrophy has been documented in several case series.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myotonic dystrophy (MD). This disorder generally has a benign course through pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/48,56\">",
"       48,56",
"      </a>",
"      ]. A minority of women experience increased weakness, which resolves after delivery. However, pregnant women with MD have an increased incidence of fetal loss, prematurity, and polyhydramnios, likely because of inherited disease in the fetus. A minority of women have prolonged labor due to poor uterine contraction. General anesthesia should be avoided in these patients because of specific complications associated with MD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18057?source=see_link&amp;anchor=H17#H17\">",
"       \"Myotonic dystrophy: Prognosis and management\", section on 'Risk of anesthesia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Facioscapulohumeral muscular dystrophy (FSHD). Among 38 women with FSHD with 105 gestations and 78 live births, rates of low birth weight, forceps-assisted deliveries, and operative deliveries were higher than the national average. In 24 percent of pregnancies, women experienced worsening muscle disease that did not resolve postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/57\">",
"       57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=see_link\">",
"       \"Facioscapulohumeral muscular dystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limb-girdle muscular dystrophy (LGMD). Permanent worsening of weakness is common in one-third to one-half of patients with LGMD, who also experience higher rates of fetal loss and have more operative deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/56,58\">",
"       56,58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"       \"Limb-girdle muscular dystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Worsening of weakness is also reported in many women with other congenital myopathies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/58\">",
"       58",
"      </a>",
"      ]. Prematurity and operative deliveries are also common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to pregnancy and polymyositis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H36#H36\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CHOREA GRAVIDARUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea is characterized by irregular, brief, unpredictable, jerky movements involving multiple parts of the body in a random sequence. Chorea from any cause beginning during pregnancy has been called chorea gravidarum. Important causes of chorea in women of reproductive age include acute rheumatic fever and the antiphospholipid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]; less common causes include Wilson's disease, hyperthyroidism, vascular disease, other hypercoagulable states, and toxins. In some patients with chorea gravidarum, a specific cause cannot be identified.",
"   </p>",
"   <p>",
"    Chorea typically begins during the second to fifth month but occasionally presents postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/60\">",
"     60",
"    </a>",
"    ]. Symptoms typically resolve spontaneously within several weeks to months or may subside shortly after delivery. If warranted, the cautious use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and corticosteroids may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     BRAIN TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of brain neoplasms does not increase during pregnancy and the types of tumors are similar to those seen in nonpregnant women of the same age. Low-grade and high-grade gliomas and meningiomas each represent about one-third of cases. No particular systemic neoplasm with brain metastases is associated with pregnancy with the exception of choriocarcinoma, in which approximately 3 to 20 percent of patients have brain metastases at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/61\">",
"     61",
"    </a>",
"    ]. Meningiomas, vestibular schwannomas (acoustic neuromas), and pituitary tumors may enlarge during pregnancy and become symptomatic.",
"   </p>",
"   <p>",
"    The changes that occur during pregnancy can have a significant effect on symptoms and tumor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Fluid retention, for example, can increase tumor edema and enlarge vascular tumors such as meningiomas and vestibular schwannomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, both meningiomas and vestibular schwannomas have sex hormone receptors, which may play a role in accelerating tumor growth during gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/64\">",
"     64",
"    </a>",
"    ]. A study of 12 pregnancies in 11 women with grade II gliomas, found significant radiologic expansion of the tumor during pregnancy as compared to prepregnancy and post delivery time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/65\">",
"     65",
"    </a>",
"    ]. In another small case series of eight patients with a glioma, pregnancy appeared to be associated with adverse effects (clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic worsening) in six [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nausea and vomiting is a common symptom of both pregnancy and cerebral neoplasms, pregnancy-related nausea and vomiting occurs very early in pregnancy and tends to improve across gestation, while tumor-related nausea and vomiting is more likely to arise late in gestation, gradually worsens, and may be accompanied by headache.",
"   </p>",
"   <p>",
"    New onset of seizures can be a symptom of eclampsia or associated with a brain tumor. Eclamptic seizures are typically generalized. Tumor-related seizures may be focal and associated with focal neurologic findings. However, secondary generalization may occur rapidly, and the focal onset therefore may be unapparent to observers. In one case series, increased seizure frequency was noted in 5 of 12 pregnancies in women who harbored grade II gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/65\">",
"     65",
"    </a>",
"    ]. &nbsp;An overview of the clinical manifestations and diagnosis of brain tumors can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and prognosis of brain neoplasms seen during pregnancy is highly dependent upon the particular cell type involved, as well as the clinical manifestations and the stage of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/67\">",
"     67",
"    </a>",
"    ]. Magnetic resonance imaging (MRI), which does not involve radiation, can be safely performed in the pregnant patient, but gadolinium is typically not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery during pregnancy is indicated in patients with malignant tumors or tumors causing severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/67\">",
"     67",
"    </a>",
"    ]. Brain irradiation when indicated may be performed during pregnancy.",
"   </p>",
"   <p>",
"    Symptomatic treatment with anticonvulsants or corticosteroids may be necessary and should be used with appropriate caution. Neither should be used prophylactically in this setting. Treatment of seizures during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"     \"Management of epilepsy and pregnancy\"",
"    </a>",
"    .) Considerations regarding the use of corticosteroids in pregnancy are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal blood pressure and fluids should be monitored closely. Antihypertensive medication should be given sparingly to avoid hypotension, which could result in cerebral hypoperfusion. Excessive hydration, which could worsen cerebral edema, should also be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link\">",
"     \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential problem can occur in patients with brain tumors during the second stage of labor. Cerebrospinal fluid pressure increases an average of 71 cm H2O above normal with painful uterine contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/69\">",
"     69",
"    </a>",
"    ]. This could potentially lead to neurologic compromise in a woman who already has a baseline elevation in intracranial pressure. Thus, careful consideration should be given to the type of delivery. Depending upon the location and size of the mass, a cesarean delivery under general anesthesia may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/70\">",
"     70",
"    </a>",
"    ]. There are insufficient data to assess risk and make a general recommendation; advice of subspecialists in neurology and neurosurgery is advised in each case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pituitary adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy also promotes the growth of lactotroph adenomas (prolactinomas). Neurologic symptoms most often develop in patients with macroadenomas (13 to 36 percent) but also occur in a few patients (less than 2 percent) with microadenomas (defined as less than 10 mm in diameter). It is preferable to reduce tumor size with a dopamine agonist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery prior to pregnancy in women with a macroadenoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41510?source=see_link\">",
"     \"Management of lactotroph adenoma (prolactinoma) during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     VENTRICULOPERITONEAL SHUNT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shunt malfunction complicates up to 25 to 50 percent of pregnancies in women with ventriculoperitoneal (VP) shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Functional occlusion of the shunt most often occurs in the third trimester. The rise in intraabdominal pressure caused by the enlarging uterus may exceed the pressure within the peritoneal catheter, resulting in the cessation of cerebrospinal fluid drainage with a subsequent elevation in intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/67\">",
"     67",
"    </a>",
"    ]. Symptoms include confusion, lethargy, nausea, vomiting, headache, nystagmus, and cranial nerve palsies. These symptoms require urgent evaluation, neuroimaging, and neurosurgical consultation.",
"   </p>",
"   <p>",
"    Preconception counseling should include description of the risks and an MRI for establishing baseline ventricular size and to verify adequate shunt function.",
"   </p>",
"   <p>",
"    Although there are no controlled studies examining the best method of delivery for pregnant women with VP shunts, there seems to be agreement that vaginal delivery can be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Shortening the second stage has been recommended by some, but not all authors to reduce the rise in intracranial pressure that occurs during pushing. However, increased intracranial pressure should not occur with a properly functioning valve.",
"   </p>",
"   <p>",
"    Cesarean delivery is recommended for neurologically unstable patients and those with obstetrical indications for surgical delivery. Both regional and general anesthesia can be used in pregnant women with VP shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/74\">",
"     74",
"    </a>",
"    ]. Prophylactic antibiotics have usually been recommended for labor and delivery to avoid shunt infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/67,72\">",
"     67,72",
"    </a>",
"    ]; however, the risk of infection is low and this practice has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/73\">",
"     73",
"    </a>",
"    ]. The antibiotics given are the same as for prophylaxis against infective endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SPINAL CORD INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant proportion of spinal cord injuries occur in women of reproductive age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/75\">",
"     75",
"    </a>",
"    ]. In contrast to males with spinal cord injury, fertility is not usually compromised. This section discusses the management of pregnancy in a woman who has had a previous spinal cord injury.",
"   </p>",
"   <p>",
"    Common complications of spinal cord injury include anemia (from iron deficiency, folate deficiency, anemia of chronic disease, and chronic renal insufficiency), urinary tract infection, decubitus ulcers, and respiratory problems. Serial urinary tract cultures or antibiotic suppression is recommended to avoid upper urinary tract infection and its associated morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/76\">",
"     76",
"    </a>",
"    ]. Thermoregulation is impaired so that hypothermia can occur from cutaneous vasodilation and inability to shiver, while hyperthermia results from impairment of the normal sweating mechanism. Due to the tendency to spasticity and contractures, muscle-strengthening exercises for the upper extremities may be recommended for appropriate patients; range of motion exercises may be useful in others [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/76\">",
"     76",
"    </a>",
"    ]. The management of chronic complications of spinal cord injury are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Baseline pulmonary function studies should be performed in those who are contemplating pregnancy and pulmonary function should be reassessed serially during pregnancy to identify women who might need ventilatory assistance in labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are insufficient data to recommend universal thromboprophylaxis during pregnancy or the puerperium for all patients with spinal cord injury; each case should be addressed individually [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal delivery is permissible. The ability to perceive labor pain is dependent upon the level of the injury. Women with cord injuries below T11 will be able to perceive labor pain, while those with lesions at T5 to T10 may have painless labors and deliveries. Such women should be monitored to avoid an unattended delivery from undetected labor. They may suspect labor from other clues such as spasticity and flexor spasm. They should also be taught uterine palpation to help detect contractions, and use of a home uterine monitor, weekly cervical examinations, and liberal hospitalization can be considered near term. Although some others have observed a higher frequency of preterm labor, most series report rates similar to that in the general obstetrical population.",
"   </p>",
"   <p>",
"    These precautions may be particularly important for women with lesions above T5-6 level for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are prone to slightly earlier delivery (36 to 40 weeks rather than 38 to 42 weeks).",
"     </li>",
"     <li>",
"      Eighty-five percent develop autonomic dysreflexia during labor. The disorder can be precipitated by distension or irritation of the cervix, vagina, bowel, or bladder (",
"      <a class=\"graphic graphic_table graphicRef51824 \" href=\"UTD.htm?12/22/12651\">",
"       table 4",
"      </a>",
"      ). The manifestations of this potentially life-threatening syndrome result from sympathetic hyperactivity below the level of the lesion, since this portion of the spinal cord has been isolated from hypothalamic control. Symptoms include malignant hypertension (which may be confused with preeclampsia), loss of consciousness, headache, nasal congestion, facial erythema, sweating, piloerection, bradycardia or tachycardia, and arrhythmia. Uteroplacental vasoconstriction may develop, leading to fetal hypoxia. The symptoms are exacerbated by contractions and wane between contractions. Continuous monitoring of the cardiac rhythm and blood pressure are warranted as cerebrovascular accidents, intraventricular hemorrhage, or myocardial infarction may occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H4#H4\">",
"       \"Chronic complications of spinal cord injury\", section on 'Autonomic dysreflexia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Epidural anesthesia extending to the T10 level should be used to prevent these manifestations, even if the patient does not perceive pain; antepartum consultation with an anesthesiologist is important [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=see_link\">",
"     \"Pharmacologic management of pain during labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An indwelling Foley catheter will prevent bladder distention and a bowel regimen is useful to prevent bowel distention from constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/77\">",
"     77",
"    </a>",
"    ]. If symptoms of autonomic dysreflexia occur, it is important to make sure the catheter is draining freely and the bowel is not impacted.",
"   </p>",
"   <p>",
"    If the patient has not yet received anesthesia and is supine, having her sit up leads to pooling of blood in the lower extremities and may reduce blood pressure. Antihypertensive medications (such as intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) are given as needed. However, patients with spinal cord injury maintain systemic blood pressure by compensatory enhancement of the renin&ndash;angiotensin&ndash;aldosterone system. For this reason, they may be very sensitive to medications that inhibit the function of angiotensin-converting enzyme (ACE inhibitors). If severe hypertension persists despite anesthesia and intravenous antihypertensive medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    may be considered, but is relatively contraindicated since it may cause cyanide intoxication in the fetus. A case report noted a dramatic benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    in a woman with autonomic dysreflexia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/9/20634/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link\">",
"     \"Treatment of specific hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RESTLESS LEGS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy appears to be a risk factor for the occurrence or worsening of restless legs syndrome; the cause is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H5#H5\">",
"     \"Restless legs syndrome\", section on 'Secondary RLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of important issues to be addressed by the physician when a woman with epilepsy becomes pregnant:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are antiepileptic drugs necessary?",
"     </li>",
"     <li>",
"      What effect do antiepileptic drugs have on the fetus?",
"     </li>",
"     <li>",
"      What effect does maternal epilepsy have on the fetus?",
"     </li>",
"     <li>",
"      What effect does pregnancy have on seizures?",
"     </li>",
"     <li>",
"      How should the patient be managed during pregnancy and delivery?",
"     </li>",
"     <li>",
"      How should the patient be managed during the postpartum period?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link\">",
"     \"Risks associated with epilepsy and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"     \"Management of epilepsy and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     HEADACHE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches may present during pregnancy. Most are migraine and tension-type headaches, but they may present some treatment challenges during this time. A minority of new headaches during pregnancy represent more serious, even life-threatening neurologic conditions. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5114?source=see_link\">",
"     \"Headache in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MYASTHENIA GRAVIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis (MG) is an autoimmune disorder resulting from abnormal T cell regulation and the production of antibodies against the acetylcholine receptor on the neuromuscular end plate of skeletal muscle. Affected patients are often young women who usually present with fatigable weakness after repetitive muscle use. Pregnancy has a variable effect on the course of myasthenia gravis. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=see_link\">",
"     \"Management of myasthenia gravis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     LOW BACK PAIN AND DISC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One- to two-thirds of all pregnant women will experience back pain. Usually this reflects the musculoskeletal consequences that ensue as a result of normal hormonal changes and weight gain. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=see_link&amp;anchor=H3#H3\">",
"     \"Musculoskeletal changes and pain during pregnancy and postpartum\", section on 'Low back pain and disc disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27218647\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy can affect many neurologic diseases, while certain neurologic diseases or their treatments may have a significant negative effect on pregnancy, labor, or delivery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of cerebrovascular disease, epilepsy, low back pain, myasthenia, polymyositis, and restless legs syndrome are discussed separately in specific topic reviews devoted to these conditions in pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"       \"Management of epilepsy and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=see_link\">",
"       \"Cerebrovascular disorders complicating pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=see_link\">",
"       \"Musculoskeletal changes and pain during pregnancy and postpartum\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=see_link\">",
"       \"Management of myasthenia gravis in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link&amp;anchor=H36#H36\">",
"       \"Initial treatment of dermatomyositis and polymyositis in adults\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are a number of issues to consider regarding women with multiple sclerosis and pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pregnancy has a protective effect against multiple sclerosis relapses, but there is an increased risk of disease exacerbation in the early postpartum period. When the protective effect during pregnancy and the increased risk in the early postpartum period are combined, the net effect is no increase in the risk of exacerbation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effect of pregnancy on multiple sclerosis activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are no definitive data, assisted reproductive technology (ART), which includes in vitro fertilization (IVF) and other similar techniques, appears to increase the risk of MS disease activity. (See",
"      <a class=\"local\" href=\"#H543013512\">",
"       'Assisted reproductive technology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available evidence suggests that maternal multiple sclerosis is associated with a modestly increased rate of caesarean delivery and lower infant birth weights. However, birth outcomes have not been systematically studied. The choice of anesthesia for delivery in mothers with MS should be based upon obstetric concerns. &nbsp;(See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect of multiple sclerosis on pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with multiple sclerosis who are planning a pregnancy or who become pregnant, we suggest stopping treatment with disease-modifying therapy. However, there is no clear consensus about this approach. Acute multiple sclerosis attacks (relapses) during pregnancy are treated with intravenous glucocorticoids, which are not teratogenic. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment of multiple sclerosis in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of neuropathies are common in pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Carpal tunnel syndrome has an increased incidence in pregnancy with symptoms commonly improving post partum. Patients may benefit symptomatically from splinting. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Carpal tunnel syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bell&rsquo;s palsy is also more common in pregnancy; treatment recommendations are not changed during pregnancy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bell's palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meralgia paresthetica is more common in late stages of pregnancy, but typically does not require treatment and resolves after delivery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Meralgia paresthetica'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpartum compression neuropathies result from compression during labor and delivery. These include femoral neuropathy, peroneal neuropathy, and obturator neuropathy. The prognosis for complete recovery is excellent; however, weakness may persist for several weeks or longer. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Postpartum compression neuropathies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle disease affects women in the childbearing years. Pregnancy may influence the course of muscle disease, and vice versa. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Muscle disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chorea gravidarum typically begins during the second to fifth month but occasionally presents postpartum. Symptoms typically resolve spontaneously within several weeks or may subside shortly after delivery. If warranted, the cautious use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      and corticosteroids may be beneficial. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chorea gravidarum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiological changes (eg, fluid retention, altered sex hormone levels) that occur during pregnancy can have a significant effect on symptoms and brain tumor growth. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Brain tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shunt malfunction complicates up to 25 to 50 percent of pregnancies in women with ventriculoperitoneal (VP) shunts requiring urgent evaluation, neuroimaging, and neurosurgical consultation. Vaginal delivery can be attempted in stable women with VP shunt. Caesarean section is recommended for neurologically unstable patients and those with obstetrical indications for surgical delivery. Prophylactic antibiotics are suggested during labor and delivery to reduce the risk of shunt infection. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Ventriculoperitoneal shunt'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of pregnant women with a spinal cord injury should included consideration of thromboprophylaxis. Home monitoring may be required in those with lesions from T5 to T10 as they may have painless labor. In addition patients with lesions above T5-6 may be prone to autonomic dysreflexia during labor and require additional anesthesia, cardiovascular monitoring, and antihypertensive treatments. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Spinal cord injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/1\">",
"      Finkelsztejn A, Brooks JB, Paschoal FM Jr, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 2011; 118:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/2\">",
"      Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/3\">",
"      Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/4\">",
"      Worthington J, Jones R, Crawford M, Forti A. Pregnancy and multiple sclerosis--a 3-year prospective study. J Neurol 1994; 241:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/5\">",
"      Sadovnick AD, Eisen K, Hashimoto SA, et al. Pregnancy and multiple sclerosis. A prospective study. Arch Neurol 1994; 51:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/6\">",
"      Houtchens MK. Pregnancy and multiple sclerosis. Semin Neurol 2007; 27:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/7\">",
"      Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995; 118 ( Pt 1):253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/8\">",
"      Verdru P, Theys P, D'Hooghe MB, Carton H. Pregnancy and multiple sclerosis: the influence on long term disability. Clin Neurol Neurosurg 1994; 96:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/9\">",
"      Ramagopalan S, Yee I, Byrnes J, et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2012; 83:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/10\">",
"      Ponsonby AL, Lucas RM, van der Mei IA, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 2012; 78:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/11\">",
"      Operskalski EA, Visscher BR, Malmgren RM, Detels R. A case-control study of multiple sclerosis. Neurology 1989; 39:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/12\">",
"      Hern&aacute;n MA, Hohol MJ, Olek MJ, et al. Oral contraceptives and the incidence of multiple sclerosis. Neurology 2000; 55:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/13\">",
"      Alonso A, Jick SS, Olek MJ, et al. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 2005; 62:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/14\">",
"      Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 1998; 105:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/15\">",
"      Hellwing K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/16\">",
"      Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012; 72:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/17\">",
"      Voskuhl RR. Assisted reproduction technology in multiple sclerosis: giving birth to a new avenue of research in hormones and autoimmunity. Ann Neurol 2012; 72:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/18\">",
"      Laplaud DA, Leray E, Barri&egrave;re P, et al. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology 2006; 66:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/19\">",
"      Hellwig K, Beste C, Brune N, et al. Increased MS relapse rate during assisted reproduction technique. J Neurol 2008; 255:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/20\">",
"      Hellwig K, Schimrigk S, Beste C, et al. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 2009; 61:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/21\">",
"      Michel L, Foucher Y, Vukusic S, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012; 83:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/22\">",
"      Kieseier BC, Wiendl H. Postpartum disease activity and breastfeeding in multiple sclerosis revisited. Neurology 2010; 75:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/23\">",
"      Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/24\">",
"      Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/25\">",
"      Airas L, Jalkanen A, Alanen A, et al. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology 2010; 75:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/26\">",
"      Franklin GM, Tremlett H. Multiple sclerosis and pregnancy: what should we be telling our patients? Neurology 2009; 73:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/27\">",
"      Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology 2009; 73:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/28\">",
"      Dahl J, Myhr KM, Daltveit AK, et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/29\">",
"      Mueller BA, Zhang J, Critchlow CW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol 2002; 186:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/30\">",
"      Chen YH, Lin HL, Lin HC. Does multiple sclerosis increase risk of adverse pregnancy outcomes? A population-based study. Mult Scler 2009; 15:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/31\">",
"      Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 115:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/32\">",
"      Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012; 79:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/33\">",
"      Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2013; 115:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/34\">",
"      Achiron A, Rotstein Z, Noy S, et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/35\">",
"      Weinreb HJ. Demyelinating and neoplastic diseases in pregnancy. Neurol Clin 1994; 12:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/36\">",
"      de Seze J, Chapelotte M, Delalande S, et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/37\">",
"      Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004; 251:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/38\">",
"      Mabie WC. Peripheral neuropathies during pregnancy. Clin Obstet Gynecol 2005; 48:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/39\">",
"      Stevens JC, Beard CM, O'Fallon WM, Kurland LT. Conditions associated with carpal tunnel syndrome. Mayo Clin Proc 1992; 67:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/40\">",
"      Padua L, Aprile I, Caliandro P, et al. Symptoms and neurophysiological picture of carpal tunnel syndrome in pregnancy. Clin Neurophysiol 2001; 112:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/41\">",
"      McLennan HG, Oats JN, Walstab JE. Survey of hand symptoms in pregnancy. Med J Aust 1987; 147:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/42\">",
"      Wand JS. Carpal tunnel syndrome in pregnancy and lactation. J Hand Surg Br 1990; 15:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/43\">",
"      Padua L, Aprile I, Caliandro P, et al. Carpal tunnel syndrome in pregnancy: multiperspective follow-up of untreated cases. Neurology 2002; 59:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/44\">",
"      Mondelli M, Rossi S, Monti E, et al. Prospective study of positive factors for improvement of carpal tunnel syndrome in pregnant women. Muscle Nerve 2007; 36:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/45\">",
"      Hilsinger RL Jr, Adour KK, Doty HE. Idiopathic facial paralysis, pregnancy, and the menstrual cycle. Ann Otol Rhinol Laryngol 1975; 84:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/46\">",
"      Beri�� A. Peripheral nerve disorders in pregnancy. Adv Neurol 1994; 64:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/47\">",
"      Vrabec JT, Isaacson B, Van Hook JW. Bell's palsy and pregnancy. Otolaryngol Head Neck Surg 2007; 137:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/48\">",
"      Sax TW, Rosenbaum RB. Neuromuscular disorders in pregnancy. Muscle Nerve 2006; 34:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/49\">",
"      Shmorgun D, Chan WS, Ray JG. Association between Bell's palsy in pregnancy and pre-eclampsia. QJM 2002; 95:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/50\">",
"      Gillman GS, Schaitkin BM, May M, Klein SR. Bell's palsy in pregnancy: a study of recovery outcomes. Otolaryngol Head Neck Surg 2002; 126:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/51\">",
"      Cohen Y, Lavie O, Granovsky-Grisaru S, et al. Bell palsy complicating pregnancy: a review. Obstet Gynecol Surv 2000; 55:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/52\">",
"      Chan LY, Tsui MH, Leung TN. Guillain-Barr&eacute; syndrome in pregnancy. Acta Obstet Gynecol Scand 2004; 83:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/53\">",
"      Luijckx GJ, Vles J, de Baets M, et al. Guillain-Barr&eacute; syndrome in mother and newborn child. Lancet 1997; 349:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/54\">",
"      Hoff JM, Gilhus NE, Daltveit AK. Pregnancies and deliveries in patients with Charcot-Marie-Tooth disease. Neurology 2005; 64:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/55\">",
"      Wong CA, Scavone BM, Dugan S, et al. Incidence of postpartum lumbosacral spine and lower extremity nerve injuries. Obstet Gynecol 2003; 101:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/56\">",
"      Gilchrist JM. Muscle disease. Adv Neurol 2002; 90:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/57\">",
"      Ciafaloni E, Pressman EK, Loi AM, et al. Pregnancy and birth outcomes in women with facioscapulohumeral muscular dystrophy. Neurology 2006; 67:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/58\">",
"      Rudnik-Sch&ouml;neborn S, Glauner B, R&ouml;hrig D, Zerres K. Obstetric aspects in women with facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and congenital myopathies. Arch Neurol 1997; 54:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/59\">",
"      Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 1997; 76:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/60\">",
"      Cardoso F. Chorea gravidarum. Arch Neurol 2002; 59:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/61\">",
"      DeAngelis LM. Central nervous system neoplasms in pregnancy. Adv Neurol 1994; 64:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/62\">",
"      Simon RH. Brain tumors in pregnancy. Semin Neurol 1988; 8:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/63\">",
"      Michelsen JJ, New PF. Brain tumour and pregnancy. J Neurol Neurosurg Psychiatry 1969; 32:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/64\">",
"      Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999; 42:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/65\">",
"      Pallud J, Mandonnet E, Deroulers C, et al. Pregnancy increases the growth rates of World Health Organization grade II gliomas. Ann Neurol 2010; 67:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/66\">",
"      Pallud J, Duffau H, Razak RA, et al. Influence of pregnancy in the behavior of diffuse gliomas: clinical cases of a French glioma study group. J Neurol 2009; 256:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/67\">",
"      Ng J, Kitchen N. Neurosurgery and pregnancy. J Neurol Neurosurg Psychiatry 2008; 79:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/68\">",
"      Stevenson CB, Thompson RC. The clinical management of intracranial neoplasms in pregnancy. Clin Obstet Gynecol 2005; 48:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/69\">",
"      MARX GF, ZEMAITIS MT, ORKIN LR. Cerebrospinal fluid pressures during labor and obstetrical anesthesia. Anesthesiology 1961; 22:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/70\">",
"      Finfer SR. Management of labour and delivery in patients with intracranial neoplasms. Br J Anaesth 1991; 67:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/71\">",
"      Yu JN. Pregnancy and extracranial shunts: case report and review of the literature. J Fam Pract 1994; 38:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/72\">",
"      Maheut-Lourmi&egrave;re J, Chu Tan Si. [Hydrocephalus during pregnancy with or without neurosurgical history in childhood. Practical advice for management]. Neurochirurgie 2000; 46:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/73\">",
"      Landwehr JB Jr, Isada NB, Pryde PG, et al. Maternal neurosurgical shunts and pregnancy outcome. Obstet Gynecol 1994; 83:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/74\">",
"      Littleford JA, Brockhurst NJ, Bernstein EP, Georgoussis SE. Obstetrical anesthesia for a parturient with a ventriculoperitoneal shunt and third ventriculostomy. Can J Anaesth 1999; 46:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/75\">",
"      Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976) 2001; 26:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/76\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion: Number 275, September 2002. Obstetric management of patients with spinal cord injuries. Obstet Gynecol 2002; 100:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/77\">",
"      Pereira L. Obstetric management of the patient with spinal cord injury. Obstet Gynecol Surv 2003; 58:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/78\">",
"      Westgren N, Hultling C, Levi R, Westgren M. Pregnancy and delivery in women with a traumatic spinal cord injury in Sweden, 1980-1991. Obstet Gynecol 1993; 81:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/9/20634/abstract/79\">",
"      Maehama T, Izena H, Kanazawa K. Management of autonomic hyperreflexia with magnesium sulfate during labor in a woman with spinal cord injury. Am J Obstet Gynecol 2000; 183:492.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4838 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20634=[""].join("\n");
var outline_f20_9_20634=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27218647\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CEREBROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MULTIPLE SCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of pregnancy on multiple sclerosis activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543013512\">",
"      Assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H478480\">",
"      Breastfeeding and multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of multiple sclerosis on pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment of multiple sclerosis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bell's palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Meralgia paresthetica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hereditary motor sensory neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postpartum compression neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MUSCLE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CHOREA GRAVIDARUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      BRAIN TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pituitary adenoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      VENTRICULOPERITONEAL SHUNT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SPINAL CORD INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RESTLESS LEGS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HEADACHE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MYASTHENIA GRAVIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      LOW BACK PAIN AND DISC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27218647\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/44/5836\" title=\"table 1\">",
"      Causes of stroke in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/12/1228\" title=\"table 3\">",
"      Safety of MS drugs in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/22/12651\" title=\"table 4\">",
"      Triggers autonomic dysreflexia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9655?source=related_link\">",
"      Bell's palsy: Prognosis and treatment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24458?source=related_link\">",
"      Cerebrovascular disorders complicating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=related_link\">",
"      Facioscapulohumeral muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5114?source=related_link\">",
"      Headache in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=related_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41510?source=related_link\">",
"      Management of lactotroph adenoma (prolactinoma) during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=related_link\">",
"      Management of myasthenia gravis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39061?source=related_link\">",
"      Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=related_link\">",
"      Musculoskeletal changes and pain during pregnancy and postpartum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18057?source=related_link\">",
"      Myotonic dystrophy: Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/13/41168?source=related_link\">",
"      Patient information: Bell's palsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=related_link\">",
"      Respiratory complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3061?source=related_link\">",
"      Treatment of acute exacerbations of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_9_20635="PTC vs ATC mortality";
var content_f20_9_20635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric patient mortality rate by trauma center designation and by injury type",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Injury",
"      </td>",
"      <td class=\"subtitle1\">",
"       PTC (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       ATC AQ (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       ATC 1 (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       ATC II (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Head injury",
"      </td>",
"      <td>",
"       82/1251 (6.6)",
"      </td>",
"      <td>",
"       87/986 (8.8)",
"      </td>",
"      <td>",
"       46/216 (21.3)",
"      </td>",
"      <td>",
"       80/727 (11)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Liver injury",
"      </td>",
"      <td>",
"       20/220 (9.1)",
"      </td>",
"      <td>",
"       36/186 (19.4)",
"      </td>",
"      <td>",
"       12/66 (18.2)",
"      </td>",
"      <td>",
"       31/96 (32.3)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spleen injury",
"      </td>",
"      <td>",
"       15/259 (5.8)",
"      </td>",
"      <td>",
"       38/223 (17)",
"      </td>",
"      <td>",
"       9/54 (16.7)",
"      </td>",
"      <td>",
"       21/236 (8.9)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PTC: Pediatric trauma center; ATC AQ: Adult trauma center with added qualification in pediatrics; ATC I: Level 1 adult trauma center; ATC II: Level 2 adult trauma center.",
"    </div>",
"    <div class=\"reference\">",
"     Reference: Potoka, DA, Schall, LC, Gardner, MJ, et al. Impact of pediatric trauma centers on mortality in a statewide system. J Trauma 2000; 49:237.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20635=[""].join("\n");
var outline_f20_9_20635=null;
var title_f20_9_20636="Respiratory disease and RA";
var content_f20_9_20636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Respiratory disease in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Interstitial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Interstitial pneumonitis/fibrosis (RA-ILD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Usual interstitial pneumonitis (UIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonspecific interstitial pneumonitis (NSIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphoid interstitial pneumonitis (LIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Desquamative interstitial pneumonitis (DIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed morphology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organizing pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid pneumoconiosis (Caplan's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apical fibrobullous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Airway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cricoarytenoid arthritis/central airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obliterative bronchiolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic small airway obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pleural",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural thickening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol (chyliform) effusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung entrapment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic cage immobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ? Lung cancer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20636=[""].join("\n");
var outline_f20_9_20636=null;
var title_f20_9_20637="UDCA response in PBC";
var content_f20_9_20637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to ursodeoxycholic acid in primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Probability of response (defined as the absence of treatment failure) to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis. Patients were randomized to UDCA (solid line) or placebo (dashed line) for the first 24 months and then all patients were treated with UDCA for the next 24 months. The probability of a beneficial response at four years was significantly higher in the patients treated with UDCA throughout the study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group, N Engl J Med 1994; 330:1342.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20637=[""].join("\n");
var outline_f20_9_20637=null;
var title_f20_9_20638="Time to recovery from first unipolar major depressive episode";
var content_f20_9_20638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F73080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F73080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Time to recovery in patients and nonclinical individuals with unipolar major depression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time to recovery from the first prospectively observed episode of major depression in patients (squares, N = 359) and nonclinical individuals (triangles, N = 216) with major depressive disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Coryell W, HS Akiskal, AC Leon, et al. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies. Arch Gen Psychiatry 1994; 51:405. Copyright &copy; 1994 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20638=[""].join("\n");
var outline_f20_9_20638=null;
var title_f20_9_20639="Tracheomalacia CXR";
var content_f20_9_20639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheomalacia following longterm intubation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a well-positioned tracheostomy tube. Note that the tracheal air column is abnormally distended by the tracheostomy cuff (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_9_20639=[""].join("\n");
var outline_f20_9_20639=null;
